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ABSTRACT
Cell therapy is defi ned as cell transplantation into the patient to treat a certain disease state. 
Th erapies utilizing cells can be divided into two main categories, (1) tissue regeneration or 
engineering and (2) drug delivery. In tissue engineering, the transplanted cells are used to 
regenerate the functions of a diseased tissue. In drug delivery, the transplanted cells are used 
as “biological factories” that produce therapeutic molecules inside the body. For successful cell 
therapy applications, cells usually must be combined with biomaterials and bioactive factors 
to mimic the growth environment in vivo. Th e properties of these scaff olds are important for 
outcomes of the treatments, because the local environment determines the functionality of the 
cells. Th us, research on cell-biomaterial interactions is essential for the progress of cell based 
therapies. Hydrogels are promising cell therapy materials, because their structure resembles the 
natural tissue environment; they consist of long polymer chains with high water content and 
elastic properties, thereby enabling cellular functionality. 
 
Th e aim of this study was to investigate hydrogels for cell therapy applications. Firstly, we 
encapsulated human retinal pigment epithelial cell line (ARPE-19) genetically engineered to 
secrete an anti-angiogenic protein (1) into alginate-poly-L-lysine-alginate (APA) microcapsules 
and (2) into a composite hydrogel of cross-linked collagen and interpenetrating hyaluronic 
acid (HA). A custom-made cell encapsulation device was designed, built and optimized, 
and pharmacokinetic/pharmacodynamic (PK/PD) model was developed to investigate the 
intravitreal drug delivery of the anti-angiogenic protein by the encapsulated cells. Secondly, 
chondrocytes were encapsulated into the cross-linked collagen/HA hydrogel supplemented with 
transforming growth factor β1 (TGFβ1). 
Using the cell encapsulation device, cell microcapsules of symmetrical shape and narrow size 
distribution were produced. Th e encapsulated ARPE-19 cells remained viable and functional 
for at least fi ve months. Th e cross-linked collagen-HA hydrogel was shown to be a suitable 
encapsulation matrix for ARPE-19 cells; the cells maintained viability and secreted the anti-
angiogenic protein at a constant rate for at least 50 days. Moreover, the hydrogel composition 
could be modifi ed to adjust the properties of the gel structure without compromising cell viability. 
Th is approach is suggested to have potential in the treatment of retinal neovascularization. Th e 
developed PK/PD model could be used to predict drug levels and therapeutic responses aft er 
intravitreal anti-angiogenic drug delivery. Th e simulations may augment the design of in vivo 
experiments. Th e collagen/HA matrix with TGFβ1 was suitable for chondrocyte encapsulation. 
Th e hydrogel supported viability and phenotypic cell stability. Th is hydrogel is strong, stable 
and biodegradable, and it can be delivered non-invasively as injection. Overall, it is potentially a 
useful delivery vehicle of chondrocytes for cartilage tissue engineering.
In conclusion, ARPE-19 cells maintain viability in diff erent hydrogels for prolonged periods and 
secrete the therapeutic transgene product constantly, supporting the suitability of ARPE-19 cells 
for cell therapy. Th e cross-linked collagen/HA hydrogel appears to be a potential matrix for cell 
therapy. It is an injectable system that supports functionality of cells, and it is applicable in drug 
delivery and tissue engineering. 
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11. INTRODUCTION
Th erapies utilizing transplanted cells are potential alternatives for the treatment of various disease 
states that cannot be treated with conventional technologies. Cell-based therapies can be used 
for the delivery of therapeutic agents, reconstruction of damaged tissues or even re-engineering 
of new organs. Most of the strategies currently used in cell therapies depend on employing a 
biomaterial scaff old that supports the transplanted cells both structurally and biochemically. Th e 
properties of the biomaterial are of key importance for the success of cell therapies; the material 
should address the appropriate physical, mass transport and biological properties critical for each 
application. Th us, the fi eld of cell therapy is greatly dependent on understanding and controlling 
the interfaces and interactions between cells and biomaterials. Research concerning biomaterial 
design and optimization, combined with cell behavior and functionality in these materials, is an 
essential fi eld for the development of cell therapies. (Berthiaume et al. 2011, Orive et al. 2014)
Th e use of cells as devices for the delivery of therapeutic molecules has been a target of increasing 
interest. Numerous novel therapeutic agents are available without eff ective delivery methods: the 
progress in molecular and cell biology has enabled the identifi cation of various new molecular 
targets and the development of novel drugs acting on these, especially diff erent peptide and 
protein medicines (Bruno et al. 2013). However, these emerging therapies are oft en limited by 
a rapid loss of molecular bioactivity and the therapeutic eff ects. Cells are promising candidates 
for prolonged delivery of these novel drugs, since they are able to deliver therapeutic molecules 
continuously over extended time periods at a specifi c target site (Murua et al. 2008, Acarregui 
et al. 2012). Moreover, cells are able to response to external stimuli and alter their secretion 
accordingly making controlled delivery of the therapeutics possible. Cells as delivery devices also 
enable the secretion of complex biological molecules that cannot be synthesized and purifi ed 
eff ectively in vitro. However, there are still many challenge associated to this technology, such 
as the production of clinical grade cell capsules, shipping and storage of the capsules and the 
possibility of immune reactions aft er transplantation (de Vos et al. 2009, van Zanten & de Vos 
2010). 
In addition to drug delivery, cell encapsulation can be used to repair an injury or replace the 
function of a failing organ in the body (Langer & Vacanti 1993). In this technology, the function 
of the transplanted cells is to assist, accelerate or induce the regeneration and repairing of 
defective and damaged tissues (Stock & Vacanti 2001, Sala et al. 2013). In the long term, 
development of this fi eld might enable the replacement of whole organs with complete tissue 
engineered structures (Atala et al. 2012). Taking into account the severe problem of donor organ 
scarcity, cell based tissue engineering can be considered as a very important approach for the 
organ replacement fi eld. Moreover, the immune rejection associated with transplanted organs 
can be eliminated when using autologous cells for tissue construction, and consequently, the use 
of immunosuppressive drugs can be avoided. Tissue engineering has been applied clinically in 
the treatment of skin and cartilage defects. However, the repair of other, more complex tissues has 
not been as successful so far due to the diffi  culties associated with the construction of functional 
vasculature and proper cell arrangement (Ikada 2006, Atala 2012). In addition, critical issues 
limiting the use of cell therapy for tissue regeneration include high costs and practical diffi  culties 
of the treatments compared to more traditional methods.
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2In cell therapy, biomaterials should replace the extracellular matrix (ECM) of the cells present 
in native tissues; as in their natural tissue environment, cells are dependent on the structural 
and biological support and diff usible properties of their surroundings (Schmidt et al. 2008, 
Dhandayuthapani et al. 2011). Th us, the used biomaterials have a key eff ect on cell viability 
and functionality, on the desired stability or degradation rate of the systems, and on immune 
response aft er transplantation. In general, an optimal biomaterial should mimic the natural tissue 
environment of the encapsulated cells to enable the best possible performance. Hydrogels have 
many appealing properties as cell encapsulation materials (Drury & Mooney 2003, Nicodemus & 
Bryant 2008). Hydrogels are networks of long polymer chains that exhibit high water content and 
tissue-like elastic properties. Th ey are structurally similar to the ECM of many tissues and thus, 
enable the organization of cells into a natural 3D architecture. Hydrogels can oft en be processed 
under relatively mild conditions that do not limit cell viability, and they may be delivered in a 
minimally invasive manner. In addition to the biomaterial scaff old, the selection of a suitable 
cell source is important for successful cell therapy. Cells used in therapeutic applications include 
genetically engineered cell lines (Chang & Prakash 1998), primary cells (Griffi  th & Naughton 
2002) and stem cells (Ramakrishna et al. 2011). Th e suitability of a certain cell type depends on 
the specifi c application.
Th e combined use of cells and biomaterials as therapies can be divided into two main 
applications: (1) immunoisolation of cells and (2) tissue engineering. Th e fi rst application refers 
to encapsulation of therapeutic cells within biomaterials for the purpose of isolation from the 
host immune system aft er transplantation (Uludag et al. 2000). Consequently, the transplanted 
cells are able to secrete therapeutic factors at a specifi c location for prolonged periods, without 
being destructed by the immune system. Th e second application involves the use of biomaterials 
as scaff olds where encapsulated or seeded cells can organize and develop into a desired tissue or 
organ (O’Brien 2011). Th e fundamental diff erence between these two applications is the isolated 
nature of the former; these cell-biomaterials systems are expected to remain as immunoisolated, 
unchangeable units that do not react with the host tissue (Fig 1a). On the contrary, cells 
encapsulated in biomaterials for tissue engineering are supposed to integrate with the host tissue 
and fi nally, form neotissue structures with the help of the surrounding environment (Fig 1b). 
Despite this diff erence, the requirements for biomaterials used in both of these approaches are 
similar in many aspects. 
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3Figure 1. Cell encapsulation in (A) immunoisolation and (B) tissue engineering. In (A), the 
biomaterial serves as a stable, immunoisolating device that maintains cell viability and functionality 
without degradation. In (B), the biomaterial serves as a temporary ECM for the cells, and is degraded 
gradually during the tissue regeneration process. Modifi ed from Murua et al. 2008 (A) and Tan & 
Marra (B).
Th e aim of this study was to investigate the encapsulation of cells in hydrogels considering both 
of these applications. Immunoisolation of cells was studied by micro- and macroencapsulation of 
a genetically engineered, therapeutic protein producing cell line. In the tissue engineering part, 
the encapsulation of chondrocytes for cartilage regeneration therapy was investigated.
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42. REVIEW OF THE LITERATURE: 
 CELLS AND BIOMATERIALS IN CELL THERAPY
2.1  Cell encapsulation
Cell therapy can be used for two main applications: for drug and cell delivery. In drug delivery, 
cells are used as “biological factories” that produce and release therapeutic molecules or drugs 
inside the body (Murua et al. 2008, Acarregui et al. 2012). To enable this, the cells must be 
immunoisolated from the host’s immune system (Uludag et al. 2000). In cell delivery, cells are 
used to treat a damaged function in the body (Stock & Vacanti 2001, Sala et al. 2013). In this 
approach, the delivered cells are supposed to replace or repair a non-functional tissue or organ.
2.1.1  Cell encapsulation for immunoisolation
Cell encapsulation for immunoisolation is a method that enables the continuous, long-term 
delivery of therapeutic factors into a selected target tissue; the encapsulated cells are transplanted 
into the body, where they produce and release therapeutic molecules (Murua et al. 2008, Acarregui 
et al. 2012). Th e principle of cell encapsulation is to isolate the transplanted cells from the host 
immune system by enclosing them within a polymeric matrix surrounded by a semipermeable 
membrane (Fig 2) (Uludag et al. 2000). Th e purpose of the membrane is to prevent immune 
rejection when the cells are transplanted into the body by excluding harmful components of 
the host immune system, such as immunoglobulins, complement and immune cells (Nafea et 
al. 2011). At the same time, the membrane should allow the bi-directional diff usion of oxygen, 
nutrients, waste and the therapeutic products to maintain the encapsulated cells viable, healthy 
and functional. In addition to the semi-permeable membrane, cell encapsulation devices oft en 
contain an internal matrix that creates a 3D microenvironment for the encapsulated cells (Li 
1998). Th is internal matrix is important for the viability and functionality of the encapsulated 
cells, as it substitutes for the ECM of native tissues. 
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Figure 2. Principle of cell immunoisolation for the delivery of therapeutic factors. Nutrients, oxygen, 
waste and therapeutic products are able to diff use through the capsule membrane, while antibodies 
and immune cells are excluded. 
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5Delivery of therapeutics using encapsulated cells off ers several advantages compared to 
conventional drug administration. Th e technique allows sustained, controlled and local delivery 
of substances, reducing systemic side eff ects, high peak concentrations and dosing interval. 
Moreover, delivery by cells enables physiologically or externally controlled systems; the cells may 
react to the physiological environment in the body and change their secretion accordingly or 
the cells may be modifi ed to regulate their secretion according to a certain external stimulus. 
Th e cells produce the therapeutic molecules de novo that ensures the bioactivity of even 
complex biological molecules that would be diffi  cult or impossible to produce and purify in 
vitro. Compared to conventional controlled drug release systems, a cell encapsulation device is 
relatively safe in the case of device rupture: breakage of a controlled release implant containing 
a drug reservoir results in very high and potentially toxic local drug concentrations. In the case 
of encapsulated cells, there is no reservoir of the drug and thus, no risk for rapid release. If the 
cells are released from the device, they most likely are destroyed as foreign by the host’s immune 
system. (Murua et al. 2008, Orive et al. 2014) 
Cell encapsulation devices are traditionally classifi ed as micro- and macrocapsules according to 
the device size (Uludag et al. 2000). Macrocapsules are usually cylindrical or planar implants in 
the size range of 0.5?1.5 mm in diameter and 1?10 cm in length. Th ey have an internal capacity 
of thousands to millions of cells, and thus, only one or a few devices are needed for suffi  cient 
production of therapeutic factors. Microcapsules are spherical beads of typically 0.2?1.0 mm 
in diameter. Since one microcapsule is able to contain only a small number of cells, several 
microcapsules need to be transplated to achieve a therapeutic level of the produced factors. In 
general, microcapsules are considered to off er better mass transfer, higher mechanical resistance, 
improved biocompatibility and non-invasive delivery compared to larger encapsulation 
devices (Hernandez et al. 2010, Acarregui 2012). On the other hand, an obvious advantage of 
macrocapsules is more simple retrieval aft er treatment compared to microcapsules that may 
have spread within the implantation site (Nafea at al. 2011). In addition, macrocapsules may 
enable a wider selection of encapsulation techniques and materials. Finally, the requirements of 
the specifi c application (cells, biomaterials and methods used for encapsulation, as well as the 
target delivery site and desired duration of the treatment) determine the suitable encapsulation 
approach, so generalizations on superiority of device size or confi guration cannot be made. 
Especially attractive targets for cell encapsulation therapy are diseases requiring long-term, 
frequent delivery of therapeutics that cannot be administered orally. A suitable combination of 
stability, durability, biocompatibility and diff usional properties of the immunoisolation device 
enables prolonged functionality of the cells, thereby allowing long-term drug delivery for the 
treatment of chronic diseases. In principle, transplantation of encapsulated cells can provide 
life-long treatment for such diseases including neurodegenerative, endocrine and Mendelian 
inherited diseases, as well as cancer (Chang 2005, Pedraz & Orive 2010). 
Cell microencapsulation: materials and techniques for production. Cell microencapsulation 
is a commonly used technology for cell immunoisolation. Th e typical cell microencapsulation 
strategy includes capturing cells inside hydrogel beads that are further coated to form a shell 
(Uludag et al. 2000, Rabanel et al. 2009). In general, bead production for cell encapsulation may 
be done using ionic, polyelectrolyte or covalent cross-linking or thermal gelation. Th e most 
commonly used matrix material is alginate cross-linked with divalent cations, such as Ca2+ or 
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Ba2+ (de Vos et al. 2006, Santos et al. 2010). In addition to ionic cross-linking, alginate can also 
be cross-linked covalently to form microbeads using e.g. photoactive cross-linkers (Rokstad 
et al. 2006). Other materials used for cell microencapsulation include chitosan (Baruch & 
Machluf 2006), agarose (Sakai et al. 2005), hyaluronic acid (HA) (Khademhosseini et al. 2006), 
collagen (Yin et al. 2003), polyethylene glycol (PEG) (Weber et al. 2006) and polyacrylates 
(such as polyhydroxyethyl methacrylate (PHEMA) and polyhydroxyethyl methacrylate-methyl 
methacrylate (PHEMA-MMA) (Fleming & Seft on 2003)). 
Th e purpose of the shell or coating is to increase capsule stability, protect cell protrusion, adjust 
permeability properties and increase biocompatibility (Rabanel 2009, Nafea et al. 2011). Th e most 
common coating type is polyelectrolyte complexation of alginate beads with poly-L-lysine (PLL) 
due to the very gentle, simple, and rapid shell formation reaction. As PLL evokes infl ammation 
and tissue fi brosis (Strand et al. 2001, Robitaille et al. 2005), alginate-PLL capsules are typically 
further coated with an alginate layer to shield the PLL from host tissue (alginate-poly-L-lysine-
alginate or APA capsules) (Th u et al. 1996 a, 1996 b, Santos et al. 2010). However, stability of the 
outer alginate layer and masking of PLL are not suffi  cient for every application. In addition to 
PLL, other cationic polyelectrolytes, such as poly-L-ornithine (Leung et al. 2008) and chitosan 
(Gåserød et al. 1999) have been used as coating materials. Other methods for shell formation 
include covalent coating with e.g. proteins (Levy & Edwards-Levy 1996) and PEG (Chandy et al. 
1999) or deposition with e.g. silica (Boninsegna et al. 2003) and agarose (Jain et al. 1995).  
Th e qualitative properties of the capsules have a notable eff ect on the functionality of the 
encapsulated cells and thus, homogeneous, spherical microcapsules without deformities provide 
the most uniform experimental results (van Schilfgaarde & de Vos 1999, Zimmermann et al. 
2005, Rabanel et al. 2009). Moreover, the quality of the microcapsules has been associated to 
their performance in vivo: smooth and spherical microcapsules induce less fi brotic overgrowth 
and foreign body reactions (de Vos et al. 2002, 2003, Bünger et al. 2003, Orive et al. 2006). 
Considering these factors, the production of microcapsules with symmetrical, spherical 
morphology and smooth surface is signifi cant for the success of associated cell therapies. 
A functional cell encapsulation method should produce microcapsules of good quality in a 
reproducible manner without limiting viability of the encapsulated cells. 
Cell microcapsules are most commonly prepared by diff erent extrusion techniques utilizing 
co-axial laminar gas fl ow, electrostatic potential, vibrating nozzle or jet cutting (Koch et al. 
2003, Schwinger et al. 2004, Xie et al. 2007, Prüsse et al. 2008) (Table 1). In these techniques, a 
polymer solution is dispersed by diff erent means to form microbeads. Other techniques for cell 
microencapsulation include emulsion and microscale methods (Table 1). Unfortunately, many 
methods for cell microencapsulation lack adequate documentation on the process and on the 
characterization of the capsules. As a result, precise comparison of the production methods is 
not always possible. Th e equipment required for cell encapsulation can limit potential research 
on the subject; the devices used to produce microcapsules are oft en expensive, diffi  cult to 
assemble and to use, and typically more suitable for large-scale experiments. At present, cell 
microencapsulation is oft en performed with commercial equipment (e.g. Inotech, Nisco). 
However, there is a need for inexpensive, convenient and fl exible laboratory-scale devices that 
would facilitate research on diff erent biomaterials and encapsulation protocols, especially in 
academia. As the properties of the produced capsules are important considering the success 
7Review of the literature
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of the experiments, the simplicity of the encapsulation system should not limit the quality of 
capsules or reproducibility of the process. Th us, the development of new devices and techniques 
for microcapsule production is an important aspect for the cell immunoisolation fi eld.
2.1.2 Cell encapsulation for tissue engineering
By defi nition, tissue engineering means the combined use of cells, biomaterials and bioactive 
factors to improve or replace biological functions (O’Brien 2011). In tissue engineering 
applications, the purpose of the encapsulation material is to serve as a 3D delivery vehicle or 
scaff olds for the cells that are transplanted. Th e basic concept of cell based tissue engineering 
includes isolation of cells from a biopsy of donor tissue, and seeding or encapsulation of these 
cells into a biomaterial scaff old, possibly with suitable bioactive molecules (Fig 3) (Stock & 
Vacanti 2001, Sala et al. 2013). Th e scaff old provides an architecture in which the seeded cells can 
organize and develop into a desired organ or tissue either prior or aft er delivery into the body. 
Preferably, the scaff old should degrade gradually with approximately the same rate as the cells are 
producing their own ECM structure; this way, the scaff old provides mechanical and biochemical 
support for the cells during the ECM building process, and is eventually fully degraded when the 
newly formed tissue is ready. 
As in the case of cell encapsulation for immunoisolation, an essential requirement for successful 
tissue regeneration is a biomaterial that creates a suitable cellular environment allowing the 
cells to function in a similar way as in the native tissue (Drury & Mooney 2003, O’Brien 2011, 
Figure 3. Th e principle of cell based tissue engineering consists of isolating cells from tissue biopsy 
(1,2), expansion of the cells (3), seeding the cells into a biomaterial scaff old (possibly with bioactive 
molecules) (4) and transplantation of this cell-biomaterial structure into the body (5). Modifi ed from 
http://textile.iitd.ac.in/highlights/fol8/01.htm. 
Bioactive 
factors 
Cells from 
biopsy 
Monolayer  
cell culture 
Expansion 
of cells 
3D biomaterial  
scaffold 
Cell/biomaterial 
graft 
1. 2. 
3. 
4. 
5. 
Cell isolation 
Implantation 
9Dhandayuthapani et al. 2011). Oft en the biomaterial is designed to mimic or resemble some 
critical aspects of the natural in vivo environment. An optimal biomaterial for tissue regeneration 
should (1) have adequate porosity for the diff usion of nutrients, oxygen, expressed products and 
waste, (2) enable the viability, proliferation and attachment of encapsulated cells, (3) degrade in 
a controlled and timed manner, (4) be able to retain and present biochemical factors and (5) be 
mechanically appropriately stiff /fl exible/stable, depending on the engineered tissue. Finally, (5) 
the material should naturally be biocompatible.
Most frequently, tissue engineering is used to repair an injury or replace the function of a 
failing organ in the body (Stock & Vacanti 2001, Atala 2009, Berthiaume et al. 2011). Th e most 
important targets are tissues that are prone to injury, disease and degeneration. Th ese tissues may 
be structural (such as bone and cartilage), barrier- and transport-related (such as skin and blood 
vessels) or biochemical and secretory (such as liver and pancreas). As the mean life expectancy 
of the developed world has increased, there is a growing demand for the development of eff ective 
ways to repair diseased and damaged tissues. Along with increasing understanding on cellular 
microenvironment combined to advances on biomaterial development, tissue engineering may 
be used to overcome the current problems of whole organ transplantations, including scarcity 
of functional organs for transplantation and the life-long use of immunosuppressive drugs. 
Other applications of tissue engineering include tissue formation for extracorporeal life support 
systems and diagnostic screening, as well as for non-clinical applications, such as drug testing for 
effi  cacy and toxicology, and basic studies on tissue development and morphogenesis (Tzanakakis 
et al. 2000, Zorlutuna et al. 2013, Sala et al. 2013).
2.2  Cell source
Th e choice of cell source for cell therapy depends on the intended application. For 
immunoisolation devices designed for long-term treatment of chronic diseases, cells capable 
of producing therapeutic factors constantly for prolonged periods are needed. Moreover, the 
adaptation of the cells inside the device is an important consideration; the encapsulated cells 
should be able to remain in a non-dividing state, since proliferation might lead to limited 
viability in central areas of the device or even disintegration of the device followed by cell release. 
In addition, the level of the secreted therapeutic product can change along cell proliferation. 
(Chang 2005, Orive et al. 2005, Murua et al. 2008) On the contrary, in tissue regeneration, the 
cells are supposed to proliferate and integrate with the surrounding tissue. In this application, 
it is important to control the diff erentation state and functionality of the cells as usually only 
the cells of proper phenotype are able to regenerate the desired tissue structure. Immunological 
reactions aft er transplantation must also be taken into account, since in tissue engineering the 
cells are not immunoisolated. (Ikada 2006, Atala 2007)
Cells used in cell therapy can be classifi ed into primary, genetically engineered and stem cells. In 
addition, the cells can be divided based on their origin to xenogeneic (derived from a diff erent 
species), allogeneic (derived from individuals of the same species) and autogeneic (derived from 
the same individual).
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2.2.1  Primary cells
Primary cells are the most obvious choice for cell therapy; these cells possess an inherent 
capacity for their native function that can be utilized therapeutically. Th e oldest and most 
widely investigated application of cell immunoisolation technology is the transplantation 
of encapsulated pancreatic islets for the treatment of diabetes. Insulin secretion from the 
encapsulated islets has been shown to result in improvements of the diabetic state both in 
preclinical and clinical experiments (Scharp & Marchetti 2014). Primary cells have also been 
immunoisolated for the treatment of neurodegenerative disorders (Emerich et al. 2006), chronic 
neuropathic pain (Jeon et al. 2006) and liver failure (Allen et al. 2001). For tissue engineering 
applications, primary cells are currently the most common cell type used. Typically, autologous, 
organ-specifi c cells are isolated from a biopsy obtained from the patient. Primary cells have been 
used for the regeneration of many diff erent tissues, such as skin (MacNeil 2007), liver (Li et al. 
2013), heart (Tee et al. 2010), blood vessels (Zhang et al. 2007), pancreas (Coronel & Stabler 
2013) and cartilage (Chung & Burdick 2008). Primary cells can also be genetically engineered 
to deliver tissue-specifi c or therapeutic proteins, such as growth factors, at the transplantation 
site (Sheyn et al. 2010). Th is approach has been used, for instance, in the engineering of cartilage 
(chondrocytes engineered to produce bone morphogenetic protein 2 (BMP-2)) (Chen et al. 
2009), pancreatic (hepatocytes engineered to produce insulin) (Chen et al. 2008) and nervous 
tissue (schwann cells engineered to produce ciliary neurotrophic factor (CNTF)) (Hu et al. 2005).
Th e main problem in the use of primary cells is their limited availability, as autologous and 
allogeneic cells are isolated from human tissues. Due to their primary nature, these cells cannot be 
proliferated in cultures on a large scale, since this will lead to changes in the original, specialized 
phenotype of the cells. For some cell types, such as neurons, hepatocytes and islet cells, expansion 
in vitro is inadequate, because the cells do not divide or the proliferation is limited in culture 
conditions (Atala 2009, Sala 2012).  In addition, for some tissues, biopsies for cell harvesting 
cannot be obtained directly (e.g. heart valve) or at all (e.g. neural tissues) (Stock & Vacanti 
2001). In the case of cell encapsulation for immunoisolation, the use of xenogeneic cells from 
nonhuman sources can in some situations be applied, but also here the risk of immunological 
reactions remains (Ríhová 2000, Chang 2005).
2.2.2  Genetically engineered cell lines
Cell lines genetically modifi ed to produce and secrete therapeutic factors present an inexhaustible 
cell source for cell therapy. Genetically engineered cells are particularly usable for drug delivery 
by immunoisolated cells, since the cells can be modifi ed to deliver the desired therapeutic 
product in an appropriate form at a suitable secretion rate. As cell lines can be increased in cell 
number easily, the availability of these cells is not limited such as in the case of primary cells. 
Accordingly, genetically engineered cells are probably the most commonly used cell type for 
the application of cell encapsulation for the delivery of therapeutic factors. (Chang & Prakash 
1998, Chang 2005, Murua et al. 2008) Several diff erent genetically modifi ed cell lines have 
been used for encapsulation, including BHK (baby hamster kidney cells) (Bloch et al. 2004, 
Zurn et al. 2000), HEK293 (human embryonic kidney cells) (Löhr et al. 2001, Xu et al. 2002) 
2001, ARPE-19 (human retinal pigment epithelial cells) (Kauper et al. 2012, Fjord-Larsen et al. 
2012), C2C12 (mouse myoblast cells) (Li et al. 2000,  Murua et al. 2009) and CHO cells (chinese 
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hamster ovary cells) (Kuijlen et al. 2006, Zhang et al. 2007). In addition, cell lines endogenously 
producing therapeutic factors, such as PC12 (rat adrenal gland cells) (Tresco et al. 1992, Yoshida 
et al 2003) and hybridoma cells (hybrid cell lines formed by fusing antibody-producing B cells 
with myeloma cells) (Okada et al. 1997, Dubrot et al. 2010) have been encapsulated for diff erent 
applications. However, for tissue engineering, cell lines are usually not the best choice, since 
these cells have lost some of their original, primary phenotype and are thus not able to regenerate 
native-like tissue structures. Moreover, cell lines are oft en derived from allogeneic or xenogeneic 
cells, and usually require immune protection aft er transplantation.
Transfection of therapeutic genes to cells is most commonly made using biological or chemical 
methods (Colosimo et al. 2000, Kim & Eberwine 2010). Biological methods refer to virus-
mediated transfection. Viral vectors generally possess high transduction effi  ciency, and stable 
or long-term transgene expression is achieved easily with retrovirus, lentivirus and adeno-
associated virus vectors (Walther & Stein 2000, Th omas et al. 2003). However, this transfection 
method is associated with safety risks including immunogenicity and carcinogenicity. Chemical 
methods or non-viral transfection include the use of cationic polymers, calcium phosphate, 
cationic lipids or cationic amino acids (Wang et al. 2013, Yin et al. 2014). Compared to viral 
vectors, the transfection effi  ciency of chemical methods is usually low and transgene expression 
poor (Douglas 2008). Yet, non-viral methods show only low cytotoxicity and they do not cause 
mutagenesis. Non-viral vectors are also able to transport genes of unlimited size and they are 
easier to prepare than virus vectors. Aft er non-viral gene transfer cell selection procedures can 
be used to fi nd the cells with stable gene expression. Th ese cells can then be used for long-term 
protein secretion from the cell capsules.
2.2.3  Stem cells
Stem cells are undiff erentiated cells that possess two properties making them attractive for cell 
therapy: (1) high proliferative capacity and (2) ability to diff erentiate into multiple specialized cell 
types (Avasthi et al. 2008, Ramakrishna et al. 2011). Stem cells can be classifi ed into pluripotent 
and adult stem cells. Pluripotent stem cells include embryonic and induced pluripotent stem cells 
(ECS, iPSC). Pluripotent cells have the broadest diff erentiation and proliferation capacity: they 
can develop into any cell type of the adult body (pluripotency), and they posses an unlimited 
self-renewal capacity, enabling propagation in culture infi nitely (Donovan & Gearhart 2001). 
ECSs are derived from early embyos of the blastocyst stage (Keller 2005, Vats et al. 2005). Th e use 
of this stem cell type is restricted by possible teratoma formation and immune rejection, as well 
as ethical issues. iPSCs are generated from adult somatic cells using specifi c transcription factors 
(Yamanaka 2012, Okano et al. 2013). As iPSC can be generated from autologous somatic cells, 
the ethical concerns and possibility of immune rejection associated to ESCs can be reduced or 
avoided. However, there are still open questions, such as the role of possible epigenetic changes of 
the cells before their conversion to iPSCs. Adult stem cells (ASCs) are found in developed tissues, 
where they divide to replenish dying cells and regenerate damaged tissues (Greenberg et al. 2012, 
Eberli & Atala 2006). Compared to ECSs, both the diff erentiation and proliferative potentials of 
ASCs are narrower; ASCs can develop to several distinct cell types of the body (multipotency), 
and they are not as easily multiplied on a large scale without diff erentation.
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Th e use of stem cells solves the important problem of availability of appropriate cells in high 
numbers; due to the self-renewal capacity, stem cells can be proliferated and diff erentiated in 
cultures to achieve high amounts of cells needed for therapeutic applications. Stem cells have 
been used for both tissue engineering and cell immunoisolation, including applications for the 
regeneration of cardiac (Bursac 2009), liver (Palakkan et al. 2013), neural (Willerth 2011), skeletal 
muscle (MacLean et al. 2012), adipose (Gomillion & Burg 2006), bone (Marolt et al. 2010) and 
cartilage tissue (Hwang & Elisseeff  2009), and for the treatment of diabetes (Montanucci et 
al. 2011, Ngoc et al. 2011, Shao et al. 2011)  and cancer (Shah 2013). Like primary cells, also 
stem cells have been genetically engineered to overexpress selected genes to promote the tissue 
regeneration process (Sheyn et al. 2010). Examples of this approach include the engineering of 
cartilage (bone marrow derived stromal cells engineered to produce transforming growth factor 
β1(TGFβ1)) (Xia et al. 2009), cardiovascular (mesenchymal stromal cells engineered to produce 
erythropoietin) (Copland et al. 2008) and nervous tissue (adult neural stem and progenitor 
cells engineered to produce glial cell line-derived neurotrophic factor (GDNF)) (Kameda et al. 
2007). A critical issue for stem cell therapy is the understanding on how to induce and control 
the permanent specialization of the precursor cells into the desired cell phenotype; the specifi c 
molecular mechanisms of diff erentation must be precisely characterized before stem cells can 
be safely applied for clinical use. Research on cell therapy concentrating on cell biology aspects 
is thus essential for the development of functional and safe therapies using stem cells. (Kim & 
Evans 2005, Nadig 2009) 
2.3  Biomaterials in cell therapy
Th ere are two main strategies in utilizing biomaterial scaff olds in cell therapy: (1) cell seeding into 
or onto a prefabricated scaff old and (2) cell encapsulation during the formation of the scaff old 
(Chan &  Leong 2008, Dhandayuthapani et al. 2011). When using a prefabricated scaff old, 
several diff erent types of precursor materials can be used and the production process can involve 
harsh or even toxic components, as long as the fi nal product is biocompatible. 2D tissues such 
as epithelium and endothelium can be engineered by seeding cells onto a prefabricated 2D 
scaff old (McHugh et al. 2013, Paz et al. 2014). Th ese constructs can be implanted into the body 
as such, or alternatively the cells can be detached from the scaff old prior to implantation (cell 
sheet engineering). Cells requiring a 3D growth environment can be seeded into a 3D porous 
scaff old.  However, cells seeded in such porous, sponge-like scaff olds do actually not grow in 3D. 
Although the cells are arranged spatially in 3D relative to each other within the scaff old, they 
still are attached in 2D inside the porous material. Th is might limit the stability of the original 
phenotype and functionality of the cells, since these cells in vivo in native tissues grow in a 3D 
environment. Cell encapsulation performed at the same time as the scaff old formation provides 
the cells such a native-like 3D environment. Yet, this approach requires the encapsulation 
materials and formation processes to be cytocompatible and suffi  ciently mild. Although this 
limits the material selection, cell encapsulation off ers several advantages: Since the cells are mixed 
with the precursors before the scaff old formation, the system can be delivered non-invasively via 
injection. Th e cells can be homogeneously distributed inside the material easier compared to 
seeding inside a preformed scaff old. Moreover, the integration of such an injectable material with 
the surrounding tissue is effi  cient, because of its ability to fi ll irregular shaped spaces at the defect 
site. (Nicodemus & Bryant 2008, Hunt & Grover 2010, Li et al. 2012)
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2.3.1  Requirements for biomaterials
Th e main characteristics of biomaterials critical for cell therapy can be classifi ed to physical, 
mass transfer and biological properties (Drury & Mooney 2003). Th e specifi c requirements for 
these properties vary depending on the application. A major challenge considering the optimal 
properties of a biomaterial for cell encapsulation is the ability to combine all the required features 
in one material; modifi cation of a certain biomaterial property oft en leads to alterations of 
some other properties during the process. For instance, increasing the mechanical strength of a 
material can limit mass transport and swelling, leading to reduced cell viability and functionality. 
Th us, a successful design of biomaterials includes a fi ne balance between the desired properties.
Physical properties. Th e two most important physical properties of cell therapy biomaterials 
are mechanics and degradation. Th e mechanical properties infl uence the encapsulated cells 
both on the macroscopic and the microscopic level (Butler et al. 2000, 2009, Pioletti 2011). 
Macroscopically, the scaff old must bear loads to provide stability to the cells or the forming 
tissue. For immunoisolated cells designed for long-term delivery of therapeutic factors, both the 
encapsulation matrix and the surrounding semipermeable membrane should provide mechanical 
strength of stiff ness (resistance to deformation) and toughness (resistance to fracture) for 
prolonged periods. In the case of tissue regeneration, the material must create a space for the 
tissue development and protect the cells during the regeneration process. On the microscopic 
level, the scaff old should be able to transmit mechanical signals in an appropriate manner to the 
encapsulated cells; cells sense the local mechanical properties of their environment by converting 
mechanical signals into chemical signals that fi nally alter gene expression (Robling & Turner 
2009). Mechanical properties similar to those of native tissue are important especially in the case 
of tissue engineering, because cell growth and diff erentiation and thus, the ability of the cells to 
regenerate tissue depends signifi cantly on mechanical input from the surrounding environment.
In cell immunoisolation for drug delivery applications, the encapsulation device is most oft en 
designed to remain intact for prolonged periods. Th erefore, the materials used in such devices 
should not degrade, or, in some cases, the degradation rate should be very slow (Orive et al. 
2014). On the contrary, biomaterials used in tissue engineering should degrade in a timed and 
controlled manner (Nicodemus & Bryant 2008, Dhandayuthapani et al. 2011). Typically, the 
degradation rate of the scaff old is desired to be coordinated with the rate of tissue formation; 
accordingly, the scaff old provides mechanical and biochemical support for the cells during the 
tissue building process, and is eventually fully degraded when the regenerated tissue is ready 
(O’Dea et al. 2013). Th e degradation products should be non-toxic and exit the body without 
interfering other organs (Nicodemus & Bryant 2008, O’Brien 2011). Materials used in cell 
encapsulation typically degrade by hydrolysis, enzyme-mediated processes or by the exchange of 
cross-linking ions with the environment. 
Mass transfer properties. To maintain cell viability, the biomaterials used in cell encapsulation 
must allow the appropriate diff usion of oxygen, nutrients and waste into, out and within the 
scaff old. In the case of tissue engineering, the most important goal considering mass transfer is 
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the suffi  cient supply of oxygen and nutrients, and the removal of waste (Dhandayuthapani et al. 
2011, O’Brien et al. 2011). Th e diff usive capacity of the scaff old becomes more evident as the size 
of the cell-biomaterial construct increases: in vivo, most cells exist within 100−200 ?m of a blood 
vessel to provide adequate diff usion (Novosel et al. 2011). However, when cells are transplanted 
into biomaterial scaff olds, the distance from the nearest vessel might increase substantially. Th us, 
the biomaterial must be suffi  ciently porous not to hinder the molecular diff usion even more. 
In the case of larger constructs, means to improve transport should be used, e.g. stimulation of 
angiogenesis inside or into the scaff old (Rouwkema et al. 2008, Novosel et al. 2011).
Considering cell immunoisolation, in addition to oxygen, nutrient and waste transport, the 
encapsulation device should be able to exclude the components of the immune system (Uludag 
et al. 2000, Nafea et al. 2011). Th is is usually achieved using a semipermeable membrane 
surrounding the more porous encapsulation matrix. Th e membrane is designed to have a 
molecular-weight-cut-off  (MWCO) capable to exclude large macromolecules; the membrane 
must allow the outward diff usion of the therapeutic, secreted product (typically ≤ 70 kDa in 
size), but at the same time reject the complement components, immunoglobulins and immune 
cells (typically ≥ 80 kDa in size) (Acarregui et al. 2012). As substances necessary for cell survival, 
such as oxygen and glucose, are small in size (< 1 kDa), they are generally able to freely diff use 
through the membrane. However, the MWCO does not exclusively determine the permeability of 
the membrane and the following mass transport. Charge and geometry of the diff using molecule, 
3D structure of the device and concentration gradients between the outer and inner sides of the 
device also aff ect the permeability characteristics of the system. Moreover, smaller molecules, 
such as cytotoxic cytokines and nitric oxide, induce immunological reactions along with the 
larger sized complement components, antibodies and immune cells (Ríhová 2000, Nafea et al. 
2011). Due to their small size, these molecules are oft en able to diff use through the membrane. 
Th us, the design of permeability and diff usive properties of the immunisolative membrane is not 
straightforward and contains compromises between the levels of cell viability and immuisolative 
capacity.
Biological properties. Th e most important biological property of materials used in cell therapy 
is biocompatibility, referring to the ability of a material to perform without toxic, injurious or 
immunological reactions in the body. Th e biomaterials used must be biocompatible both with 
the transplanted, encapsulated cells and with the host tissue. In cell immunisolation devices, the 
materials should stay inert in relation to the host tissue environment, without causing any immune 
responses (Ríhová 2000, Rokstad et al. 2014). Instead, in tissue engineering, biocompatibility 
includes the desired interactions of the material with the host tissue, and fi nally integration with 
the surrounding environment (Drury & Mooney 2003, Dhandayuthapani 2011). An important 
consideration on biocompatibility is also the characteristics of the cell encapsulation process as 
this should not cause damage to the cells. 
Apart from nontoxicity, the materials used in cell therapy should promote the desired, 
application-dependent cellular functions varying from the long-term production of therapeutic 
proteins to regeneration of new tissues (Ma 2008). Diff erent approaches to improve these cell-
biomaterial interactions are discussed in the following section 2.3.2. In general, the biological 
performance of the material in cell therapy is a complex combination of composition, structure, 
morphology, degradation and mechanical properties. 
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2.3.2  Hydrogels 
Diff erent types of hydrogels are the most commonly used materials for cell encapsulation. 
Hydrogels have many appealing properties as encapsulation materials in cell therapy (Th anos 
& Emerich 2008, Nicodemus & Bryant 2008): Th ey are networks of long polymer chains 
that exhibit high water contents and tissue-like elastic properties. Hydrogels are structurally 
relatively similar to the ECM of many tissues and thus, enable the organization of cells into a 
natural 3D architecture and provide suffi  cient mass transfer. Hydrogels can oft en be processed 
under relatively mild conditions that do not limit cell viability, and they may be delivered in 
a minimally invasive manner. Moreover, many properties important to the functionality of the 
scaff olds in vivo, such as swelling, mechanical properties, degradation and diff usion can be 
modifi ed and controlled through a variety of diff erent processing conditions. Hydrogels can 
be formed through a variety of gelation mechanisms where polymer chains are cross-linked 
by covalent, ionic or physical bonds. Th e commonly used mechanisms for the preparation of 
hydrogels for cell encapsulation include thermal gelation, ionic interaction, physical self-
assembly, photopolymerization and chemical cross-linking. (Tan & Marra 2010, Li et al. 2012)
Based on the polymer origin, hydrogels can be classifi ed into three major types: natural, synthetic 
and hybrid hydrogels. Natural materials inherently contain biological signals and are thus able to 
regulate cell functionality to some extent. Synthetic hydrogels, on the contrary, are biologically 
inert and in most cases require modifi cation with biological factors to promote interactions with 
cells. However, compared to natural polymers, synthetic materials are more easily available; 
they provide the possibility for controlled and reproducible large scale synthesis, while natural 
polymers require isolation from variable sources and complex purifi cation. Moreover, synthetic 
materials can be manipulated at the molecular level using e.g. specifi c molecular weights, block 
structures, degradable linkages and gel formation modes in the synthesis. Hybrid hydrogels 
refer to materials consisting of both natural and synthetic polymers. Th e idea is to combine the 
benefi cial characteristics of these material types: the synthetic part provides reproducible and 
controlled production and structure, and the natural part bioactivity. Regardless of the material 
type used, precise control of the matrix architecture and composition are very critical factors for 
successful cell encapsulation. Natural and synthetic hydrogels commonly used in cell therapy are 
presented in Table 2. (Zhu & Marchant 2011, El-Sherbiny & Yacoub 2013)
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Table 2. Hydrogels commonly used in cell therapy. Origin, molecular structure and typical 
applications of the hydrogels are presented. CI = cell immunoisolation, TE = tissue engineering 
Origin Material Molecular structure Typical 
applications
Natural Alginate
              
Micro- and 
macrocapsules 
for CI, scaff old 
for TE
HA
                 
Microcapsules 
for CI, Scaff old 
for TE
Collagen *
                        
              Glycine                   Proline                  Hydroxyproline
Internal matrix 
in micro- and 
macrocapsules 
for CI, scaff old 
for TE
Chitosan
         
Microcapsules 
and capsule 
coatings for CI, 
scaff old for TE
Fibrin - (protein) Scaff old for TE
Agarose
                 
Micro- and 
macrocapsules 
for CI, scaff old 
for TE
Review of the literature
17
Synthetic PEG                                Micro- and 
macrocapsules 
for CI, scaff old 
for TE
PVA
                                    
Micro- and 
macrocapsules 
for CI, scaff old 
for TE
PHEMA, 
PHPMA, 
PHEMA-
MMA
              
Microcapsules 
for CI, scaff old 
for TE
PNIPAAm
                                   
Scaff old for TE
Co-polymers 
of PEG and 
PGA/PLA/
PLGA
e.g. PLA-PEG 
                   
Scaff old for TE
Pluronic 
F127
(PEG-PPG-
PEG)
           
Scaff old for TE
Synthetic 
self-
assembling 
peptides
e.g. RADA16 Scaff old for TE
*Collagen is a family of macromolecules, a typical characteristic of which is the high content of glycine, proline 
and hydroxyprolin. HA = hyaluronic acid, PEG = polyethylene glycol, PVA = polyvinyl alcohol, PHEMA = 
polyhydroxyethyl methacrylate, PHPMA = polyhydroxypropyl methacrylate, PHEMA-MMA = polyhydroxyethyl 
methacrylate-methyl methacrylate, PNIPAAm = poly-N-isopropylacrylamide, PGA = polyglycolic acid, PLA = 
polylactic acid, PLGA = polylactic-co-glycolic acid, PPG = polypropylene glycol, RADA16 = Arg-Ala-Asp-Ala
Bioactive hydrogels and the extracellular matrix. Due to the complex nature of native ECM, the 
design of biomaterials for replacing the ECM of encapsulated cells is not straightforward. ECM is 
a non-cellular network structure composed of water, proteins and polysaccharides that is present 
within all tissues and organs (Bosman & Stamenkovic 2003, Frantz et al. 2010). It provides 
physical support for the cells, and initiates biochemical and biomechanical signals required for 
tissue morphogenesis, diff erentiation and homeostasis (Kim et al. 2011, Hubmacher & Apte 
2013). ECM aff ects cell behavior both by direct signaling and by modulating soluble signals: 
ECM contains matrix adhesion molecules and receptors where cells are able to attach (Fig 4). 
In addition, ECM binds soluble growth factors and other bioactive molecules and regulates 
their distribution, activation, and presentation to cells. Interactions of cells with these ECM 
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components elicit signal transduction leading to altered gene expression and fi nally, to a specifi c 
biological response (Fig 4). ECM is a dynamic structure that is constantly being remodeled by 
degradation, deposition or post-translational modifi cations of its components. Th e composition 
of ECM is highly regulated and tissue-specifi c; the physical, topological and biochemical 
composition of ECM can vary considerably from one tissue to another or even within one 
tissue. Th us, knowledge on the detailed composition and functions of ECM of diff erent tissues is 
important for the design of cell therapy biomaterials. Naturally, complex bioactive and dynamic 
environments are not easily mimicked with simple biomaterials. Th erefore, diff erent types of 
modifi cations have been performed to achieve bioactive, ECM-like microenvironments and 
improved cell functionality (Shin et al. 2003, Zhu & Marchant 2011, Fisher et al. 2014). Several 
diff erent bioactive molecules or peptide sequences have been incorporated into hydrogels to 
achieve bioactivity, including cell-adhesive peptides, enzyme-sensitive peptides and growth 
factors (Fig 5). Such bioactive or biomimetic hydrogels have shown promising results, and they 
are currently a target of great interest and active research in the fi eld of cell therapy. However, 
as the experience with these modifi ed hydrogels is limited, the practical usability in clinical 
situations is still to be shown.
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response 
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Figure 4. An example on how ECM regulates cell behavior. Cells bind through specifi c transmembrane 
receptors (1) to signaling molecules (e.g. growth factors, GFs) presented by ECM and (2) to the 
structural components of the ECM. Th ese interactions initiate a complex signal transduction cascade 
that leads to changes in gene expression and, eventually, to a specifi c biological response. Th e insert 
illustrates how the 3D structure of ECM can control the presentation of bioactive molecules both 
spatially and temporally. Modifi ed from Lee et al. 2011.
Cell-adhesive hydrogels. Cell attachment to the ECM is an obvious prerequisite for a number 
of important cell functions involved in tissue development, organization and maintenance. 
Bioadhesive peptides incorporated into hydrogels to promote cell adhesion are mainly derived 
from six ECM proteins, including fi bronectin, vitronectin, bone sialoprotein, laminin, collagen 
and elastin. Th e most commonly used cell-adhesive peptide sequence is RGD (Arg–Gly–Asp) 
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derived from the integrin-binding domain of fi bronectin, laminin and collagen (Fig 5) (Niu et 
al. 2005). Other typical peptide sequences used for cell adhesion include fi bronectin-derived 
KQAGDV, REDV and PHSRN (Park et al. 2010), laminin-derived YIGSR, IKVAV and PDGSR 
(Hynd et al. 2007), collagen-derived DGEA and GFOGER (Mineur et al. 2005), and elastin-
derived VAPG  (Mann & West 2002) (reviewed in Zhu & Marchant 2011, Ayres-Sander & 
Gonzalez 2013).
Enzyme-sensitive hydrogels. For successful tissue regeneration, the biomaterial scaff old is 
desired to degrade in a controlled manner. Th e most natural-like strategy is to incorporate 
specifi c cleavage sites sensitive for degradation by enzymes to enable the cells’ own stimuli to 
control the degradation. Most ECM proteins, such as collagen, laminin and fi brin, have specifi c 
cleavage sites for certain enzymes including matrix metalloproteinases (MMPs), plasmin and 
elastase (Lu et al. 2011, Bosman & Stamenkovic 2003). Especially important are MMPs that 
aff ect cellular environment through regulated degradation and processing of ECM proteins. 
Th us, MMP-sensitive sequences including collagen-derived GPQGIAGQ and peptide library-
derived GPQGIWGQ, APGL and LGPA have been used in biomimetic hydrogel design widely 
(Nagase & Fields 1996, Lutolf et al. 2003, Raeber et al. 2005, reviewed in Zhu & Marchant 2011). 
Another approach to create biodegradable hydrogels is the incorporation of sequences sensitive 
to hydrolytic enzymes (e.g. polyester segments such as polylactic acid (PLA) and polyglycolic 
acid (PGA)), leading to degradation by hydrolysis (Han & Hubbel 1997, Clapper et al. 2007).
Growth factor -bearing hydrogels. Growth factors are appealing in cell therapy applications 
since they play a key role in modulating many cell functions, such as diff erentiation, migration 
and proliferation. To mimic the function of the ECM as a reservoir of growth factors, these 
molecules have been incorporated into hydrogels during or aft er the hydrogel fabrication both 
covalently or non-covalently (Silva et al. 2009, Lee et al. 2011). Commonly used growth factors 
in cell therapy include vascular endothelial growth factor (VEGF) (migration, proliferation and 
survival of endothelial cells) (Cleland et al. 2001, Peters et al. 2002), BMP (bone and cartilage 
diff erentiation) (Saito et al. 2001, Selvig et al. 2002), TGFβ (proliferation and diff erentiation of 
bone-forming cells) (Mierisch et al. 2002, Vehof et al. 2002) and nerve growth factor (NGF) 
(survival and proliferation of neural cells) (Kapur & Schochet 2003, Fjord-Larsen et al. 2010) 
(reviewed in Chen & Mooney 2003, Lee et al. 2011.
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Figure 5. A schematic fi gure of a bioactive hydrogel with cell-adhesive and enzyme-sensitive peptides 
(CAP, ESP) and growth factors (GF) incorporated into the structure, and typical examples of these 
modifi cations. Th e modifi cations enable regulated cell attachment and specifi c cellular responses, as 
well as controlled degradation kinetics. Modifi ed from Zhu & Marchant 2011.
2.4  Therapeutic applications
Cell therapy has been investigated for the treatment of a wide range of diff erent disease states 
and injuries. Selected examples of the therapeutic applications of cell immunoisolation and 
tissue engineering are presented in Tables 3 a and b, respectively. In addition, two representative 
examples of these approaches in diff erent stages of development are described in more detail: 
(1) for cell immunisolation, the treatment of diseases of the posterior eye and (2) for tissue 
engineering, repair of cartilage tissue. Cell encapsulation for posterior eye drug delivery is a new 
application with only a few documented studies. On the contrary, cell based cartilage engineering 
is a relatively old approach in the tissue engineering fi eld, and has already been investigated 
widely. Finally, the situation of clinical translation of cell therapy application and associated 
challenges are discussed.
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2.4.1  Treatment of diseases of the posterior eye 
Drug delivery into the back of the eye via conventional routes (topical or systemic 
administration) is very ineffi  cient (Urtti 2006, Gaudana et al. 2010). Th is is due to the anatomical 
and physiological restrictions of the eye, as it is a relatively isolated organ with many barriers 
(Fig 6) (Nakhlband & Barar 2011). Th ere are two main blood-ocular barrier systems in the eye: 
the blood-aqueous barrier limits the entry of substances from the systemic circulation into the 
anterior chamber, while the blood-retinal barrier regulates the molecular diff usion between the 
systemic blood and retina. At the ocular surface, the corneal and conjunctival epithelia, and rapid 
drainage of eye drop solutions prevent molecules from entering the eye (Järvinen et al. 1995). 
Inside the eye, blood fl ow factors and aqueous humour turnover remove molecules. Aft er topical 
administration, typically less than 5% of the dose enters the eye, and only less than 0.01% reaches 
the posterior segment. Similarly, only a minimal portion of the dose administered systemically 
will reach the posterior eye, leading to possible systemic side-eff ects with the required large 
doses. Intravitreal (IVT) injection is the most effi  cient and commonly used delivery route for 
drugs targeted to the posterior segment (Del Amo & Urtti 2008, Th rimawithana et al. 2011). 
However, prolonged treatments of chronic eye diseases oft en require repeated injections that are 
both inconvenient for the patients and expensive for the health care system. In addition, frequent 
injections can cause complications, such as infections and retinal detachment (Sampat & Garg 
2010). 
 
Figure 6. Main structures and barriers of the eye. Th e tear fi lm and corneal and conjunctival 
epithelia at the ocular surface serve as barriers for topically administered drugs (I). For systemically 
administered drugs, the blood-retinal and blood-aqueous barriers limit entry into the eye (II). Ones 
in the vitreous, drugs can be removed through diff usion into the anterior chamber (3) or across the 
blood-retinal barrier (4). From the anterior chamber, drugs can be eliminated by venous blood fl ow 
aft er diff using across the iris surface (1) or by the aqueous humour outfl ow (2). III shows the route for 
IVT injection. Modifi ed from Nakhlband & Barar 2011.
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Diseases aff ecting the posterior eye include age related macular degeneration (AMD), diabetic 
retinopathy (DR) and retinopathy of prematurity (ROP) (Neely et al. 1998, Campochiaro 2013). 
Th ese are severe conditions leading to deterioration or loss of vision without treatment; currently, 
in the industrial countries, ROP, DR and AMD are the leading causes of blindness in infants, 
adults and the elderly, respectively. Although eff ective therapeutic agents for certain forms of 
these diseases have already been developed, associated treatments are complicated by delivery 
issues, since repeated IVT injections must be used for administration (Andreoli & Miller 2007, 
Emerson & Lauer 2007, Farjo & Ma 2010). Th us, the main challenge is the development of safe, 
eff ective, non-invasive and long-acting drug delivery systems for the treatment of the posterior 
eye. As intravitreal delivery is invasive, various controlled release delivery systems have been 
designed to avoid repeated dosing or to extend the dosing interval (Hsu 2007, Del Amo & Urtti 
2008, Th rimawithana et al. 2011). Such systems include biodegradable and non-biodegradable 
polymer implants, liposomes and micro- and nanoparticles. 
Due to the diffi  culties associated with posterior eye drug delivery, cell encapsulation technology 
can be considered as a potential alternative for long-term treatment of diseases aff ecting the back 
of the eye. Intravitreal implantation of encapsulated cells would enable the continuous, long-
term delivery of therapeutic factors into the posterior segment, without the need for repeated, 
invasive dosing. Moreover, due to the immunosuppressive nature of the eye microenvironment 
i.e. ocular immune privilege, cell encapsulation might be an especially suitable therapy form for 
ocular diseases; the unique anatomical features of the blood-retinal barrier, the lack of direct 
lymphatic drainage and the high concentrations of immunosuppressive molecules probably will 
assist the survival of the transplanted cells (Streilein 2003 a, 2003 b, Taylor 2009). Th e feasibility 
of this approach has already been demonstrated with successful intravitreal implantation of 
encapsulated cells for long-term delivery of a neurotrophic factor for the treatment of retinal 
degenerative diseases (Tao et al. 2002, Th anos et al. 2004, Sieving et al. 2006, Zhang et al. 2011, 
Kauper et al. 2012). 
2.4.2  Cartilage repair 
Cartilage is a connective tissue that reduces friction at joints and provides structural support 
in many parts of the body. Cartilage has a low cell density of less than 5% of the tissue volume, 
and, unlike other connective tissues, it does not contain any blood vessels. (Poole et al. 2001, 
Mollenhauer 2008) Due to these characteristics, cartilage exhibits poor capacity for self-repair, 
and thus, cartilage injuries are diffi  cult to treat. Th e unhealed cartilage defects eventually lead 
to degenerative osteoarthritis that is one of the most common causes of disability in developed 
countries with the incidence level of 10–12% of people in western population (Hunter 2011). 
Owing to its limited ability to regenerate, cartilage is a potential candidate for tissue engineering. 
Indeed, the development of cell based cartilage repair techniques has been active already since 
the 90’s, and currently, approaches combining  appropriate cells, biomaterials and signaling 
factors are gradually moving on to the regeneration of native-like, functional cartilage tissue (Fig 
7). (Chung & Burdick 2008, Stoddart et al. 2009)          
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Figure 7. Th e process of cell based cartilage regeneration. Chondrocytes or stem cells isolated 
from the patient are proliferated in vitro, and the proliferated cells are seeded or encapsulated into 
biomaterial scaff olds. Typical scaff old types are hydrogels, sponges and meshes. Th e cell/biomaterial 
graft  is either injected/implanted directly to the body or cultured in vitro prior to implantation. Th e 
culture conditions can be controlled using growth factors or other bioactive molecules, mechanical 
stimulation and bioreactors. Finally, the implanted cells are desired to regenerate cartilage tissue at 
the defect site, while the biomaterial scaff old is gradually degraded. Modifi ed from Chung & Burdick 
2008.
Cartilage is composed of sparsely distributed cartilage cells, chondrocytes, embedded within a 
dense ECM. Th e ECM of cartilage is primarily composed of type II collagen and proteoglycans 
creating a matrix with optimal mechanical properties for functionality. Th e most well-known 
cell based repair strategy for large cartilage injuries is autologous chondrocyte implantation 
(ACI) that uses in vitro enriched chondrocytes from cartilage biopsy (Brittenberg et al. 1994, 
Brittenberg 2008). Th e use of autologous chondrocytes is challenging, however, due to two 
main reasons: (1) the low cell density of cartilage and thus, limited availability of autologous 
chondrocytes and (2) the phenotypic instability during in vitro proliferation leading to 
dediff erentiated chondrocytes with limited capacity for cartilage regeneration (Melero-Martin 
& Al-Rubeai 2007). As an alternative to chondrocytes, bone marrow - and adipose-derived 
stem cells have gained increasing interest as cell sources for cartilage regeneration, and they are 
currently a target of active research (Vinatier et al. 2009a). 
In general, the basic requirements of a biomaterial scaff olds for cartilage regeneration are similar 
to the ones discussed earlier in section 2.3.1, namely suitable bioactivity and -compatibility, mass 
transfer, mechanical properties and degradation. In the case of cartilage tissue, specifi c emphasis 
should be laid on the physical properties of the material; due to the load distributing function of 
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cartilage tissue, appropriate mechanical characteristics and degradation kinetics of the scaff old 
are of particular importance as the material should provide appropriate physical support for the 
implanted cells (Lu et al. 2000, Stoddart et al. 2009). Moreover, the material should adhere and 
integrate with the surrounding native cartilage and subchondral bone, and adapt to fi ll up the 
defect size. Naturally, for the production of ECM typical for cartilage tissue, the material must 
support or restore the chondrocytic phenotype of the encapsulated cells. 
Several biomaterials have been studied as cell delivery vehicles for cartilage tissue engineering 
(Frenkel & Cesari 2004, Viala & Andreopoulos 2009). Commonly used natural materials include 
collagen, gelatin, alginate, agarose, chitosan, fi brin, chondroitin sulfate and hyaluronic acid. Most 
of the clinically used scaff olds are based on these natural materials (e.g. Hyalograft  C, Neocart, 
CaReS, Cartipatch and Chondron) (Freymann et al. 2013, Kon et al. 2013). Representative 
synthetic materials used for cartilage repair include PEG, PGA, PLA, polylactic-co-glycolic acid 
(PLGA) and polyvinyl alcohol (PVA). Materials have been applied in diff erent forms, such as 
hydrogels, porous sponges and meshes. 
In addition to a biomaterial scaff old, the cartilage regenerating potential of chondrocytes or stem 
cells has been promoted using diff erent stimulating factors, including both biological molecules 
and biophysical stimuli. Most commonly used biological molecules are diff erent growth 
factors, such as TGFβ, fi broblast growth factor (FGF), BMP and insulin-like growth factor 
(IGF) (Vinatier et al. 2009b, Gaissmaier et al. 2008). Th ese factors are required to promote and 
maintain chondrocytic phenotype and thus, to regulate cartilage development and homeostasis 
of the mature tissue. Biophysical stimuli include oxygen tension and mechanical signals (Fini 
et al. 2013, Lee et al. 2006, Malda et al. 2003). As an avascular tissue, chondrocytes naturally 
experience low oxygen tension, and hypoxia has been shown to support chondrocytic phenotype. 
Similarly, as under physiological conditions cartilage is subjected to various mechanical stimuli, 
these kinds of signals can be used to maintain and promote functionality of the cells. To apply 
such biophysical signals, bioreactors with specifi c physicochemical parameters, mechanical 
stimuli and fl uid fl ow have been designed to improve in vitro culture conditions (Mabvuure et al. 
2012). 
In conclusion, cell-based therapy has proved to be a feasible strategy for cartilage repair and 
moreover, such therapies have already shown acceptable clinical results (Filardo et al. 2013, 
Kon et al. 2013). However, the goal of regenerating a tissue equal to native cartilage in terms 
of quality and stability has not been reached yet. To achieve this aim, more advanced strategies 
combining the delivery of cells with optimal biomaterial scaff olds, bioactive factors and stimuli 
in a precisely controlled manner have to be developed. Eventually, the success of therapies relies 
on understanding the complex events of cartilage regeneration and maintenance of the mature 
tissue on a molecular level.
2.4.3  Challenges and translation to clinical use
Tissue engineering. Despite active research and promising results in the tissue engineering fi eld, 
only a few products have been translated to actual therapies, including skin replacement and 
cartilage repair (Table 3 b). Th e early success in skin and cartilage engineering provoked high 
expectations within the fi elds, but, in general, these expectations have not been met and the 
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shift  from experimental studies to clinical trials has been slow. One reason for this is that skin 
and cartilage have some exceptional properties compared to many other tissues of the body: as 
skin and cartilage do not require extensive vascularization and have a relatively low metabolic 
rate, the strategy of simply combining cells and biomaterials could be used to create tissue 
structures with certain level of functionality (Berthiaume et al. 2011). Th is is not the case for 
the majority of tissues that require a complex microvascular system and precise spatial control 
of several components inside the graft  enabling appropriate homo- and heterotypic cell-cell 
interactions (Ikada 2006, Atala 2012). Th us, the main challenges for creating functional tissue 
engineered structures are the ability to construct a functional vascular supply and to control the 
3D arrangement of diff erent cell types inside the graft  (Novosel et al. 2011, Rice et al. 2013).
Another issue limiting tissue engineering therapies is the lack of suitable cells in suffi  cient 
quantities; primary cells isolated from the patient are oft en not easily multiplied without 
changing the original phenotype of the cells that enables functional tissue regeneration (Ikada 
2006, Sala et al. 2013). Although stem cells are very promising alternative for regenerative 
therapies, deeper understanding on stem cell biology is needed before they can be successfully 
used for clinical applications (Kim & Evans 2005, Nadig 2009). Naturally, the starting materials 
(cells and scaff olds) must be strictly controlled to enable clinical use. Finally, critical problems 
exist in the translation of the experimental products to clinical use (Berthiaume et al. 2011). 
Medical practitioners are looking for products that are eff ective, reliable, easy to use and cost-
eff ective. Th e current cell based tissue engineering products are oft en expensive and diffi  cult to 
use: they require cell culture processes, specifi c transport and storage, and have a limited shelf-
life. Consequently, the clinical use of the products will probably remain very limited before they 
can be show to provide signifi cantly improved therapeutic outcomes compared to traditional 
methods. Th us, it is important to address the clinical usability of tissue engineering products 
already in the experimental phase.
Cell immunoisolation. Compared to cell based tissue engineering, the clinical translation of 
cell encapsulation for drug delivery has been more slow; no applications of cell encapsulation 
for drug delivery has yet proceeded to clinical use. However, several clinical trials have been 
conducted and are currently ongoing (Table 3 a), the results being usually promising or modestly 
promising. Yet, also clear failures have been seen (Farag et al. 2009, Gross et al. 2011). Despite 
the obvious advantages of protein delivery by encapsulated cells, this approach still possesses 
diffi  culties compared to conventional delivery methods. Th e techniques for production of cell 
capsules are complicated; the presence of living cells requires several additional considerations for 
the manufacturing processes, and technologies enabling the reproducible production of clinical 
grade cell capsules on a large-scale are still to be developed (de Vos et al. 2009, van Zanten & de 
Vos 2010). Moreover, issues related to shipping and storage of cell-based products set limitations 
for use, as techniques enabling simple and eff ective long-term storage of cell capsules do not exist 
currently. Consequently, protein delivery using cells is impractical and more expensive compared 
to traditional methods. Biosafety is another major concern associated to cell encapsulation: both 
the cells and biomaterials have to be strictly controlled in terms of purity and biocompatibility 
(Ríhová 2000, Rokstad et al. 2014). Th e possibility of immune response aft er transplantation 
towards either the encapsulated cells or the encapsulation materials is a substantial concern: 
immune rejections may lead to infl ammation and fi brotic overgrowth of the capsules. Th is might, 
in turn, lead to limited viability of the encapsulated cells and prevent protein diff usion out from 
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the capsules. General issues that might restrict the eff ectiveness of drug delivery by encapsulated 
cells are problems with long-term cell viability and protein production, as well as durability of 
the capsules.
Despite the challenges associated to cell therapies, they still possess potential for signifi cant 
improvements in therapeutic outcomes. Th us, active research and development of associated 
technologies to enable the translation of cell therapy applications to clinical use is justifi ed and 
important. As an interdisciplinary research fi eld, development of cell therapies requires close 
cooperation between diff erent areas, such as material science, chemistry, biology, pharmacy, 
engineering and medicine.
Review of the literature
29
3. AIMS OF THE STUDY
Th e general objective of this study was to investigate the encapsulation of cells in hydrogel 
materials for cell therapy applications. Th e applications involved were (1) cell immunoisolation 
for long-term delivery of therapeutic proteins and (2) tissue engineering for regeneration of non-
functional tissues or organs.
Th e specifi c aims were
1. to develop a  laboratory-scale device for the production of cell microcapsules and to use 
this device for the microencapsulation of ARPE-19 cells genetically engineered to secrete an 
anti-angiogenic protein.
2. to investigate the encapsulation of chondrocytes into a composite hydrogel of collagen and 
hyaluronic acid for cartilage tissue regeneration.
3. to investigate the encapsulation of ARPE-19 cells genetically engineered to secrete an anti-
angiogenic protein into a composite hydrogel of collagen and hyaluronic acid for the long-
term treatment of retinal neovascularization.
4. to develop a PK/PD model to simulate intravitreal drug delivery for the anti-angiogenic 
treatment of retinal neovascularization. 
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4. OVERWIEW OF THE MATERIALS AND METHODS
In Table 4, the main materials and methods used in the studies are described. Th e Roman 
numerals in brackets refer to the studies where each material/method has been used. UE refers to 
materials/methods used in unpublished experiments.
Table 4. Summary of the materials and methods used in studies I–III and in unpublished experiments.
Cells sVEGFR1 ARPE-19 RPE cell line genetically engineered to 
produce sVEGFR1 (I, III, UE)
sVEGFR1 HEK293 Human embryonic kidney cell line 
genetically engineered to produce 
sVEGFR1 (UE)
Primary chondrocytes Cells of cartilage tissue, isolated from 
bovine knees (II, UE)
Encapsulation material Sodium alginate, PLL, CaCl2, BaCl2 APA capsules (I, UE)
Type II bovine collagen, 4SPEG, 
sodium hyaluronate
Incorporated growth factor TGFβ1 (II, UE)
Type I bovine collagen, 4SPEG, 
sodium hyaluronate
(III, UE)
Encapsulation method Microencapsulation based on coaxial 
gas-fl ow extrusion
Ionic cross-linking (alginate and Ca2+ and 
Ba2+ ions), polyelectrolyte complexation 
(alginate and PLL) (I, UE)
Matrix encapsulation Covalent cross-linking (collagen and 
4SPEG), interpenetrating HA (II, III, UE)
Microcapsule and 
device characterization
Production of diff erent sized 
microcapsules with diff erent device 
settings (nozzle and needle size, gas 
fl ow rate)
Determination of microcapsule diameters 
and size variability within and between 
repeats (microscopy, LAS EZ program) (I)
Material 
characterization of type 
I collagen/HA/4SPEG
Diff usion experiments using diff erent 
sized FITC-dextrans
Determination of diff used FITC dextran 
amounts as a function of time (fl uorescence 
measurement) (III)
Material 
characterization of type 
II collagen/HA/4SPEG
Release experiments of TGFβ1 Determinatio of released TGFβ1 as a 
function of time (ELISA) (II)
Optimization of 
protocol for APA 
microencapsulation
Production of microcapsules using 
diff erent material concentrations, 
incubation times, solvents and 
separation methods. 
Determination of cell viability (alamarBlue) 
(UE)
Characterization of the 
encapsulated cells
Viability: alamarBlue metabolic test Fluorescence measurement (I−III, UE)
Viability: LIVE/DEAD staining 
(calcein AM/EthD-1 or FDA/PI)
Imaging with fl uorescence or confocal 
microscopy (I−III, UE)
sVEGFR1 secretion: ELISA Spectrofotometric measurement (I, III, UE)
sGAG production: Blyscan assay Spectrofotometric measurement (II)
DNA quantifi cation: Picogreen assay Fluorescence measurement (II)
Gene expression: qRT-PCR COL1A1, COL2A1, ACAN, GAPDH (II)
PK/PD modeling Matlab soft ware (III)
RPE = retinal pigment epithelium, sVEGFR1 = soluble vascular endothelial growth factor receptor 1, PLL = 
poly-L-lysine, APA = alginate-poly-L-lysine-alginate, 4SPEG = polyethylene glycol ether tetrasuccinimidyl 
glutarate, TGFβ1 = transforming growth factor β1, HA = hyaluronic acid, EthD-1 = ethidium homodimer-1, 
Calcein AM = calcein acetoxymethyl ester, FDA = fl uorescein diacetate, PI = propidium iodide, sGAG = sulfated 
glycosaminoglycan, qRT-PCR = quantitative reverse transcription polymerase chain reaction, COL1A1 = type I 
collagen gene, COL2A1 = type II collagen gene, ACAN = aggrecan gene, GAPDH = glyceraldehyde-3-phosphatase 
gene, FITC = fl uorescein isothiocyanate
Materials and methods
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5. STUDY I: A laboratory-scale device for the 
straightforward production of uniform, small 
sized cell microcapsules with long-term cell 
viability 
Study 1
I
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Microencapsulated and genetically engineered cells may be used for prolonged delivery of therapeutically
active proteins. The objective of this study was to develop a simple, inexpensive and ﬂexible laboratory-scale
device for the production of cell microcapsules, especially capsules of small diameter (b300 μm). Many
microencapsulation devices are expensive, difﬁcult to assemble and to use, and often more suitable for large-
scale experiments. However, the simplicity and low price of the encapsulation system should not limit
the quality of capsules and reproducibility of the process: for successful in vitro and in vivo experiments
it is important to be able to produce uniform, spherical microcapsules without deformities with high
reproducibility. In addition, an advantage of the present procedure compared to other similar, co-axial
laminar gas ﬂow systems is the possibility to produce also small microcapsules, less than 200 μm in diameter,
with narrow size distribution. First, design, optimization and reproducibility testing of this custom-built
device were carried out. Second, microencapsulated retinal pigment epithelial cells (ARPE-19) capable of
secreting soluble vascular endothelial growth factor receptor 1 (sVEGFR1) were engineered. The cells
remained viable in alginate-poly-L-lysine-alginate microcapsules and secreted sVEGFR1 for prolonged
periods.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
Transplantation of microencapsulated cells secreting therapeutic
factors is a potential alternative for long-term treatment of various
disease states such as neurodegenerative, endocrine and mendelian
inherited diseases, as well as cancer [1]. Since the original introduc-
tion of the concept [2] and the ﬁrst experiment with cell micro-
capsules [3], many different techniques and devices to produce
microcapsules have been developed.
The most common techniques applied in cell microencapsulation
are emulsiﬁcation, extrusion and co-extrusion, but also new technol-
ogies, such as microﬂuidics, microlithography andmicromolding have
emerged (for ref. see [4]). Emulsion methods are simple and easy to
scale-up, but only large sized beadswith broad size distribution can be
produced [4]. Extrusion methods utilize the co-axial laminar gas ﬂow,
electrostatic potential, vibrating nozzle and jet cutting [5–8]. In co-
axial gas ﬂow extrusion, the beads are produced when the polymer
solution is dispersed with a laminar co-axial gas ﬂow. This method
was the ﬁrst cell encapsulation technique to be developed and has
thus been used for a long time. It is easy to set up and is a fairly gentle
procedure for the encapsulated cells. Furthermore, this method is not
severely limited by the high viscosity of the polymer solutions used in
the encapsulation process [5,6,8].
At present, cell microencapsulation is often performed with
commercial equipment (e.g. Inotech, Nisco). However, there is a
need for inexpensive and convenient laboratory-scale devices for
microencapsulation experiments, especially in academia. Some
custom-built microencapsulation devices and methods have been
developed previously [9–16]. However, in these studies the descrip-
tion of the device has not been detailed, the quality and size
uniformity of the microcapsules has not been especially good, the
production of small sized microcapsules has not been possible or the
construction and calibration of the system has required special skills.
Our purpose was to design a microencapsulation apparatus that is as
simple and convenient as possible, without compromising the quality
of the produced capsules. Unlike the previous reports on laboratory-
scale devices, we aimed here to produce microcapsules with deﬁned
and adjustable sizes, extending also to microcapsules of less than
200 μm in diameter. Advantages of small cell microcapsules include
more effective exchange of nutrients and other molecules between
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Study 1
encapsulated cells and the environment, improved mechanical
stability and reduced immunological reactions after transplantation
[17].
2. Materials and Methods
2.1. Chemicals
The matrix polymer of microbeads was sodium alginate (UP LVG,
FP-303-02) from Novamatrix (Norway). The beads were cross-linked
with calcium chloride (CaCl2*2H2O, Riedel-de-Haen, Germany) and
barium chloride (BaCl2*2H2O, Merck, Germany). The coating material
poly-L-lysine (PLL) hydrobromide (15–30 kDa) was from Sigma, USA.
2.2. Design of the microencapsulation device
The encapsulation apparatus is based on coaxial gas-ﬂow ex-
trusion. The microcapsules are produced by dispersing the extruded
alginate with an inert gas using a nozzle that allows co-laminar ﬂow
(Fig. 1). The nozzle was built in the workshop of Department of
Chemistry, Aalto University, Finland. For the production of uniformly
sized capsules it is important to center the needle accurately in the
opening of the nozzle. This is achieved with a control tube through
which the needle is positioned in the nozzle (Fig. 2A). The control tube
ends 2–3 mm before the nozzle and the needle protrudes circa 1 mm
out from the nozzle opening (Fig. 1). Nitrogen gas is connected to
the nozzle (Fig. 2D) and it ﬂows through 10 equally sized holes
surrounding the needle and the output hole (Fig. 2B, C). Alginate-cell
suspension is pumped from a syringe using a computer controlled
step motor, enabling precise adjustment of the alginate ﬂow. The
needles used for extrusion are HPLC needles from Hamilton (the
outer/inner diameters of which are 0.26 mm/0.13 mm (gauge 31) –
0.41 mm/0.21 mm (gauge 27), point style 3 with blunt end). The
overall setup of the system is depicted in Fig. 3. The construction
material of the nozzle was Kel-F® (polychlorotriﬂuoroethylene).
The device can be disinfected with ethanol or autoclaved and it can
be placed into a laminar ﬂow hood to ensure sterile production of
capsules.
2.3. Cell culture
The cells for encapsulation were ARPE-19 cells that were ge-
netically modiﬁed to secrete soluble vascular endothelial growth
factor receptor 1 (sVEGFR1) protein. This cell line has proven suitable
for genetic engineering and microencapsulation [18]. ARPE-19 cells
remain viable in a non-dividing state for long periods and are suitable
for prolonged delivery of secreted proteins.
sVEGFR1 cDNA encoding extracellular Ig-domains 1–5 was am-
pliﬁed by PCR using the following primers: Forward 5′-GGG GAC AAG
TTT GTA CAA AAA AGC AGG CTA TGG TCA GCT ACT GGG ACA CC-3′,
Reverse 5′-GGG GAC CAC TTT GTA CAA GAA AGC TGG GTT CAG TGA
TGG TGA TGG TGA TGT GTG ATA TAA AAG CTT ATG TTT CTT CCC AC-3′.
The PCR products were cloned to pDONR201 (Invitrogen) vector using
the Gateway system (Invitrogen) BP reaction. The sVEGFR1 cDNAwas
transferred to a third generation lentiviral vector plasmid with CAG
promoter and WPRE element using Gateway system LR reaction. The
lentiviral vector was produced using calcium phosphate transfection
and concentrated by ultracentrifugation as previously described [19].
200,000 ARPE-19 cells were seeded into the 6-well plate one day
Fig. 1. A diagram showing the gas and alginate jets through the nozzle. (A) Nitrogen
source (B) rotameter to adjust the rate of the gas ﬂow (C) syringe (D) needle (E) control
tube (F) alginate jet (G) cross-linking solution. The blue (/grey) colour indicates gas
ﬂow.
Fig. 2. A technical drawingof the encapsulationnozzle. (A)Control tube throughwhich the
needle is inserted to the nozzle, (B) a cylinder with 10 equal sized holes for gas ﬂow, (C)
nozzle opening, where the control tube places the needle accurately to the center, (D)
connection tube for gas ﬂow to the nozzle. In the upper left corner is a CAD ﬁgure of the
nozzle.
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prior to gene transfer. Transduction was done in 1 ml of cell culture
medium (DMEM-F12 supplemented with 10% FBS) with the multi-
plicity of infection (MOI) 10. Fresh medium was added to the cell
culture the following day. The cells were incubated at 37 °C and 7%
CO2 in the growth medium of DMEM/F-12 (Gibco, 31330) with 10%
fetal bovine serum, 1% l-glutamine, and 1% penicillin–streptomycin.
The medium was changed twice a week.
2.4. Microencapsulation
The encapsulation was carried out as previously described [17]
with minor modiﬁcations. Brieﬂy, the beads were prepared by using
sterile ﬁltered 1.2% sodium alginate solution (in 150 mM NaCl) and
cross-linked with 68 mM CaCl2 (3 min) and 20 mM BaCl2 (5 min)
(both in 13 mM HEPES). The Ca-Ba-alginate beads were further
coated with 0.1% poly-L-lysine (5 min) and 0.125% sodium alginate
(5 min) (both in 150 mM NaCl) and washed 3 times in 13 mM HEPES
buffer. After CaCl2, BaCl2 and poly-L-lysine incubations the solutions
were exchanged by centrifuging for 2 min at 1000×g. After in-
cubation in 0.125% alginate and washings the microcapsules were
ﬁltered with BD Falcon cell strainers, pore size 100 μm.
To prepare cell microcapsules, sVEGFR1 ARPE-19 cells were
detachedwith trypsin, countedwith a hemacytometer and suspended
in 1.2% alginate solution at a density of 2.5×106 cells/ml alginate. The
cell density was optimized according to cell viability and protein
secretion by testing different cell densities between 1.0×105–
4.0×106 cells/ml alginate. Then, the microcapsules were produced
as described above. The cell microcapsules were transferred into the
growth medium (as above) and incubated at 37 °C and 7% CO2. The
medium was changed twice a week. The cell microcapsules used for
long term cell viability and protein secretion studies had a diameter of
250 μm.
2.5. Quality of microcapsules and reproducibility of the device
The reproducibility of the encapsulation system was tested by
preparing Ca-alginate microbeads by using two different nozzles
(nozzle 1 and nozzle 2, output holes 1 mm and 0.8 mm, respectively),
each with 5–6 different gas ﬂow rates. In each case ﬁve independent
measurements were carried out. We used 2% alginate and 68 mM
CaCl2 solutions in these experiments. The 2% alginate concentration
was chosen to demonstrate that the encapsulation system is
functional when alginate solutions of high viscosity are used. The
microcapsules were ﬁltered, transferred to 13 mM HEPES buffer and
photographed with a digital camera connected to an inverted phase
microscope (Leica). From the photographs, the diameters of the
microcapsules were determined using LAS EZ program (Leica). At
least 50 capsules/batch (one gas rate) were measured and the mean
average diameters and standard deviations were calculated.
2.6. Cell viability
Cell viability was measured using the Alamar blue metabolic test
(Invitrogen) and ﬂuorescent LIVE/DEAD staining (Molecular Probes).
Alamar blue: In the Alamar blue viability test the active ingredient
resazurin, a non-ﬂuorescent indicator dye, is converted to bright red-
ﬂuorescent resoruﬁn via the reduction reactions of metabolically
active cells. The amount of ﬂuorescence produced is proportional to
the number of living cells. In this viability test, a known number of
microcapsules (50–100) were incubated in 10% Alamar blue solution
for 4 h. After incubation, 100 μl of the incubation mediums were
transferred to a new plate and the ﬂuorescence was measured with a
plate reader (Varioskan Flash) by using excitation/emission wave-
lengths of 530 nm/590 nm. Microcapsules without cells were used as
a negative control. The number of microcapsules was determined
from photographs taken with a Canon system camera connected to a
stereomicroscope (Meiji) using Image J software.
LIVE/DEAD staining: The ﬂuorescent cell viability/cytotoxicity
tests were performed with a LIVE/DEAD kit (Molecular Probes). In
this assay, the living cells are stained green by the ﬂuorescent calcein
that is hydrolyzed from non-ﬂuorescent calcein AM by the intracel-
lular esterases. Ethidium homodimer-1 (EthD-1) enters only the
damaged cells and yields increased red ﬂuorescence signal upon
binding to nucleic acids. Microcapsules were incubated in 2 mM
calcein AM and 4 mM EthD-1 solution for 20 min. The concentrations
and the incubation time were optimized according to the manufac-
turer's instructions by comparing living and killed cells. Stained cells
were observed under ﬂuorescent microscope (Zeiss) using excitation/
emission ﬁlters 498 nm/518 nm (for calcein AM) and 595 nm/610 nm
(for EthD-1) and photographedwith a digital camera connected to the
microscope.
2.7. sVEGFR1 secretion
The secretion of sVEGFR1 protein from the microencapsulated
cells was determined from medium samples with the ELISA meth-
od by using a commercially available Human Soluble VEGFR1/Flt-1
Immunoassay-kit (Quantikin) in accordance with the manufacturer's
protocol.
3. Results
3.1. Optimization of device parameters
The parameters affecting the size and quality of the produced
microcapsules were (1) rate of gas ﬂow, (2) rate of alginate ﬂow,
(3) distance between the needle tip and the cross-linking solution,
(4) size of the nozzle opening, (5) size of the needle. Factors 2 and 3
mainly had an effect on the quality of microcapsules, and the optimal
parameters determined were 50 μl/s (0.3 mm/s) and 4 cm, respec-
tively. Factors 1, 4, and 5 had themost decisive effect on the size of the
microcapsules. Smaller needle sizes or nozzle opening diameters
resulted in smaller microcapsules. Additionally, by increasing the gas
ﬂow, smaller sized microcapsules were formed. However, microcap-
sule size can be reduced by increasing the rate of gas ﬂow only up to a
certain threshold value. Beyond this level ‘satellites’ (microbeads with
a diameter around 1/10th of the normal capsule size) are generated.
To vary the size over a large scale, nozzles with different sized
openings and different gauge needles were tested while keeping all
other dimensions of the nozzles constant (Table 1). With different
Fig. 3. The cellmicroencapsulation system. (A) Rotameter to adjust the rate of the gasﬂow,
(B) computer controlled stepmotor to adjust the ﬂow rate of the alginate-cell suspension,
(C) encapsulation nozzle, (D) cross-linking solution, (E) connection for the gas.
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nozzles and needles, the size of the microcapsules can be varied from
180 μm to 1000 μm. In this study, two nozzles with different openings
(1 and 0.8 mm) were used in the reproducibility experiments.
3.2. Quality and reproducibility
The size ranges of the microcapsules produced with the used
nozzles were 330–470 μm (nozzle 1) and 180–350 μm (nozzle 2). The
size distributions inside single repeats (intrabatch variation) were
narrow. On average, the standard deviations were 2–5%, depending
on the applied gas ﬂow rate (Fig. 4). In addition, the deviations
between the experiments (interbatch variation) appeared to be small,
on average the standard deviations (calculated using average
diameters of each batch) were 2–3% (Fig. 5). The microcapsules had
a symmetrical spherical shape, no tails or deformities were seen
(Fig. 4).
3.3. Cell microencapsulation
No additional problems were found when utilizing the device for
cellmicroencapsulation. At the highest rates of gasﬂow (57 and 66 ml/
s) some satellites were also formed, but they did not contain any cells.
Thus, the satellites could be ﬁltered from the microcapsules without
losing any cells. Furthermore, no emptymicrocapsuleswere generated
with this system. (Figs. 6a, b and 7) Because the ARPE-19 cells do not
proliferate in the microcapsules, the appearance of the cell micro-
capsules did not change during the culture period (Figs. 6c and 7).
Viability measurements: The Alamar blue test indicates that the
microencapsulated cells remain viable for over four months after the
encapsulation procedure (Fig. 8). The viability was more variable
during the ﬁrst days after encapsulation, but stabilized later to a
constant level. Results from LIVE/DEAD staining indicate that most of
the cells were viable after the microencapsulation (Fig. 9). The
percentage of viable cells was estimated to be over 95% one day after
the microencapsulation.
sVEGFR1 secretion: sVEGFR1 production from the microencapsu-
lated cells increased during the ﬁrst two weeks. Thereafter, the
secretion rate decreased and ﬁnally settled to a constant level, circa
0.17 pg/h/microcapsule (Fig. 10).
4. Discussion
In this article, an inexpensive and convenient laboratory scale
device for the production of cell microcapsules of good quality and
narrow size distribution is presented. The device allows production of
small microcapsules, even below 200 μm in diameter. The micro-
encapsulated cells were shown to be viable and to secrete therapeutic
sVEGFR1 protein over prolonged periods.
As mentioned earlier, other custom-built microencapsulation
devices have been reported before [9–16]. However, many descrip-
tions of the equipment are so general that building identical system
with the information provided is impossible [12,15,16]. In other cases,
the construction methods are demanding, and require, e.g., photoli-
thography and reactive ion-etching methods or separate adjustment
of microstages [13,14]. Sometimes the main objective of the
procedure has been to scale up the production of microcapsules for
large-scale in vivo experiments [10,13], which is not the purpose of
the present study. Moreover, none of the simpler devices reported
have been shown to produce microcapsules less than 300 μm in
diameter, of monodisperse size and without deformities. Finally, the
apparatus introduced in this study is easy to build and to use and
allow the production of small, good quality microcapsules with
narrow size distributions.
Commonly, custom-built microencapsulation devices are designed
for a speciﬁc application, most often for the encapsulation of
pancreatic islets [9–11]. Our purpose was to develop an apparatus
with a ﬂexible design to allow adaptation for many applications.
Primary variables and settings of the device are the diameter of the
nozzle opening, the gauge size of the needle, the applied ﬂow rate of
gas and alginate, and the distance between the needle tip and the
collecting solution. These parameters can be adjusted to ﬁt the needs
Table 1
Equipment settings for the production of microcapsules of different size ranges.
Diameter of the nozzle
opening (mm)
Outer/inner diameter of
the needle (mm) (gauge)
Diameter of
capsules (μm)
Rate of gas
ﬂow(ml/s)
0.8 0.26/0.13 (g31) 220–360 22–44
1 0.26/0.13 (g31) 330–470 22–48
1 0.31/0.16 (g30) 370–630 22–48
1.2 0.36/0.18 (g28) 550–1000 18–44
Fig. 4. The inﬂuence of the nozzle, needle and gas ﬂow rate on microcapsule
morphology. (A) Nozzle 1, g30 needle, gas rate 22 ml/s, (B) nozzle 1, g31 needle, gas
rate 22 ml/s, (C) nozzle 1, g31 needle, gas rate 26 ml/s, (D) nozzle 1, g31 needle, gas rate
31 ml/s, (E) nozzle 1, g31 needle, gas rate 35 ml/s, (F) nozzle 1, g31 needle, gas rate
44 ml/s. Scale bar=300 μm.
600
200
300
400
500
Nozzle1
Nozzle2
0
100
20 30 40 50 60 70
D
ia
m
et
er
of
 m
ic
ro
ca
ps
ul
es
 (μμ
m
)m
Gas flow rate (ml/s)
Fig. 5. Interbatch variation of microcapsule diameter. The microcapsules were
produced using two different nozzles (nozzle 1, output hole 1 mm; nozzle 2, output
hole 0.8 mm) and different gas ﬂow rates. The size of the needle usedwas g31. The error
bars represent standard deviations between the repeats. The results are from ﬁve
independent measurements.
Fig. 6. sVEGFR1 ARPE-19 cell microcapsules viewed with a phase contrast microscope.
(A), (B) Two different sized microcapsule batches at day one after encapsulation
(C) Microcapsules from ﬁgure (B) at day 150 after encapsulation. (4× objective, scale
bar 200 μm).
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of a speciﬁc research purpose when, for instance, different encapsu-
lation protocols and biomaterials are used. Importantly, the only
modiﬁcation required is the diameter of the nozzle opening, which
is a minor alteration and easy to perform. The device is suitable for
in vitro and for small transplantation studies: when using, for in-
stance, 1 ml of alginate suspension, a fairly large amount of beads
(approximately 10,000) can be produced within a few minutes of
extrusion, an amount which is usually enough for laboratory-scale
experiments.
Microcapsule preparation can easily be performed in a completely
sterile manner to ascertain the suitability of the capsules for in vivo
experiments. The only parts which are in direct contact with cells
are the syringe, the needle and the vessels for the encapsulation
materials, which are easy to sterilize. Since the nozzle is not in contact
with the cell-polymer suspension, the sterility of this part is not so
critical – however, if it is found useful, the nozzle can also be auto-
claved. In addition, the gas used can be passed through a sterilizing
ﬁlter before entering the nozzle. Naturally, the whole encapsulation
process should be made in a laminar ﬂow hood. For reproducible
results it is important to avoid blockage of the device: blocking of
the nozzle is not a concern since the polymer-cell suspension makes
no contact. If the same needles are to be used more than once
adequate washing should be performed shortly after the encapsula-
tion process.
ARPE-19 was shown to be a promising cell line for long-term cell
therapy applications. Since ARPE-19 cells do not proliferate in the
microcapsules, the durability of the microcapsules is maintained well
during extended cultures and cell escape from the microcapsules is
not signiﬁcant. Furthermore, a predictable and stable viability and
recombinant protein secretion proﬁle can be achieved due to the long
term non-dividing state of ARPE-19 cells.
Many studies have been published about the effects of the
microcapsule size on molecular permeability, mechanical stability
and biocompatibility of cell microcapsules [e.g. 20–23]. These are
crucial factors for the success of cell therapy. The trend seems to be
towards smaller sizedmicrocapsules as they have been shown to offer
many advantages compared to the more traditional microcapsules.
Yet, the exact optimal size for microcapsules depends onmany factors
including the cell line, cell density and biomaterials used. The
advantages of small microcapsules include better mass-transfer,
mechanical stability, smaller implant size, and more favourable
immunological properties [17]. Moreover, the quality of the micro-
capsules has been associated with the success of in vivo experiments:
smooth and spherical microcapsules induce less ﬁbrotic overgrowth
and foreign body reactions [24]. Considering these factors, it is
important to produce small, spherical and smooth surfaced micro-
capsules. To our knowledge, no other inexpensive custom-built
microencapsulation system produces uniformly sized, high quality
microcapsules under 200 μm in diameter with high reproducibility.
Fig. 7. sVEGFR1 ARPE-19 cell microcapsules viewed with a stereomicroscope (0.5×
objective, dark ﬁeld option).
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Fig. 8. Viability of sVEGFR1 producing ARPE-19 cells in the microcapsules. The viability
is reported as Alamar blue ﬂuorescence as a function of time. The results are average
values calculated from three independent measurements. The error bars represent
standard deviations between the repetitions.
Fig. 9. LIVE/DEAD staining of sVEGFR1 ARPE-19 cells one day after cell microencap-
sulation. Live cells are stained green and dead cells red. (A) A ﬁgure consisting of
approximately 10 microcapsules. (B) Two separate microcapsules with a schematically
constructed shell.
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Fig. 10. Secretion rate of sVEGFR1 from the engineered andmicroencapsulated ARPE-19
cell subline. The results represent average values from three independent measure-
ments. The error bars represent standard deviations between the repetitions.
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5. Conclusions
A simple, inexpensive, convenient and ﬂexible cell microencapsu-
lation system was developed. With the device, it is possible to
reproducibly manufacture uniform, spherical microcapsules with
diameters of under 300 μm. Cells encapsulated with this system
showed prolonged viability and the ability to secrete therapeutic
protein from the microcapsules.
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Abstract In this study, chondrocytes were encapsulated into
an injectable, in situ forming type II collagen/hyaluronic acid
(HA) hydrogel cross-linked with poly(ethylene glycol) ether
tetrasuccinimidyl glutarate (4SPEG) and supplemented with
the transforming growth factor β1 (TGFβ1). The chondro-
cyte–hydrogel constructs were cultured in vitro for 7 days
and studied for cell viability and proliferation, morphology,
glycosaminoglycan production, and gene expression. Type II
collagen/HA/4SPEG formed a strong and stable hydrogel, and
the chondrocytes remained viable during the encapsulation
process and for the 7-day culture period. In addition, the
encapsulated cells showed spherical morphology characteris-
tic for chondrocytic phenotype. The cells were able to produce
glycosaminoglycans into their extracellular matrix, and the
gene expression of type II collagen and aggrecan, genes
specific for differentiated chondrocytes, increased over time.
The results indicate that the studied composite hydrogel with
incorporated chondrogenic growth factor TGFβ1 is able to
maintain chondrocyte viability and characteristics, and thus, it
can be regarded as potential injectable cell delivery vehicle for
cartilage tissue engineering.
Keywords Cartilage tissue engineering . Chondrocyte .
Injectable hydrogel . Type II collagen . Hyaluronic
acid . Transforming growth factor β1
Introduction
Cartilage is a connective tissue composed of sparsely distrib-
uted cartilage cells, chondrocytes, embedded within a dense
extracellular matrix (ECM). The ECM of cartilage is primarily
composed of type II collagen and proteoglycans providing the
tissue with sufficient mechanical properties for function
in vivo. Physiologically, articular cartilage acts as a load-
bearing, low-friction, wear-resistant cushion located at the
ends of long bones to enable painless skeletal movements.
As an avascular, aneural, and alymphatic tissue with low cell
density, cartilage exhibits poor capacity for self-repair. Con-
sequently, cartilage injuries are difficult to treat, and they may
lead to osteoarthritis of the joint. Cell-based tissue engineering
is a potential approach to regenerate damaged cartilage [1–3].
The most well-known cell-based repair strategy for large
cartilage injuries is autologous chondrocyte implantation that
uses in vitro enriched chondrocytes from cartilage biopsy [4].
However, in a monolayer culture, isolated chondrocytes lose
their differentiated phenotype and shift towards a fibroblast-
like phenotype [2, 5]. Interestingly, this process is reversible:
the cells are able to recover their differentiated phenotype
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when they are relocated into a suitable 3D environment [2, 6].
The original cell transplantation protocol has been improved
by combining the expanded chondrocytes into suitable 3D
biomaterial scaffolds [2]. In addition, the incorporation of
specific growth factors to the chondrocyte–biomaterial con-
structs has been shown to promote the tissue regeneration
process [7].
Several biomaterials have been studied as cell delivery
vehicles for cartilage tissue engineering. Natural [collagen,
alginate, agarose, chitosan, fibrin, and hyaluronic acid (HA)]
and synthetic materials [polyethylene glycol (PEG),
polyglycolic acid, polylactic acid, polylactic-co-glycolic acid,
and polyvinyl alcohol] have been used for chondrocyte en-
capsulation [reviewed in 8, 9]. Moreover, different material
forms have been explored including hydrogels, porous
sponges, and fibrous meshes [2]. An optimal biomaterial
should (1) degrade in a controlled manner without cytotoxic
byproducts and it should (2) promote cell viability,
chondrocytic phenotype, and cartilage-like ECM production.
To promote these cellular functions, the scaffold should (3)
allow the bidirectional diffusion of nutrients and waste prod-
ucts. The material should (4) adhere and integrate with the
surrounding native cartilage and adapt to fill up any defect
size. In addition, the scaffold should provide (5) sufficient
mechanical strength and stability [10, 11].
The aim of this study was to develop a biomaterial system
for chondrocyte delivery in the form of an injectable, in situ
forming hydrogel. Injectable materials are able to fill
irregular-shaped defects, which promotes integration of the
transplanted cells and biomaterials with the surrounding tis-
sue. Moreover, injectability allows homogenous cell distribu-
tion, easy incorporation of growth factors, and the use of less
invasive surgical procedures. In situ gelling enables the for-
mation of a mechanically stable scaffold for the transplanted
chondrocytes [12, 13]. Furthermore, due to structural similar-
ity with cartilage tissue, hydrogels can exhibit the required
mechanical, swelling, and lubricating properties [14]. To cre-
ate a delivery vehicle resembling closely cartilage tissue, type
II collagen and the glycosaminoglycan HA were chosen as
basic components of the hydrogel; both polymers are physio-
logical components of cartilage, collagens consisting 60 %
and glycosaminoglycans 25–30% of the tissue dry weight [8].
To form a sufficiently strong and stable, in situ forming
construct, a chemical cross-linker poly(ethylene glycol) ether
tetrasuccinimidyl glutarate (4SPEG) was used. This molecule
has previously shown to be nontoxic for chondrocytes [15]. In
addition, the rheological properties and mechanical stability of
the composite type II collagen/HA/4SPEG hydrogel have
been characterized and found to be suitable for tissue engi-
neering applications [16]. Consequently, type II collagen/HA/
4SPEG hydrogel was considered as a functional delivery
vehicle as it is injectable, biodegradable, and forms a mechan-
ically stable scaffold for chondrocytes in situ.
To promote the chondrocytic phenotype, transforming
growth factor β1 (TGFβ1), a growth factor abundant in native
cartilage, was included into the vehicle. Transforming growth
factor β (TGFβ) family consists of five members (TGFβ1–5)
predominantly expressed in cartilage and bone, and they play
an important role in cartilage development. Especially, TGFβ1
has been shown to stimulate the synthesis of proteoglycans
and type II collagen in chondrocytes [17, 18].
In this study, isolated primary chondrocytes were encapsu-
lated in type II collagen/HA/4SPEG/TGFβ1 hydrogel after
2 weeks expansion in a standard monolayer culture. The
encapsulated cells were studied for 7 days in terms of cell
morphology, viability, proliferation, GAG production, and
gene expression. The results demonstrated that this hydrogel
system is able to promote and maintain viability and
chondrocytic properties of the encapsulated cells. In addition,
the vehicle is injectable and forms a mechanically stable
hydrogel in situ.
Materials and methods
Materials
Type II collagen from calf articular joints was purchased from
Elastin Products Company (USA, Missouri), sodium
hyaluronate (MW 0.75–1.0 MDa) from Contipro group
(Czech Republic), and 4SPEG (MW 10 000) from JenKem
Technology USA (USA, Texas). All other reagents were
purchased from Sigma-Aldrich (Finland) unless otherwise
stated. The multiplate reader used in fluorometric and spec-
trophotometric measurements was Varioskan Flash (Thermo
Fisher Scientific, USA).
Hydrogel formation
4SPEG reacts with the amino groups of collagen fibers to
form a cross-linked hydrogel in approximately 8 min at 37 °C
(Fig. 1). The HA component was mixed with the collagen
solution before cross-linking to form an interpenetrating HA
network inside the collagen gel. The concentrations of colla-
gen, HA, and TGFβ1 were chosen based on our preliminary
results. For the formation of collagen/HA/4SPEG hydrogel,
1,000 μl collagen solution (5 mg/ml in 0.05 M acetic acid)
was mixed with 350 μl HA solution [5 mg/ml in phosphate
buffered saline (PBS)], and the pH was adjusted to 7.4 with
1 M NaOH. TGFβ1 was suspended into this collagen/HA
mixture to achieve a final concentration of 10 ng/ml. The gel
formation was initiated by the addition of 100 μl 4SPEG
(100 mg/ml in PBS) to obtain a final concentration of
1 mM, a cross-linking density that has been shown to be
optimal in a previous study [16]. The solutions were incubated
at 37 °C for 1 h to ensure gel formation.
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Release experiments of TGFβ1 from the hydrogel
To study the release profile of encapsulated TGFβ1 out from
the hydrogel, release experiments for 4 weeks were per-
formed. Briefly, 10 ng/ml TGFβ1 was encapsulated in the
type II collagen/HA/4SPEG hydrogel, and 200 μl of the gel
was pipetted into 48-well plates. Then, 1 ml of PBSwas added
on the gels, and the PBS was sampled for the released TGFβ1
every other day. The gels were kept at 37 °C in a humidified
atmosphere of 5 % CO2. The concentrations of TGFβ1 were
analyzed with ELISA method using Human TGFβ1
Quantikine ELISA Kit (R&D Systems) according to the man-
ufacturer’s protocol. Human recombinant TGFβ1 from the
ELISA kit was used as a standard. In addition, dilutions of
the original TGFβ1 stock encapsulated in the hydrogel were
analyzed to confirm consistency with the kit standard. Release
was studied from three repeats with six parallel samples each.
Chondrocyte isolation and culture
Chondrocytes were isolated from bovine knees with a method
adapted from Pulkkinen et al. [19]. The knees were obtained
from a local slaughterhouse Heikin Liha PLC and used for
research purposes with the permission of the supplier. Briefly,
cartilage was harvested from femoral trochlear groove of 1.5–
2-year-old bovines and minced to small pieces (approximately
2 mm2) with a scalpel. The cartilage pieces were incubated
overnight in digestion medium consisting of 0.5 mg/ml colla-
genase type 1A dissolved in chondrocyte growth medium
[Dulbeccos Modified Eagles Medium (DMEM/F12, Gibco)
containing 10 % fetal calf serum, 1 % L-glutamine, 1 %
fungizone amphotericin B, 100 units/ml penicillin/
streptomycin, and 50 μg/ml ascorbic acid] at 37 °C in a
humidified atmosphere of 5 % CO2. The digested cartilage
was filtered through 70-μl nylon mesh (Prinsal, Finland), and
the isolated chondrocytes were collected by centrifugation,
washed once with PBS, and counted. In total, cells were
isolated from four separate bovines, two knees/animal, and
the cells from the same animal were pooled before using in
experiments. The primary chondrocytes were either seeded
directly to monolayer cultures for expansion or stored in liquid
nitrogen for future use. The seeded cells were expanded for
2 weeks in monolayers with one subculture (from passage 1 to
passage 2, p1→p2) and maintained at 37 °C under 5 % CO2
in chondrocyte growth medium. The seeding density of
chondrocytes was 10,000–15,000 cells/cm2. Medium was
changed three times per week.
Chondrocyte encapsulation
Chondrocytes were encapsulated in type II collagen/HA/
4SPEG hydrogels after 2 weeks expansion in monolayers.
After detachment, the chondrocytes from p2 were suspended
in 100-μl glucose solution (4 g/l in PBS) and mixed with
collagen/HA/TGFβ1 solution of pH 7.4. (see section “Hydro-
gel formation”). After this, the gel formation was initiated by
adding 1 mM cross-linker 4SPEG, and 200 μl of the cell–
polymer solution was pipetted into 48-well plates. The plates
were incubated at 37 °C under 5 % CO2 for 1 h for gel
formation and stabilization, and subsequently, chondrocyte
growth medium was added (1 ml/well) on top of the hydrogels.
Cell density in the hydrogels was adjusted to 20*106/ml. This
seeding density is supposed to be high enough for functional
cell behavior but does not require very extensive cell isolation
processes. The chondrocyte–hydrogel constructs were main-
tained at 37 °C under 5%CO2 for 7 days withmedium changes
every other day. The morphology of the chondrocytes was
observed with a standard phase contrast microscope (Leica).
Cell viability and proliferation
Chondrocyte viabil i ty was measured using the
alamarBlue metabolic test (Invitrogen) and fluorescent
LIVE/DEAD staining.
Fig. 1 Reaction of 4SPEG with
collagen triple helix. 4SPEG
reacts with the amino groups of
collagen fibers to form a cross-
linked hydrogel structure
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alamarBlue: In this viability experiment, the chondrocyte–
hydrogel constructs were incubated in 10 % alamarBlue solu-
tion for 3 h. After incubation, 100 μl of the incubation me-
diums were transferred to a new plate and the fluorescence
was measured with a plate reader using excitation/emission
wavelengths of 530/590 nm. Hydrogels without cells were
used as a negative control. Viability was measured from six
repeats with three parallel samples each.
LIVE/DEAD staining: The fluorescent cell viability/
cytotoxicity experiment was performed with the dyes fluores-
cein diacetate (FDA) and propidium iodide (PI). The chon-
drocyte–hydrogel constructs were incubated in FDA/PI solu-
tion (concentrations 1 and 10 μg/ml, respectively) for 5 min,
and subsequently observed under a confocal microscope
(Leica SP5 II) using excitation/emission wavelengths of 490/
515 nm (for FDA) and 536/617 nm (for PI). LIVE/DEAD
staining was done from six repeats with one or two parallel
samples for each repeat.
Glycosaminoglycan production
The amounts of sulfated glycosaminoglycans (sGAGs) in the
cell–hydrogel constructs were quantified using the Blyscan
Assay (Biocolor, UK). In addition, the DNA amounts were
quantified with a fluorescent Picogreen Assay (Molecular
Probes, Invitrogen) for the normalization of sGAG amounts.
Before these measurements, the cell–hydrogel samples were
digested with 0.5 mg/ml Proteinase K overnight at 60 °C.
Blyscan assay The measurement was performed applying the
manufacturer’s protocol using bovine tracheal chondroitin 4-
sulfate to create the standard curve. The absorbances were
measured with a plate reader at 656 nm.
Picogreen assay The measurement was performed following
the manufacturer’s protocol using Lambda DNA as a stan-
dard. The fluorescence was measured with a plate reader at
480/520 nm.
The sGAG/DNA amounts were measured from six repeats
with two parallel samples for each time point.
Gene expression
The expressions of type I collagen (COL1A1), type II collagen
(COL2A1), aggrecan (ACAN), and glyceraldehyde-3-
phosphatase (GAPDH) were determined with quantitative
real-time PCR (qRT-PCR). The samples were processed with
a rotor–stator homogenizer (Qiagen), and RNA isolated using
Aurum Total RNA Mini Kit (Bio-Rad). The concentrations
and purities of RNA samples were measured with SpectroStar
Nano UV/Vis absorbance spectrometer (BMG Labtech). The
RNAs were reverse transcribed to cDNAwith High Capacity
RNA-to-cDNAKit. qRT-PCRwas performed in StepOnePlus
Real-Time PCR System using Taqman probes (for assay IDs,
see Online resource 1) and TaqMan gene expression Master
Mix. Relative expression levels of the target genes were
calculated by the 2−ΔΔCt method, and the expression levels
were normalized to the reference gene GAPDH. All the re-
agents and devices for cDNA synthesis and qRT-PCR were
fromApplied Biosystems. The gene expression was measured
from six repeats with two parallel samples for each time point.
Statistics
Statistical comparison between time points in the gene expres-
sion analysis was done using Permutation test with Monte
Carlo p-value.
Results
Release experiments of TGFβ1 from the hydrogel
No detectable concentration of TGFβ1 could be observed in
any samples of the release experiments (any repeat, any time
point). Thus, the concentrations of TGFβ1 were under the
detection limit of 31.5 pg/ml during the whole 1-month ex-
periment. When taking into account the amount of encapsu-
lated TGFβ1 (10 ng/ml or 2 ng/200 μl hydrogel), sampling
interval (48 h) and duration of the study (4 weeks), it can be
concluded that the release of TGFβ1 would be slow. Constant
release at the limit of quantitation would result in complete
growth factor release in 128 days.
Chondrocyte encapsulation and hydrogel formation
No practical problems were found during the chondrocyte
encapsulation process. A homogeneous suspension was easily
achieved when mixing cells with the hydrogel components,
and this low-viscosity solution could be easily pipetted or
injected. In addition, after a proper pH adjustment, strong
and stable gels were achieved repeatedly. Cell morphology
was spherical, and this shape was maintained for the whole
culture period with no visible change from day 1 to day 7
(Fig. 2).
Cell viability and proliferation
LIVE/DEAD staining: Based on the FDA/PI staining, most of
the chondrocytes remained viable during the encapsulation
process and the culture period (Fig. 3). The cells were equally
distributed inside the hydrogel, and they exhibited a round
morphology.
alamarBlue: According to the alamarBlue metabolic test,
the metabolic activity of the cell population was stable for
most of the culture period and increased slightly during the
152 Drug Deliv. and Transl. Res. (2014) 4:149–158
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last 2 days (increase in fluorescence signal from day 1 to day 7
was approximately 20%) (Fig. 4). There were no considerable
variations between parallel samples or between different
repeats.
Proteoglycan content
Results from the sGAG quantification indicated that the en-
capsulated cells were able to produce GAGs and accumulate
them into their ECM and into the surrounding medium
(Fig. 5). The sGAG/DNA amounts in the samples increased
almost twofold during the culture period (from 1.3 μg/μg at
day 1 to 2.4 μg/μg at day 7) and the amounts secreted into the
medium almost threefold (from 0.6 μg/μg at day 1 to 1.6 μg/
μg at day 7).
Gene expression
According to the qRT-PCR analysis, the expression of both
type II collagen and aggrecan, genes specific for the differen-
tiated chondrocyte phenotype, increased over the 7-day period
(Fig. 6). For type II collagen, the increase was approximately
16-fold, and for aggrecan, 10-fold from day 1 to day 7. The
increase in aggrecan expression was gradual, while the in-
crease in type II collagen level was more abrupt. The expres-
sion of type I collagen, a gene indicating dedifferentiation of
Fig. 2 Phase contrast microscope
images of chondrocytes
encapsulated in type II collagen/
HA/4SPEG/TGFβ1 hydrogel. a 1
and b 7 days after encapsulation.
20x magnification, scale bar=
200 μm
Fig. 3 Confocal images of
LIVE/DEAD stained
chondrocytes in type II collagen/
HA/4SPEG/TGFβ1 hydrogel.
a, b 1 and c, d 7 days after
encapsulation. a, c 10×
magnification and b, d 20×
magnification. Living cells are
stained green and dead cells red.
Figures are projection images
constructed from the imaged
z-stacks
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chondrocytes, increased fourfold from day 1 to day 7 after a
slight decrease from day 1 to day 4. According to the statistical
analysis, the increase in gene expression levels of collagen
type II and aggrecan was significant both from day 1 to day 4
(p<0.01) and from day 1 to 7 (p<0.005). For collagen type I,
only the change from day 1 to day 7 was significant
(p<0.005).
Discussion
Cell-based therapies are currently considered as highly poten-
tial alternatives for the treatment of articular cartilage defects.
Due to the low cell density of cartilage (cells occupying <5 %
of the tissue volume), isolated primary chondrocytes must be
expanded in vitro before they can be used for treatment.
However, chondrocytes cultured in monolayers lose their
phenotypic characteristics and dedifferentiate towards a
fibroblast-like phenotype [6]. This dedifferentiation is charac-
terized by a decrease in the expression of type II collagen and
proteoglycans, while the expression of type I collagen is
increased. In addition, the round morphology, characteristic
for differentiated chondrocytes, is lost and the cells appear as
spindle shaped. The tissue engineering strategy of autologous
chondrocyte implantation is to apply the ability of
dedifferentiated chondrocytes to restore their primary pheno-
type when located into a suitable 3D environment [2, 6]. Thus,
biomaterial research and the design of 3D scaffolds for chon-
drocyte delivery is a crucial aspect in cartilage regeneration
therapies. As an alternative to chondrocytes, also stem cells
have gained significant interest in the field of cartilage tissue
engineering [2, 9]. As with chondrocytes, the use of stem cells
benefits from the utilization of 3Dmatrixes both as culture and
transplantation scaffolds.
In this study, the potential of an injectable, in situ gel
forming type II collagen/HA/4SPEG composite for phenotyp-
ically stable chondrocyte transplantation was investigated,
and the suitability of this vehicle was characterized by means
of cell viability and morphology, GAG production, and gene
expression. The material selection was based on the structure
and components of native cartilage tissue. As the main mac-
romolecule of articular cartilage, type II collagen is a rational
choice for the scaffold. Indeed, type II collagen has been
shown to be more beneficial compared to type I for the
promotion and maintenance of chondrocytic phenotype
[20–25]. However, type I collagen has been more frequently
used in cartilage tissue engineering [reviewed in, e.g., 8, 11,
26], both due to better availability and gel forming properties
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compared to type II. Collagen has been used in forms of
porous, preformed scaffolds, and plain and cross-linked
hydrogels. To our knowledge, the studied hydrogel is the first
injectable, in situ gel forming, cross-linked type II collagen
based vehicle for chondrocyte transplantation.
HA is a natural GAG found in cartilage and synovial fluid.
As well as contributing to the structural properties of the
ECM, HA may also have important regulatory functions in
cartilage. It has been reported that HA has a role in maintain-
ing the chondrogenic cell phenotype with a direct biological
effect through CD44 receptors of chondrocytes [27].
Due to the load distributing function of cartilage tissue,
appropriate physical characteristics of the scaffold are of
importance. The biomaterial should resemble the mechanical
properties of native cartilage and provide appropriate physical
support for the implanted chondrocytes. However, plain,
noncross-linked type II collagen gel has insufficient mechan-
ical strength and is also prone to enzymatic degradation
[28–30]. Therefore, the gel was strengthened and stabilized
using the cross-linker 4SPEG [16]. This molecule is a
pegylated, branched structure with four terminal N-
hydroxysuccinimidyl (NHS) groups. The NHS groups react
with amine groups of collagen generating a cross-linked,
stabilized structure. Mechanical properties of the formed
collagen/HA/4SPEG hydrogel have been shown to be suitable
as a vehicle for cell therapy of nucleus pulposus, tissue of
which the cells presents a similar phenotype to that of
chondrocytes [16]. In addition, 4SPEG has been shown to
be nontoxic for encapsulated chondrocytes [15].
A potential disadvantage of biomaterials used in cartilage
tissue engineering is the decrease in size, or shrinkage, of the
cell–biomaterial constructs by time. For instance, in chondro-
cyte seeded collagen-GAG matrices, significant decreases in
the original diameters were observed after in vitro culture:
scaffold without cross-linking decreased 80 % after 1 week
and scaffolds with different cross-linkers decreased 30–60 %
after 4 weeks [31, 32]. This phenomenon is mainly dependent
on chondrocyte-mediated contraction and to a less extent on
the degradation of the scaffold material [33]. Shrinking may
impair the tissue regeneration process by limiting cell prolifer-
ation due to pore volume reduction in the material. Further-
more, decrease in the size of the scaffold can cause a loss of
contact between the transplanted construct and the surrounding
tissue and thus prevent the integration of the tissue engineered
graft with host tissue [32]. According to our studies, chondro-
cyte seeded type II collagen/HA/4SPEG hydrogels did not
show any considerable shrinking during in vitro culture (visual
observation). Moreover, previous studies have demonstrated
that no size reduction of this hydrogel was observedwhen used
for nucleus pulposus cell encapsulation [16].
The use of injectable biomaterials for chondrocyte delivery
has been shown to be a potential approach in many studies
[reviewed in 13]. The particular advantage of the studied type II
collagen/HA/4SPEG is, apart from its appropriate hydrogel
components, the usability of the system. Firstly, the gel com-
ponents are available commercially, so no synthetic steps are
needed. Secondly, the properties of the material are practical
from the clinical point of view; as a low-viscosity solution prior
to cross-linking, the vehicle is easy to handle and simple to
inject. The cross-linking reaction results in a stable hydrogel
with a gel formation time of 8 min, a very suitable time-scale
for surgical purposes. Besides easy preparation, the cell–hydro-
gel constructs were sufficiently stable to allow simple culture
and handling, and no visual signs of degradation were seen.
The studied type II collagen/HA/4SPEG hydrogel pos-
sesses certain advantages compared to the conventional and
simple hydrogels used for chondrocyte encapsulation, such as
alginate, collagen, HA, and PEG hydrogels. Firstly, plain gels
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Fig. 6 Relative gene expression levels of type I collagen, type II colla-
gen, and aggrecan of the type II collagen/HA/4SPEG/TGFβ1 encapsu-
lated chondrocytes. The expression levels of hydrogel/cell samples are
shown in proportion to the levels on day 1. GADPH was used as a
reference gene. The results are average values of six repeats with two
parallel samples for each time point. The error bars represent standard
deviations between repeats. *p<0.01, difference between days 1 and 4,
and **p<0.005, difference between days 1 and 7
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without any cross-linking are generally not sufficiently stable
mechanically to serve as a scaffold for cartilage regeneration.
Secondly, the mechanically more stable materials, such as
alginate, do not have suitable gelling kinetics to enable deliv-
ery via injection. Thirdly, hydrogels formed of polymers for-
eign to the body, such as PEG and alginate gels, may be
nondegradable or degrade into unnatural components, which
might lead to adverse reactions. On the contrary, type II
collagen/HA/4SPEG can be delivered conveniently via injec-
tion, and it forms a mechanically stable hydrogel structure.
The gel degrades gradually mainly to collagen and HA that are
natural components of cartilage and the body. It can be con-
cluded that the studied type II collagen/HA/4SPEG hydrogel
possesses a combination of properties advantageous for a
chondrocyte delivery material.
Because the properties of traditional hydrogels are well
known, we did not consider a comparative analysis of these
materials with the studied hydrogel meaningful; comparison
of, e.g., the gene expression of chondrocytes in collagen/HA/
4SPEG and alginate will be difficult to interpret as our gel
system and alginate gel have fundamental differences in com-
position, injectability, and biodegradation. Some benefits of
the studied hydrogel (e.g., injectability and biodegradation)
can be studied only in vivo. In summary, the advantages of the
studied material compared to conventional hydrogels are ev-
ident, and we demonstrate in this study that the material also
supports viability and differentiation of chondrocytes.
The release of TGFβ1 from this hydrogel was fairly slow
(even months). This is beneficial for cartilage regeneration,
since the chondrogenic TGFβ1 would be present for a long
time so that the transplanted chondrocytes have time to syn-
thesize new cartilage tissue. In this study, the purpose of
TGFβ1 was to test the incorporation of bioactive protein into
the hydrogel system. TGFβ1 was chosen due to its important
role in cartilage formation [18] and promising results on the
use of TGFβ1 with chondrocytes [34–36]. In addition, the
extracellular type II collagen increases the effects of TGFβ1 in
dose-dependent fashion in chondrocyte 3D cultures [37, 38].
Yet, to investigate the specific effect of this growth factor in
the hydrogel system, more detailed experiments with non-
TGFβ1 control samples would be needed. In principle, this
hydrogel could also host a combination of growth factors to
mimic more closely the in vivo conditions. Investigation of
the effects of growth factors on chondrocytes is, however,
beyond the scope of this study.
The results showed that chondrocytes survived viable in
the encapsulation process and remained viable for the 7-day
culture period (Figs. 3 and 4). The percentage of dead cells
was less than 10 % (Fig. 3). Cell morphology was spherical,
characteristic for differentiated chondrocytes (Figs. 2 and 3).
Moreover, the cells showed relatively homogeneous distribu-
tion in the hydrogel without aggregration. This was seen in
collated confocal images that represent z-stacks through the
entire hydrogel depth (Fig. 3). In addition, an animation and
an image showing the 3D structure of a hydrogel segment
with LIVE/DEAD stained chondrocytes were constructed to
demonstrate the distribution of cells (Online resources 2 and
3). Besides the 7-day cultures, preliminary long-term experi-
ments of 4 weeks were performed. The data indicated that the
encapsulated chondrocytes maintained their viability also dur-
ing long in vitro periods (increase in alamarBlue fluorescence
signal from day 1 to day 30 was approximately 15 %) (Online
resource 4). Furthermore, the cells appeared as round for the
whole 4 weeks (Online resource 5), and the hydrogels showed
no visible shrinkage.
The biosynthetic activity of the encapsulated chondrocytes
was maintained for 7 days indicated as accumulation of GAGs
into the cell–hydrogel constructs and medium (Fig. 5). This
suggests that the encapsulated cells were able to produce
ECM characteristic for cartilage tissue. This was also demon-
strated in the quantitative gene expression analysis according
to which the expression of chondrogenic genes, type II colla-
gen and aggrecan, increased during 7 days (Fig. 6). The results
suggest compatibility of the material with chondrocytes, and
levels of the selected genes indicate maintenance of
chondrocytic properties of the encapsulated cells. The reason
for the fairly short study period was the intended application
of this system. The scope of the study was to determine the
feasibility of the vehicle for cell delivery purpose, an applica-
tion where the delivered cells would only briefly be attained in
the hydrogel before their introduction into the biological en-
vironment of the joint. Thus, due to the considerable differ-
ences in the environment in vitro and in vivo, detailed long-
term in vitro experiments are not considered specifically in-
formative or important.
Besides type II collagen and aggrecan, also the expression
of type I collagen, indicative of phenotypic dedifferentiation,
was increased (Fig. 6). However, this phenomenon has been
observed also in previous studies [e.g., 39–41]. The mechan-
ical properties and external stimuli in the native tissue will
influence the expression of type I collagen. Thus, although
some dedifferentiation can be observed in vitro, we believe
that after implantation in vivo, the expression of chondrogenic
markers would be restored. It is also worth reporting that the
increase in expression level of type I collagen was consider-
ably less than that of type II. Moreover, type I collagen is a
crucial component of cartilage maturation, and it is known that
chondrocytes exposed to TGFβ1 will demonstrate elevated
COL1A1 expression [42]. Thus, the observed increase in the
type I collagen expression could indicate that the 3D cell
construct is still within a dynamic phase of maturation and
the differentiation process of the chondrocytes is ongoing in
the type II collagen/HA/4SPEG hydrogel.
The conditions for chondrocytes in vivo are different from
those in vitro according to, e.g., multiple growth factor, nutri-
ent and oxygen availability, and mechanical load.
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Consequently, in vitro experiments do not give a complete
view of the material for actual cartilage regeneration in the
body, and further studies are needed to evaluate the in vivo
functionality of the vehicle. Most importantly, the biocompat-
ibility, integration with surrounding tissue and ability of de-
livered cells to regenerate cartilage tissue, must be investigat-
ed in vivo with suitable animal models and test animals.
Nevertheless, our study demonstrated the feasibility of the
type II collagen/HA/4SPEG hydrogel as an injectable, in situ
gel forming chondrocyte delivery vehicle for cartilage repair.
Conclusions
In this study, compatibility of type II collagen/HA/4SPEG/
TGFβ1 hydrogel with primary chondrocytes was demonstrat-
ed with the maintenance and promotion of viability and
chondrocytic properties of the encapsulated cells. In addition,
this in situ gel forming vehicle has the practical advantages of
injectability, easy availability without synthetic chemistry,
stable hydrogel structure, and the possibility for incorporation
of bioactive factors. It can be concluded that type II collagen/
HA/4SPEG hydrogel incorporated with TGFβ1 is potential as
a delivery vehicle of chondrocytes in cartilage tissue
engineering.
Acknowledgments The authors would like to acknowledge Hannu
Kautiainen (MedCare Ltd., Äänekoski, Finland) for assistance with sta-
tistical analysis. This study was supported by the Finnish Funding Agen-
cy for Technology and Innovation (projects Novel biomaterials for carti-
lage tissue engineering and PrinCell II) and by the Emil Aaltonen
foundation.
Conflict of interest All the authors declare that they have no conflict of
interest.
The experiments comply with the current laws of Finland.
No animal or human studies were carried out by the authors for this
article.
References
1. Poole AR, Kojima T, Yasuda T, Mwale F, Kobayashi M, Laverty S.
Composition and structure of articular cartilage: a template for tissue
repair. Clin Orthop Relat Res. 2001;391:S26–33.
2. Chung C, Burdick JA. Engineering cartilage tissue. Adv Drug Deliv
Rev. 2008;60(2):243–62.
3. Mollenhauer JA. Perspectives on articular cartilage biology and
osteoarthritis. Injury. 2008;39:S5–12.
4. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson
L. Treatment of deep cartilage defects in the knee with autologous
chondrocyte transplantation. N Engl J Med. 1994;331(14):889–95.
5. Brittberg M. Autologous chondrocyte implantation–technique and
long-term follow-up. Injury. 2008;39:S40–9.
6. Melero-Martin JM, Al-Rubeai M (2007) In Vitro Expansion of
Chondrocytes. In: Ashammakhi N, Reis R, Chiellini E, editors.
Topics in Tissue Engineering. 2007;chapter 1,pp. 1–37
7. Gaissmaier C, Koh JL, Weise K. Growth and differentiation factors
for cartilage healing and repair. Injury. 2008;39:S88–96.
8. Lu L, Valenzuela RG, Yaszemski MJ. Articular cartilage tissue
engineering. e-biomed. J Regen Med. 2000;1:99–114. doi:10.1089/
152489000420113.
9. Vinatier C, Bouffi C, Merceron C, Gordeladze J, Brondello JM,
Jorgensen C, et al. Cartilage tissue engineering: towards a
biomaterial-assisted mesenchymal stem cell therapy. Curr Stem Cell
Res Ther. 2009;4(4):318–29.
10. Frenkel SR, Di Cesare PE. Scaffolds for articular cartilage repair. Ann
Biomed Eng. 2004;32(1):26–34.
11. Kim IL, Mauck RL, Burdick JA. Hydrogel design for cartilage tissue
engineering: a case study with hyaluronic acid. Biomaterials.
2011;32(34):8771–82.
12. Lum L, Elisseeff J. Injectable Hydrogels for Cartilage Tissue
Engineering. In: Ashammakhi N, Ferretti P, editors. Topics in
Tissue Engineering. 2003;chapter 4,pp. 1−25
13. Amini AA. Nair LS (2012) Injectable hydrogels for bone and carti-
lage repair. Biomed Mater. 2012;7(2):024105.
14. Spiller KL, Maher SA, Lowman AM. Hydrogels for the repair of
articular cartilage defects. Tissue Eng Part B Rev. 2011;17(4):281–
99.
15. Taguchi T, Xu L, Kobayashi H, Taniguchi A, Kataoka K, Tanaka J.
Encapsulation of chondrocytes in injectable alkali-treated collagen
gels prepared using poly(ethylene glycol)-based 4-armed star poly-
mer. Biomaterials. 2005;26(11):1247–52.
16. Collin EC, Grad S, Zeugolis DI, Vinatier CS, Clouet JR, Guicheux JJ,
et al. An injectable vehicle for nucleus pulposus cell-based therapy.
Biomaterials. 2011;32(11):2862–70.
17. Grimau E, Heymann D, Redini F. Recent advances in TGF-β effects
on chondrocyte metabolism. Potential therapeutic roles of TGF-β in
cartilage disorders. Cytokine Growth Factor Rev. 2002;13(3):241–
57.
18. Blaney Davidson EN, van der Kraan PM, van den Berg WB. TGF-β
and osteoarthritis. Osteoarthr Cartil. 2007;15(6):597–604.
19. Pulkkinen HJ, Tiitu V, Valonen P, Hamalainen ER, Lammi MJ,
Kiviranta I. Recombinant human type II collagen as a material for
cartilage tissue engineering. Int J Artif Organs. 2008;31(11):960–9.
20. Nehrer S, Breinan HA, Ramappa A, Young G, Shortkroff S, Louie
LK, et al. Matrix collagen type and pore size influence behaviour of
seeded canine chondrocytes. Biomaterials. 1997;18(11):769–76.
21. Nehrer S, Breinan HA, Ramappa A, Shortkroff S, Young G, Minas T,
et al. Canine chondrocytes seeded in type I and type II collagen
implants investigated in vitro. J Biomed Mater Res. 1997;38(2):95–
104.
22. Nehrer S, Breinan HA, Ramappa A, Hsu HP, Minas T, Shortkroff S,
et al. Chondrocyte-seeded collagen matrices implanted in a chondral
defect in a canine model. Biomaterials. 1998;19(24):2313–28.
23. Veilleux NH, Yannan IV, Spector M. Effect of passage number and
collagen type on the proliferative, biosynthetic, and contractile activ-
ity of adult canine articular chondrocytes in type I and II collagen-
glycosaminoglycanmatrices in vitro. Tissue Eng. 2004;10(1–2):119–
27.
24. Bosnakovski D, MizunoM, Kim G, Takagi S, Okumura M, Fujinaga
T. Chondrogenic differentiation of bovine bone marrow mesenchy-
mal stem cells (MSCs) in different hydrogels: influence of collagen
type II extracellular matrix on MSC chondrogenesis. Biotechnol
Bioeng. 2006;93(6):1152–63.
25. Lu Z, Doulabi BZ, Huang C, Bank RA, Helder MN. Collagen type II
enhances chondrogenesis in adipose tissue-derived stem cells by
affecting cell shape. Tissue Eng Part A. 2010;16(1):81–90.
26. Chang CH, Lin FH, Kuo TF, Liu HC. Cartilage tissue engineering.
Biomed Eng Appl Basis Comm. 2005;17(2):61–71.
27. AkmalM, SinghA, AnandA, Kesani A, AslamN, Goodship A, et al.
The effects of hyaluronic acid on articular chondrocytes. J Bone Joint
Surg Br. 2005;87(8):1143–9.
Drug Deliv. and Transl. Res. (2014) 4:149–158 157
Study 2
50
28. Orban JM, Wilson LB, Kofroth JA, El-Kurdi MS, Maul TM, Vorp
DA. Crosslinking of collagen gels by transglutaminase. J Biomed
Mater Res A. 2004;68(4):756–62.
29. O’Halloran D, Collighan RJ, Griffin M, Pandit AS. Characterization
of a microbial transglutaminase cross-linked type II collagen scaffold.
Tissue Eng. 2006;12(6):1467–74.
30. Ibusuki S, Halbesma GJ, Randolph MA, Redmond RW, Kochevar
IE, Gill TJ. Photochemically cross-linked collagen gels as three-
dimensional scaffolds for tissue engineering. Tissue Eng.
2007;13(8):1995–2001.
31. Lee CR, Breinan HA, Nehrer S, Spector M. Articular cartilage
chondrocytes in type I and type II collagen-GAG matrices exhibit
contractile behavior in vitro. Tissue Eng. 2000;6(5):555–65.
32. Lee CR, Grodzinsky AJ, Spector M. The effects of cross-linking of
collagen-glycosaminoglycan scaffolds on compressive stiffness,
chondrocyte-mediated contraction, proliferation and biosynthesis.
Biomaterials. 2001;22(23):3145–54.
33. Subramanian A, Lin HY. Crosslinked chitosan: its physical properties
and the effects of matrix stiffness on chondrocyte cell morphology
and proliferation. J Biomed Mater Res A. 2005;75(3):742–53.
34. Park H, Temenoff JS, Holland TA, Tabata Y, Mikos AG. Delivery of
TGF-β1 and chondrocytes via injectable, biodegradable hydrogels
for cartilage tissue engineering applications. Biomaterials.
2005;26(34):7095–103.
35. Xiaohong H, Ma L, Wang C, Gao C. Gelatin hydrogel prepared
by photo-initiated polymerization and loaded with TGF-β1 for
cartilage tissue engineering. Macromol Biosci. 2009;9(12):1194–
201.
36. Faikrua A, Wittaya-Areekul S, Oonkhanond B, Viyoch J. In vivo
chondrocyte and transforming growth factor-β1 delivery using the
thermosensitive chitosan/starch/β-glycerol phosphate hydrogel.
J Biomater Appl. 2012;28: In press
37. QiWN, Scully SP. Extracellular collagen modulates the regulation of
chondrocytes by transforming growth factor-β1. J Orthop Res.
1997;15(4):483–90.
38. Qi WN, Scully SP. Effect of type II collagen in chondrocyte
response to TGF-β1 regulation. Exp Cell Res. 1998;241(1):
142–50.
39. Galois L, Hutasse S, Cortial D, Rousseau CF, Grossin L, Ronziere
MC, et al. Bovine chondrocyte behaviour in three-dimensional type I
collagen gel in terms of gel contraction, proliferation and gene
expression. Biomaterials. 2006;27(1):79–90.
40. Chung C, Erickson IE, Mauck RL, Burdick JA. Differential behavior
of auricular and articular chondrocytes in hyaluronic acid hydrogels.
Tissue Eng Part A. 2008;14(7):1121–31.
41. Freyria AM, Ronzière MC, Cortial D, Galois L, Hartmann D,
Herbage D, et al. Comparative phenotypic analysis of articular
chondrocytes cultured within type I or type II collagen scaffolds.
Tissue Eng Part A. 2009;15(6):1233–45.
42. Khan IM, Francis L, Theobald PS, Perni S, Young RD, Prokopovich
P, et al. In vitro growth factor-induced bio engineering of mature
articular cartilage. Biomaterials. 2013;34(5):1478–87.
158 Drug Deliv. and Transl. Res. (2014) 4:149–158
Study 2
51
7. STUDY III: Encapsulated cells for long-
term secretion of soluble VEGF receptor 1: 
material optimization and simulation of ocular 
drug response 
Study 3
III

53
Encapsulated cells for long-term secretion of soluble 
VEGF receptor 1: material optimization and simulation 
of ocular drug response
Leena-Stiina Kontturia* , Estelle C Collinb, Lasse Murtomäkic, Abhay S Panditb, Marjo 
Yliperttulaa, Arto Urttia
aCentre for Drug Research, Division of Pharmaceutical Biosciences, University of Helsinki, 
Helsinki, 00014, Finland
bNetwork of Excellence for Functional Biomaterials, National University of Ireland, Galway, 
Ireland
cDepartment of Chemistry, Aalto University, Aalto FI-00076, Finland
*Corresponding author. e-mail: leena.kontturi@helsinki.fi . Tel.: +358 9191 59155
Abstract
Anti-angiogenic therapies with vascular endothelial growth factor (VEGF) inhibiting factors are 
eff ective treatment options for neovascular diseases of the retina, but these proteins can only 
be delivered as intravitreal (IVT) injections. To sustain a therapeutic drug level in the retina, 
VEGF inhibitors have to be delivered frequently, every 4–8 weeks, causing inconvenience for 
the patients and expenses for the health care system. Th e aim of this study was to investigate 
cell encapsulation as a delivery system for prolonged anti-angiogenic treatment of retinal 
neovascularization. Genetically engineered ARPE-19 cells secreting soluble vascular endothelial 
growth factor receptor 1 (sVEGFR1) were encapsulated in a hydrogel of cross-linked collagen 
and interpenetrating hyaluronic acid (HA). Th e system was optimized in terms of matrix 
composition and cell density, and long-term cell viability and protein secretion measurements 
were performed. sVEGFR1 ARPE-19 cells in the optimized hydrogel remained viable and secreted 
sVEGFR1 at a constant rate for at least 50 days. Based on pharmacokinetic/pharmacodynamic 
(PK/PD) modeling, delivery of sVEGFR1 from this cell encapsulation system is expected to lead 
only to modest VEGF inhibition, but improvements of the protein structure and/or secretion 
rate should result in strong and prolonged therapeutic eff ect. In conclusion, the hydrogel matrix 
herein supported the survival and protein secretion from the encapsulated cells. Th e PK/PD 
simulation is a convenient approach to predict the effi  ciency of the cell encapsulation system 
before in vivo experiments.
Key words: cell encapsulation, ARPE-19 cells, hydrogel, recombinant protein, vascular endothelial 
growth factor inhibitor, retinal neovascularization, pharmacokinetic/pharmacodynamic 
modeling 
Study 3
54
Introduction
Many pathologic conditions in the eye involve the development of abnormal blood vessels or 
neovascularization, which disrupts retinal structure and function, and causes irreversible loss of 
vision (1–3). Such neovascular diseases of the retina, including e.g. retinopathy of prematurity 
(ROP), diabetic retinopathy (DR) and the wet form of age-related macular degeneration (AMD), 
are the leading causes of blindness in industrial countries in all age groups. Despite identifi ed 
molecular targets and eff ective treatment options for neovascularization, the issue of drug 
delivery into the eye has remained a critical limitation of potential therapies (4). Drug delivery 
to the retina via the systemic or topical route is notably ineff ective with less than 0.01% of the 
administered dose reaching the target (5,6). Th is is caused by the relatively isolated anatomical 
position of the eye and many restrictive barriers (the blood-ocular barriers, the corneal and 
conjunctival epithelia), blood fl ow factors and rapid drainage of eye drop solutions from the 
ocular surface. Consequently, IVT injection is the only effi  cacious route for retinal drug delivery. 
However, the treatment of chronic retinal diseases requires repeated IVT injections, a process 
inconvenient for the patient and costly for the health care system.  In addition, frequent IVT 
injections can cause complications, such as infections and retinal detachment. 
Pathologic neovascularization is a consequence of disrupted balance between angiogenic and 
anti-angiogenic factors (1?4). Especially, the overexpression of the angiogenic VEGF has been 
shown to be involved in several pathologic ocular conditions and currently, VEGF is considered 
as the key stimulating factor in retinal neovascularization. Consequently, anti-VEGF therapeutic 
agents have been widely used to treat these diseases. Indeed, VEGF-inhibiting compounds, such 
as pegaptanib (Macugen®) (7), bevacizumab (Avastin®) (8), ranibizumab (Lucentis®) (9) and 
afl ibercept or VEGF Trap-Eye (Eylea®) (10), have shown positive results, such as prevention or 
slowing the progression of neovascularization. Yet, also these treatments are limited by delivery 
issues; the prolonged treatment with these factors requires repeated IVT injections every 4−8 
weeks to sustain therapeutic drug levels in the retina. Th us, the development of safe, eff ective and 
long-acting drug delivery systems for anti-angiogenic factors (e.g. soluble vascular endothelial 
factor receptor 1, sVEGFR1 (11)) would be a major improvement in the treatment of neovascular 
diseases of the retina.
Cell encapsulation technology is a method that enables the continuous, long-term delivery of 
therapeutic factors from the encapsulated cells into a target tissue. Typically, the cell encapsulation 
device isolates the transplanted cells from the host immune system with a polymeric matrix 
surrounded by a semipermeable membrane. Th e cells can be genetically engineered to secrete a 
therapeutic protein or they may be primary cells that have a therapeutic eff ect as such (e.g. islets 
of Langerhans for the treatment of diabetes [12]). Due to the diffi  cult access to the back of the 
eye, cell encapsulation technology is an attractive alternative for long-term treatment of retinal 
diseases. In principle, transplantation of a single cell capsule can provide ocular treatment for 
many years (13?15). Cell encapsulation has been proven to be feasible for intraocular delivery of 
a neurotrophic factor for the treatment of retinal degenerative diseases (16?20). 
In cell encapsulation devices, the internal matrix is critical for the viability and functionality of 
the encapsulated cells; the cells are dependent on their environment within the device in the 
same way as they depend on the extracellular matrix (ECM) in the tissues (21,22). Accordingly, 
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the objective of this study was to fi nd an optimal hydrogel matrix for the encapsulation of 
sVEGFR1 ARPE-19 cells. Th e selected material was a composite hydrogel of type I collagen 
and HA. To create an injectable hydrogel system, polyethylene glycol ether tetrasuccinimidyl 
glutarate (4SPEG) was used to cross-link the collagen molecules. 4SPEG has been shown to be 
non-toxic for adipose derived stem cells, chondrocytes and nucleus pulposus cells (23–25). It 
forms a stable, cross-linked hydrogel structure by reacting with the amino groups of collagen 
in a few minutes gelation time (Fig. 1). Th e strength and diff usional properties of the gel can be 
modifi ed by adjusting the concentrations of collagen, HA and 4SPEG. Since collagen and HA 
are both natural components of the eye tissue, they are expected to serve as a suitable ECM for 
ARPE-19 cells. 
+ ?
Collagen
4SPEG
Figure 1. Reaction of 4SPEG with collagen triple helix. 4SPEG reacts with the amino groups of 
collagen fi bers to form a cross-linked hydrogel structure. 
Overall, we encapsulated genetically engineered ARPE-19 cells that secrete sVEGFR1 into 
collagen/HA/4SPEG hydrogels. Diff erent compositions were tested by varying the concentrations 
of collagen, HA and 4SPEG to develop an optimal hydrogel structure for prolonged therapeutic 
eff ects. In addition, diff erent cell densities inside the hydrogel were studied. With the selected gel 
composition and cell density, long-term viability and protein secretion studies were performed. 
Finally, we simulated the PK/PD profi les of clinical intravitreal anti-angiogenic treatments and 
sVEGFR1 delivery from the encapsulated cells. 
Materials and Methods
Materials 
Type I collagen, solubilized from calf skin, was purchased from Elastin Products Company 
(USA, Missouri), sodium hyaluronate (MW 0.75-1.0 MDa) from Contipro group (Czech 
Republic), and 4SPEG (MW 10 000) from JenKem Technology USA (Allen, TX, USA). All other 
reagents were purchased from Sigma-Aldrich (Finland) unless otherwise stated. Th e multiwell 
plate reader used in fl uorometric and spectrophotometric measurements was Varioskan Flash 
(Th ermo Fisher Scientifi c, Waltham, MA, USA).
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Hydrogel formation
4SPEG forms a cross-linked hydrogel structure with collagen in approximately 8 minutes at 37oC 
(24). Th e HA component was mixed with the collagen solution before cross-linking to form an 
interpenetrating HA network inside the collagen gel. For the formation of collagen/HA/4SPEG 
hydrogel, 1000 ?l collagen solution (in 0.05 M acetic acid) was mixed with 350 ?l HA solution 
(in 5XPBS), and the pH was adjusted to 7.4 with 1M sodium hydroxide. Th e gel formation was 
initiated by the addition of 100 ?l 4SPEG (in 1XPBS). Th e solutions were incubated at 37 oC for 1 
h to ensure gel formation. Th e tested concentration were 1.25–10 mg/ml for collagen, 0–5 mg/ml 
for HA and 0.5–16 mM for 4SPEG (fi nal concentration in the hydrogel).
Cell culture
ARPE-19 cells (ATCC CRL-2302) were genetically engineered to secrete a modifi ed sVEGFR1 
protein consisting of the extracellular Ig domains 1–5 of the native sVEGFR1. Th e molecular 
weight of this modifi ed sVEGFR1 is approximately 70 kDa. Th e stable transfection was carried 
out using a third generation lentiviral vector plasmid (Invitrogen) and calcium phosphate 
precipitation method as previously described (26). Th e cells were culture at 37 °C under a 
humidifi ed atmosphere of 7% CO2 in the growth medium of DMEM/F-12 (Gibco, 31330) with 
10% fetal bovine serum, 1% L-glutamine and 1% penicillin-streptomycin. Th e medium was 
changed three times a week.
Cell encapsulation in hydrogels
sVEGFR1 ARPE-19 cells were detached with trypsin-EDTA solution, suspended in 100 ?l 
glucose solution (4 g/l in PBS) and mixed with collagen/HA solution at pH 7.4 (see section 
“Hydrogel formation”). Aft er this, the gel formation was initiated by adding the cross-linker 
4SPEG, and 200 μl of the cell-polymer solution was pipetted into 48-well plates. Th e plates were 
incubated at 37oC under 7% CO2 for 1 hour for gel formation and stabilization, and subsequently, 
growth medium was added (1 ml/well) on top of the hydrogels. Th e cell-hydrogel constructs were 
maintained at 37oC under 7% CO2 with medium changes every other day. Cells were observed 
regularly with a standard phase contrast microscope (Leica).
Cell viability
Cell viability was measured using the alamarBlue metabolic test (Invitrogen) and fl uorescent 
LIVE/DEAD staining. 
AlamarBlue: In the alamarBlue viability test the active ingredient resazurin, a non-fl uorescent 
indicator dye, is converted to bright red-fl uorescent resorufi n via the reduction reactions of 
metabolically active cells. Th e amount of fl uorescence produced is proportional to the number 
of living cells. In this viability experiment, the cell-hydrogel constructs were incubated in 10% 
alamarBlue solution for 3 h. Aft er incubation, 100 μl of the incubation media were transferred 
to a new plate and the fl uorescence was measured with a plate reader using excitation/emission 
wavelengths of 530/590 nm. Hydrogels without cells were used as a negative control.
LIVE/DEAD staining: Th e fl uorescent cell viability/cytotoxicity experiment was performed 
with fl uorescein diacetate (FDA) and propidium iodide (PI). FDA is a cell-penetrable lipophilic 
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probe that is cleaved in the cells by the esterases, and thereby converted to green fl uorescent 
compound (fl uorescein). Th e probe reports about enzymatic activity (required to activate its 
fl uorescence) and cell-membrane integrity (required for intracellular retention of the fl uorescent 
product), thus indicating cell viability. PI is a red-fl uorescent, membrane impermeable DNA 
stain that is generally excluded from viable cells and consequently labels only dead cells. Th e cell-
hydrogel constructs were incubated in FDA/PI solution (concentrations 1 ?g/ml and 10 ?g/ml, 
respectively) for 5 min, and subsequently observed under a confocal microscope (Leica SP5 II) 
using excitation/emission wavelengths of 490/515 nm (for FDA) and 536/617 nm (for PI). 
sVEGFR1 secretion
Th e secretion of sVEGFR1 protein from the hydrogel encapsulated cells was determined from 
medium samples with the ELISA method using a commercially available Human Soluble 
VEGFR1/Flt-1 Immunoassay-kit (Quantikine, R&D Systems, MN, USA) in accordance with the 
manufacturer’s protocol.
Optimization experiments
To obtain information on eff ect of hydrogel composition on cell viability, diff erent concentrations 
of collagen (1.25–10 mg/ml), HA (0–5 mg/ml) and 4SPEG (0.5–16 mM) were investigated. Also, 
diff erent cell densities (5–80 million cells/ml) were tested to fi nd an optimal encapsulation 
density for cell viability, sVEGFR1 secretion and stability of the system. We performed 3–5 
independent experiments for each variable with 4 parallel samples for each condition.
Long-term experiments
Long-term experiments were performed with the gel composition and cell density selected based 
on the optimization experiments. Th e encapsulated cells were studied in terms of cell viability 
and sVEGFR1 secretion for 50 days. 3 independent experiments with 4 parallel samples were 
performed.
Diffusion experiments 
Molecular diffusion in the hydrogel was studied using ? uorescein isothiocyanate (FITC)-
dextrans with different molecular weights (4, 20, 40 and 250 kDa). The experiments were 
performed in 24-well Transwell plates with polycarbonate membrane inserts of pore size 8 ?m 
(Corning). 75 ?l of hydrogel was prepared on each insert (to achieve the same gel thickness as 
in the cell encapsulation experiments). Then, 100 ?l of dextran solutions (1000 ?g/ml in PBS) 
were loaded on the apical chambers, and 600 ?l of PBS in the basolateral chambers. The plates 
were incubated at 37oC in horizontal shaking, and samples were collected from the basolateral 
chambers periodically. The ? uorescence of the samples were measured with a plate reader using 
excitation/emission wavelengths of 490/530 nm, and the dextran concentrations were calculated 
using standard curves generated with the stock solutions. 4 independent experiments with 6 
parallel samples for each dextran size were performed. Diffusion coef? cients of dextrans were 
calculated using the equation D = (P x h)/K, where D = diffusion coef? cient, P = apparent 
permeability (obtained from the slope of the cumulatively diffused dextran vs. time graph), h = 
the height of the hydrogel and K = hydrogel/water partition coef? cient (assumed to be 1).
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PK/PD modeling
PK/PD simulations of sVEGFR1 and VEGF concentrations in the eye were done with Matlab 
soft ware (MathWorks, USA). Th e simulation model is based on the production and elimination 
rates of sVEGFR1 and VEGF, and the association-dissociation reactions of sVEGFR1 to VEGF, 
and VEGF to VEGF receptor (Fig. 2, Table 1, Supplementary material 1). Th e parameters were 
obtained from previous publications or derived based on published studies (Table 1). Secretion 
rate of sVEGFR1 was taken from the long-term in vitro experiments of this study. A device with 
the size scale suitable for intravitreal implantation was assumed to be a hollow fi ber of 1 mm in 
diameter and 1 cm in length. Th e amount of cells in the device was estimated based on the device 
size, and the secretion rate of sVEGFR1 was estimated based on the cell number. 
sVEGFR1 VEGF VEGFR
R1
E1 E2
R2
A1 A2
D1 D2
[sVEGFR1 · VEGF]
[sVEGFR1 · VEGF]
[VEGF · VEGFR]
[VEGF · VEGFR]
Figure 2. Principle of the PK/PD model. Th e model is based on the production and elimination rates 
of sVEGFR1 and VEGF, and the association-dissociation reactions of sVEGFR1 to VEGF and VEGF 
to VEGFR. Explanations for the factors can be found from table 1. [sVEGFR1 · VEGF] = sVEGFR1-
VEGF complex, [VEGF · VEGFR] = VEGF-VEGFR complex
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Table 1. Descriptions, parameters and equations in the PK/PD simulation model. Th e initial (steady-
state) VEGF concentration was estimated based on the levels in the eyes of wet AMD patients. Other 
parameters in the model are based on PK studies made with rabbits.
Factor Equation Values Ref.
R1, secretion rate of  sVEGFR1 from 
the encapsulated cells
- R1 = 133 (pg/ml)/h1 data in this study
R2, production rate  of VEGF ke2 x Css,VEGF ke2 = 0.376 1/h
Css, VEGF = 275 pg/ml2
R2 = 103 (pg/ml)/h1
27–363
E1, elimination rate of sVEGFR14 ke1 x CsVEGFR1 ke1 = 0.00866 1/h 37–435
E2, elimination rate of VEGF4 ke2 x CVEGF ke2 = 0.376 1/h 27
A1, association rate of  sVEGFR1 to 
VEGF
ka1 x CsVEGFR1 x CVEGF ka1 = 0.108 1/(pM x h) 44
D1, dissociation rate of sVEGFR1 from 
VEGF
kd1 x C[sVEGFR1 · VEGF] kd1 = 3.6 1/h 44
A2, association rate of  VEGF to 
VEGFR
ka2 x CVEGF x CVEGFR ka2 = 0.0547 1/(pM x h) 44,45
D2, dissociation rate of  VEGF from 
VEGFR
kd2 x C[VEGF · VEGFR] kd2 = 4.86 1/h 44,45
Density of VEGFR CVEGFR =
CssVEGFR - C[VEGF · VEGFR]6
CssVEGFR = 14 400 pg/ml 467
1R1 and R2 equal to 200 pg/h and 155 pg/h, respectively (volume of the vitreous humour is expected 
to be 1.5 ml)
2Css, VEGF = the steady-state or initial concentration of VEGF without inhibition
3The steady state or initial concentration of VEGF without inhibition is an average value estimated 
based on the results of several publications. Since the VEGF concentration of AMD patients is usually 
measured from aqueous humour instead of the vitreous, we estimated the intravitreal concentration 
based on the values of aqueous humour. This is possible, since it has been shown that VEGF levels in 
the vitreous correlate with those of aqueous humour (33–36).
4Elimination rates of sVEGFR1-VEGF and VEGF-VEGFR complexes did not have any notable ef-
fect on the simulated concentrations of intravitreal VEGF or sVEGFR1. Thus, for simplicity, the 
elimination rate of sVEGFR1-VEGF complex was set to equal the elimination of sVEGFR1, and the 
elimination of VEGF-VEGFR complex was not included in the model.
5The elimination rate of sVEGFR1 is estimated based on intravitreal pharmacokinetics of other mac-
romolecules.
6The total amount of VEGF receptors is expected to remain constant, so the concentration of VEGFR 
can be calculated based on the steady-state or initial concentration of VEGFR and VEGF-VEGFR 
complexes at every time point.
7The total density of VEGFR in the vitreous is calculated using the area of the eye: the amount of 
VEGFR/cm2 is multiplied by half of the area of a ball of 1.5 ml in volume, which is estimated to cor-
respond the area of the back of rabbit’s eye.
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Results
Optimization experiments
Collagen concentration. Cell viabilities in hydrogels of 5–10 mg/ml collagen were equal (Fig. 3A). 
Th e concentration of 5 mg/ml was selected for the long-term experiments, since compared to 
concentrations of 7.5 and 10 mg/ml, it was easier to handle. Concentrations of 1.25–5 mg/ml led 
to a weaker and less stable hydrogel structure compared to higher concentrations. Consequently, 
these concentrations were not included in the 30 days experiment. 
HA concentration. In the case of varying HA concentrations, slight diff erences in cell viability 
were seen (Fig. 3B). Th e higher the HA concentration was, the lower the viability. Th e diff erences 
in viability were, however, not signifi cant. Since the cells were most viable in a composition 
with no added HA (concentration of HA 0 mg/ml), plain collagen gel was selected for further 
experiments.
4SPEG concentration. Diff erent 4SPEG concentrations had signifi cant eff ects on cell viability 
and stability of the hydrogels (Fig. 3C). At 8 and 16 mM concentrations, 4SPEG did not form 
a proper hydrogel. Instead, the structure was very weak and started to degrade soon aft er its 
formation. In addition, these hydrogels did not support cell viability, and the cells died within 5 
days aft er encapsulation. At 4 mM concentration of cross-linker, moderately more stable gel was 
formed, but also this composition started to degrade aft er one week, and the encapsulated cells 
lost their viability in 20 days. On the contrary, 4SPEG concentrations of 0.5–2 mM led to stable 
hydrogel structures and cell viability. Viability in gels of 2 mM 4SPEG was slightly lower than 
in the gels of 0.5 and 1 mM 4SPEG. Th e 0.5 mM 4SPEG gels were less stable than 1 mM 4SPEG 
gels during the 30 days of culture, and some cells were able to migrate out from the 0.5 mM gel. 
Consequently, 4SPEG concentration of 1 mM was chosen for long-term experiments. 
Cell density. Diff erent cell encapsulation densities of 5–80 million/ml were investigated. 
According to the results, the optimal cell density was 20–40 million/ml; densities under 20 
million/ml or over 40 million/ml led to smaller and less stable cell viabilities (Fig. 3 D). In 
addition to the cell viability, preliminary measurements of sVEGFR1 secretion from hydrogels 
with cell densities of 20 million and 40 million cells/ml were performed. According to the 
results, there was no signifi cant diff erence in the protein secretion rate between these densities 
(Supplementary material 2), and thus, the cell density of 20 million/ml was chosen for further 
experiments. 
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Figure 3. Viability of sVEGFR1 ARPE-19 cells encapsulated in collagen/HA/4SPEG hydrogels of dif-
ferent compositions and with diff erent cell densities. Eff ect of (A) collagen, (B) HA, (C) 4SPEG con-
centrations and (D) cell density on cell viability. Viability is reported as alamarBlue fl uorescence as 
a function of time. Th e graphs are representative results from 3–4 independent experiments with 4 
parallel samples. Th e error bars represent standard errors between the parallel samples.
As a conclusion, the hydrogel composition selected for long-term experiments was 5 mg/ml 
collagen cross-linked with 1 mM 4SPEG  and not supplemented with HA. Th e optimal cell 
density was 20 million/ml.
Diffusion experiments
Diff usion experiments were performed with the optimized hydrogel composition (5 mg/ml 
collagen, 1 mM 4SPEG) for long-term in vitro cell experiments. Th e accumulation of FITC-
dextrans (4 - 250 kDa) into the receiver compartments in Transwells is shown in Fig. 4A. Th ere 
was practically no diff erence between the diff usion rate of 40 kDa and 250 kDa dextrans, which 
indicates that molecules over 40 kDa in size can move relatively freely inside the hydrogel. Th e 
diff usion coeffi  cient ranged from 9.5 x 10−8 to 2.6 x 10−7 cm2/s (Fig. 4B).
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Figure 4. Diff usion of FITC-dextrans through the collagen/4SPEG hydrogel (5 mg/ml collagen, 1 
mM 4SPEG). (A) Cumulative diff usion of dextrans as a function of time. (B) Diff usion coeffi  cients 
(D) of 4–250 kDa dextrans. Graph (A) shows the results from one representative experiment from the 
4 independent experiments. Th e results in (B) are average values of the 4 independent measurements. 
Error bars represent standard deviations between the repeats.
Long-term experiments
Cell viability. According to the alamarBlue metabolic test, viability of the ARPE-19 cells in the 
hydrogels remained stable for 50 days in culture (Fig. 5). In addition, LIVE/DEAD staining 
showed that most of the cells were alive in the hydrogel soon aft er the encapsulation process and 
in the end of the culture period (Fig. 6A,B). 
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Figure 5. Viability of sVEGFR1 ARPE-19 cells encapsulated in the selected hydrogel composition of 5 
mg/ml collagen cross-linked with 1 mM 4SPEG and cell density of 20 million/ml. Viability is reported 
as alamarBlue fl uorescence as a function of time. Th e results are average values of 3 independent 
measurements. Error bars represents standard deviations between the repeats.
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Figure 6. Confocal images of LIVE/DEAD stained sVEGFR1 ARPE-19 cells in collagen/4SPEG 
hydrogel (A) 3 and (B) 50 days aft er encapsulation. Living cells are stained green and dead cells red. 
10X magnifi cation. Scale bar = 80 ?m
sVEGFR1 secretion. Th e protein measurements indicated that the encapsulated cells secreted 
sVEGFR1 for 50 days (Fig 7). Th e secretion rate varied from 4.9 ng/h/4 million cells (hydrogel 
of 200 ?l with 20 million cells/ml) on day 1 to 6.3 ng/h/4million cells on day 19. In general, the 
protein secretion rate was relatively constant during the culture period, especially aft er the fi rst 
ten culture days.  
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Figure 7. Th e secretion rate of sVEGFR1 protein from the sVEGFR1 ARPE-19 cells encapsulated 
in collagen/4SPEG hydrogel reported as (ng/h)/4 million cells. Th e results are average values of 3 
independent measurements. Error bars represents standard deviations between the repeats.
PK/PD simulations
At the selected cell density of 20 million/ml, 157 000 cells can be encapsulated inside a hollow 
fi ber of 1 mm in diameter and 1 cm in length. Based on the results from the long-term 
experiments, the secretion rate of sVEGFR1 from such a device encapsulated with sVEGFR1 
ARPE-19 cells would be approximately 200 pg/h. Using this value in the PK/PD model, the 
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sVEGFR1 concentration reaches an intravitreal steady state concentration of 13 ng/ml aft er 14 
days (time to reach 95% of Css) (Fig. 8A). However, this secretion rate may not to be adequate to 
decrease the level of intravitreal VEGF signifi cantly: the VEGF concentration was simulated to 
decrease from the initial level of 275 pg/ml to 244 pg/ml (i.e. 11% inhibition) (Fig. 8A). 
Diff erent approaches to reach higher VEGF inhibition were simulated. Firstly, VEGF inhibition 
can be increased by improving the affi  nity of sVEGFR1 to VEGF (decreasing the Kd value). In 
Fig. 8B the concentrations of sVEGFR1 and VEGF are shown in a situation, where the affi  nity 
of sVEGFR1 to VEGF is set similar to that of VEGF Trap (afl ibercept), a commercially available 
VEGF inhibitor with high affi  nity to the substrate. At this affi  nity to VEGF, sVEGFR1 is able 
to decrease VEGF level to 93 pg/ml (66% inhibition) at the same secretion rate of 200 pg/h. 
Secondly, by increasing the secretion rate of sVEGFR1 to tenfold (2 ng/h), VEGF concentrations 
decrease to 114 pg/ml (59% inhibition) (Fig. 8C). If both of these modifi cations are combined 
(higher affi  nity to VEGF and higher secretion rate), VEGF is blocked almost completely (99% 
inhibition) (Fig. 8D).
To validate the model, simulations obtained with the model were compared to results of in vivo 
studies from literature. According to the comparisons, the model is functional (Supplementary 
material 3).
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Figure 8. Simulation results from the PK/PD modeling of intravitreal sVEGFR1 delivery by the 
encapsulated cells for 120 days. Intravitreal sVEGFR1 and VEGF concentrations followed by delivery 
of a system with (A) the sVEGFR1 ARPE-19 cells investigated in this study, (B) a modifi ed sVEGFR1 
protein with a higher affi  nity to VEGF, (C) cells with higher production rate of sVEGFR1 and (D) 
both the modifi cations of (B) and (C): cells secreting sVEGFR1 protein with a higher affi  nity to VEGF 
with higher productivity. 
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Discussion
Th e objective of this study was to investigate a cross-linked collagen-HA hydrogel as a matrix for 
encapsulation of genetically engineered sVEGFR1 expressing ARPE-19 cells, to fi nd the optimal 
gel composition for the encapsulation of this cell line and to simulate the intravitreal inhibition 
of VEGF by sVEGFR1. In general, the characteristics of biomaterials used in cell encapsulation 
are critical for the success of associated therapies; in this study, the concentrations of collagen 
and cross-linker were shown to be important factors. Th e materials should address the physical, 
mass transport and biological properties inherent to each application. Research concerning 
biomaterial design and optimization is thus an essential fi eld for the development of cell-based 
therapies. Since hydrogels have many appealing properties as encapsulation materials, we chose 
to use a collagen based hydrogel for this application (47–49). Hydrogels are cross-linked networks 
of long polymer chains that exhibit high water contents and tissue-like elastic properties. Th ey 
are structurally similar to the ECM of many tissues and therefore enable the organization of cells 
into a natural 3D architecture. Hydrogels can oft en be processed under relatively mild conditions 
that do not limit cell viability, and they may be delivered in a minimally invasive manner. 
Cell encapsulation systems typically consist of a surrounding semipermeable membrane and an 
internal matrix substituting for the ECM of the cells (21,22). For most cell types, the internal 
matrix is essential for a successful encapsulation system; as in their natural tissue environment, 
cells are dependent on the structural support and diff usible properties of their surroundings. 
Accordingly, a suitable matrix promotes cell viability and functionality, and provides mechanical 
functions by maintaining the cells dispersed without aggregation. Synthetic and natural matrix 
materials have been used for cell encapsulation systems, including collagen, alginate, chitosan, 
laminin, Matrigel, polyethylene glycol (PEG) and polyvinyl alcohol (PVA) (reviewed in 14,15,21). 
An optimal matrix material should fulfi ll several requirements. It should be compatible with 
the encapsulated cells, the surrounding membrane and the host tissue. It must allow diff usion 
of nutrients, waste and the therapeutic factors. For long-term functionality, the material must 
be suffi  ciently stable mechanically. Finally, loading of the material inside the semipermeable 
membrane structure should be possible. 
Th e cross-linked collagen material used is expected to function as a suitable encapsulation 
material for ARPE-19 cells, since it provides a tissue-like environment for the cells, and the 
gel formation does not limit cell viability. Th e hydrogel can be used as an injectable system by 
adding the cross-linker 4SPEG aft er the cells have been mixed with the polymers; this way, the 
gel formation takes place in a few minutes aft er the addition of the cross-linker, enabling the 
delivery by injection. For instance, this allows easy loading of the cell-hydrogel suspension to 
the semipermeable membrane device, as the suspension can be injected inside the device in a 
liquid form, prior to cross-linking. According to the optimization results, the hydrogel system 
is robust; the hydrogel composition can be varied within a large scale without compromising 
cell viability (Fig. 3A–D). Consequently, the hydrogel may be tuned for many applications 
according to specifi c demands. Th e optimized composition in this study (5 mg/ml collagen 
cross-linked with 1 mM 4SPEG) was optimal for the long-term cell encapsulation system. Th e 
diff usion coeffi  cients of the FITC-dextrans (mw. 4–250 kDa) in the hydrogel (9.5 x 10−8–2 .6 x 
10−7 cm2/s) were in the same range as in alginate and agarose, two hydrogels widely used in cell 
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encapsulation (50). Th erefore, permeability of the hydrogel seems to allow fl uxes of nutrients and 
secreted compounds. 
Originally, a hydrogel consisting of collagen and HA was selected for the encapsulation, since 
the combination of two components of the ocular vitreous was supposed to be benefi cial for 
ARPE-19 cells, a cell line derived from RPE cells. However, the results indicated that HA is not a 
favourable component for the ARPE-19 cell encapsulation, because better cell viability was seen 
with a plain collagen gel. Th is might be due to physical reasons: as HA is not part of the cross-
linking structure of collagen/4SPEG hydrogel, the addition of HA will decrease the tightness 
of the internal hydrogel architecture. Apparently, ARPE-19 cells live better in a more compact 
environment. 
Considering cell density, the best viability and protein secretion was achieved at cell densities of 
20–40 million/ml. At cell densities over 40 million/ml, the nutrient supply and waste removal 
may not be adequate. Th ese conclusions are valid for gel thickness of 2 mm (in this study). If the 
geometry of the hydrogel is diff erent, the situation might change. When the diff usion distance 
becomes shorter, the cells may remain viable even at higher cell densities. Naturally, also the 
outer environment has a signifi cant eff ect on cell survival. For example, in vivo conditions in the 
vitreous are diff erent compared to the in vitro environment in this study. Th erefore, defi nitive 
conclusions on optimal cell density cannot be drawn based on in vitro experiments, but they do 
provide approximate values to be used as a basis for future in vivo experiments.
In this study, sVEGFR1 ARPE-19 cells were shown to remain viable aft er encapsulation in 
collagen/4SPEG hydrogel and to secrete sVEGFR1 protein at least for 50 days. Importantly, both 
the viability and protein secretion remained stable, and did not show any declining trend. Th is is 
essential for the therapeutic applicability of the system, as the aim is the constant release of the 
therapeutic product for a long time. Even though the encapsulated cells were followed here for 
50 days, it is likely that the viability and protein secretion will remain constant longer. Th e system 
stabilizes in a few days aft er the encapsulation, and thereaft er, cell functions seem to remain at 
the same level.
ARPE-19 is a suitable cell line for encapsulation as the cells survive the encapsulation process 
and remain viable in various gel conditions. ARPE-19 cells have a long lifespan, and they can 
be maintained in a non-dividing state over long periods (51). Th is is an essential feature for a 
cell line to be used in an encapsulation system for long-term, stable delivery of therapeutics. 
Moreover, ARPE-19 cells can be genetically modifi ed to produce therapeutic proteins constantly 
(16,17,26,52). In this study, the suitability of ARPE-19 cells for encapsulation in a cross-linked 
collagen/HA hydrogel was shown.  Previously, ARPE-19 cells have been encapsulated in alginate-
poly-L-lysine-alginate microcapsules (26,52). In addition, genetically engineered ARPE-19 
cells have been encapsulated in hollow fi ber membranes of polyethersulfone (1) for intravitreal 
implantation for the treatment of retinal degenerative diseases (CNTF producing ARPE-19 cells) 
(16, 17) and (2) for implantation into the central nervous system to treat Alzheimer’s disease 
(NGF producing ARPE-19 cells) (53,54). In clinical trials, the CNTF secreting capsule has shown 
positive safety profi le and stable production of the therapeutic protein for over 2 years (18–20). 
Also the NGF producing cell capsule has shown promising results, but further refi nement of the 
technology is needed (55).
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Th e studied collagen/(HA)/4SPEG hydrogel may be used as an internal matrix inside a 
semipermeable membrane device. In addition to the conventional cell encapsulation, an 
interesting option would be to use the cell-hydrogel matrix as a plain injectable device, 
without a surrounding membrane. Th is is an attractive option due to its minimally invasive 
administration mode and simplicity as compared to implantable devices. Th e critical question 
is the immunoprotective capability of the hydrogel structure; it must enable suffi  cient 
immunoprotection for the encapsulated cells from the host tissue, and on the other hand 
maintain cell viability and functionality by allowing diff usion of nutrients, waste and secreted 
products. In addition, the mechanical properties (stability, strength) are essential for an injectable 
cell delivery system, since there is no additional protection of the semipermeable membrane. 
Th is kind of injectable delivery system is a more novel approach compared to cell encapsulation 
devices with a separate membrane and intra-capsular structures. To our knowledge, no reports 
on such injectable cell encapsulation devices for ocular applications have been published. 
Notably, the eye can be considered as a potential site for this kind of cell therapy due to the 
immunosuppressive nature of the ocular microenvironment, or ocular immune privilege; the 
unique anatomical features of the blood-retinal barrier, the lack of direct lymphatic drainage, 
and the high concentrations of immunosuppressive molecules probably would assist the survival 
of the transplanted cells (56–58).
PK/PD modeling is an advantageous tool for the investigation of drug effi  cacy and safety before 
in vivo experiments (59,60). Th e eff ects of diff erent modifi cations of the delivery system can 
be tested simply and quickly. Th us, utilizing the simulations, the systems can be optimized to 
a certain level already in the phase of in vitro experiments. Th is saves eff orts and money by 
reducing the need for laborious and expensive in vivo experiments. Previously, VEGF inhibitors 
have been investigated with simulations in terms of their intravitreal activity aft er IVT injection 
(61–63).  In these models, relative total biologic activity of the VEGF inhibitors have been 
calculated by taking into account both the concentration and binding affi  nity of these antibodies. 
However, according to the knowledge of the authors, no models combining the inhibitor activity 
to intravitreal VEGF concentrations has been published. With the model developed in this 
study, both intravitreal sVEGFR1 and VEGF concentrations can be simulated, giving additional 
information on the therapeutic potency of the anti-angiogenic treatment.
According to the PK/PD simulations, the actual sVEGFR1 ARPE-19 cell encapsulation system 
presented in this study would not be adequate as such for the therapy of wet AMD, since the 
predicted reduction of the intravitreal VEGF level was only moderate (approximately 10%). In 
most cases, this is probably not suffi  cient to prevent pathologic neovascularization. However, 
the therapeutic effi  ciency can be improved by modifying the system by either increasing 
the affi  nity of sVEGFR1 to VEGF or by increasing the secretion rate of the protein from the 
cells. Naturally, both of these approaches can also be combined. Th e potency and biological 
activity of VEGF inhibitors can be improved signifi cantly by affi  nity maturation based on the 
principles of mutation and selection or by designing fusion proteins with a combination of 
optimal structures important for binding. Resulting optimized proteins can have considerably 
higher binding affi  nities, such as in the case of bevacizumab and VEGF Trap (64,65). Th ere are 
also many eff ective techniques to increase the translation levels of the transfected gene. Several 
aspects, including methods of transfection, clone screening and selection, and the design of 
the expression vector (e.g. selection of promoter and enhancer elements, addition of specifi c 
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sequences for stabilization and targeting, and codon optimization for enhanced translation) can 
be used to obtain the desired production level of the recombinant product (66–68). With suitable 
engineering, potency and transgene expression can be improved by orders of magnitude.
Th e most uncertain parameter in the model is the initial intravitreal concentration of VEGF. 
Th is uncertainty is a result of two main reasons: (1) Since VEGF concentrations in the eyes of 
patients with AMD are usually measured from aqueous humour instead of the vitreous (28?32), 
the initial intravitreal VEGF concentration is estimated based on the shown correlation of 
aqueous and vitreous humour VEGF concentrations (33–36). Th is estimation might bring some 
uncertainty to the simulations, since the ratio of vitreous to aqueous VEGF concentrations 
has been reported to range from 0.9 to 5.7 (33–36). (2) Th e aqueous humour concentrations 
of VEGF in AMD seem to be quite variable between patients and disease states; the VEGF 
concentrations have been reported to vary over 16-fold (28–32). Consequently, it is not possible 
to give the initial VEGF concentration a certain, fi xed value. However, based on a sensitivity 
analysis on the eff ects of varying VEGF concentrations on the simulation results of the PK model 
(Supplementary material 4), changes in the initial VEGF level do not have a signifi cant eff ect 
on the simulation outcome. An exception is a modifi ed system with slow secretion of sVEGFR1 
combined to a very high affi  nity of sVEGFR1 to VEGF: in this system, the inhibitory eff ect is 
decreased along increasing VEGF concentrations. Th is should be taking into consideration when 
designing modifi cations to achieve an improved delivery system; based on the results of the 
model, increased affi  nity must not be used as the only modifi cation, but should be combined 
with an increased secretion rate. 
Intravitreal delivery of VEGF inhibitors by encapsulated cells off ers several advantages compared 
to the currently used delivery method. Th e most evident benefi t is the avoidance of frequent IVT 
injections associated with patient inconvenience and expensive treatment regimens, as well as 
reduction of associated health risks (69).  In addition, the potential risks associated with high 
peak concentrations of VEGF inhibitors followed by injection can be avoided, since encapsulated 
cells allow continuous and stable delivery of the anti-angiogenic product. For instance, the 
intravitreal Cmax of bevacizumab has been reported to be 400 ?g/ml one day aft er injection in 
rabbit eyes (37,70). Probably, the actual local peak concentration is even higher, if measured 
immediately aft er injection. Yet, according to in vitro assays, the median inhibition concentration 
of bevacizumab is 22 ng/ml (71), a concentration over 18 000 times lower than the Cmax. Th us, 
it is evident that a much lower VEGF inhibitor concentration than the one delivered via IVT 
injection would be suffi  cient for therapeutic effi  ciency. Without the need for considering the 
maintenance of therapeutic levels between injections, the amount of used drug could be reduced 
signifi cantly. Th is might be of particular value in the case of VEGF inhibitors: since VEGF in an 
important physiological regulator of angiogenesis, complete blockage of this growth factor might 
cause adverse eff ects, especially in high-risk subgroups (72). With a cell encapsulation system, 
the delivery of the inhibitors can be controlled more carefully and set to a level that inhibits 
pathological neovascularization, but at the same time allowing normal VEGF function in the 
body. 
Naturally, as a non-established technology for drug delivery, cell encapsulation still possesses 
several aspects that need to be carefully considered before these devices can enter the clinical 
practice. Th ings to be improved include biosecurity, standardized technology, reproducibility, 
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scale-up and cost. Particularly, it is important to develop reproducible and biocompatible 
materials for making stable and immunocompatible devices. Diff erent cell-based devices are 
currently being investigated for clinical application. Th e results have oft en been either promising 
or modestly promising (e.g. 18–20, 73–75), but also clear failures have been seen (76, 77). 
Along with the technical and biological advances and increasing experience in the fi eld, cell 
encapsulation technology has the potential to solve many long-term drug delivery associated 
problems.
Conclusions
In this study, we encapsulated genetically engineered cells that secrete soluble VEGF receptor 
1 in cross-linked collagen/HA hydrogels. In the optimized gel composition, the cells remained 
viable and secreted the anti-angiogenic protein constantly for prolonged periods. PK/PD 
simulation model was developed for investigating and predicting intravitreal drug delivery with 
anti-angiogenic systems.  Th e model can be used to guide delivery system design before in vivo 
experiments. Th e anti-angiogenic protein delivery by encapsulated cells may off er constant and 
prolonged drug activity in the retina without repeated dosing. Th is approach for the treatment of 
neovascular retinal diseases warrants further studies. 
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8.  ADDITIONAL UNPUBLISHED EXPERIMENTS 
8.1 Encapsulation of sVEGFR1 producing ARPE-19 and 
HEK293 cells in APA microcapsules: optimization of the 
encapsulation protocol
sVEGFR1 producing ARPE-19 and HEK293 cells were encapsulated in APA microcapsules using 
protocols with varying parameters. Th e variables were (1) the concentrations of alginate, PLL 
and the cross-linking solutions (CaCl2, BaCl2), (2) incubation times in PLL and cross-linking 
solutions, (3) solvent used to dissolve alginate and (4) method used so separate the capsules from 
diff erent solutions during the encapsulation process. Th e microcapsules were evaluated based on 
cell viability (alamarBlue) and durability of the capsules during cell culture (amount of ruptured 
or deformed capsules and possible cell escape from the capsules, visual observation). Results are 
presented in Table 5.
Table 5. Results from the optimization experiments of APA microencapsulation protocol for 
sVEGFR1 ARPE-19 and HEK293 cells. Values or alternatives of the variables, results and magnitude 
of the eff ect are described.
Variable Values/alternatives Results Magnitude of eff ect
[alginate]1 1.2, 1.5, 2 % Th e higher the 
concentration, the stronger 
the capsules and the lower 
the cell viability.
Moderate
[PLL] + 
incubation time
0, 0.1%, 3−10 min PLL-coated capsules 
stronger, but cell viability 
lower. Th e longer the 
incubation time, the 
stronger the capsules and 
lower the cell viability.
Signifi cant for HEK293 
cells, moderate for 
ARPE-19 cells
[CaCl2] + 
incubation time
40 mM, 68 mM, 100mM, 3−10 
min
No notable eff ect on 
cell viability or capsule 
durability.
-
[BaCl2] + 
incubation time
1.5 mM, 10 mM, 20 mM, 3−10 
min
Th e higher the 
concentration or longer 
the incubation time, the 
lower the cell viability and 
the stronger the capsules.
Moderate for HEK293 
cells, slight for ARPE-
19 cells
Solvent2 H2O, 150 mM NaCl, PBS Lower cell viability 
with H2O, no diff erence 
between NaCl and PBS. 
No notable eff ect on 
capsule durability.
Moderate for HEK293 
cells, slight for ARPE-
19 cells
Separation 
method3
Centrifugation, BD Falcon cell 
strainers, custom-made strainers
No notable eff ect on 
cell viability or capsules 
durability.
-
PBS = phosphate buff ered saline
1[ ] = concentration
2Solvent used to dissolve alginate
3Method used so separate the capsules from diff erent solutions during the encapsulation process.
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Based on the results, the optimized protocol was determined to be the following:
1. Cells encapsulated in 1.2% alginate dissolved in 150 mM NaCl
2. Cross-linking with 68 mM CaCl2 (3 min) and 20 mM BaCl2 (5 min)
3. Coating with 0.1% PLL (5 min)
4. Coating with 0.125% alginate dissolved in 150 mM NaCl
Separation was done by centrifugation in all other phases, except with BD Falcon cell strainers in 
the last phase (separation of the capsules from 0.125% alginate). Th is selection was done based 
on practical reasons.
Conclusions
In the encapsulation of sVEGFR1ARPE-19 cells, the parameters could be varied on a large 
scale without signifi cant eff ects on cell viability. sVEGFR1 HEK293 cells were more sensitive; 
the viability of these cells decreased signifi cantly in certain capsule types. Most importantly, 
sVEGFR1 HEK293 cells could not survive in capsules with a PLL coating, but without a PLL 
coating the capsules were very weak: cell escape and capsule disintegration was seen in a few 
days aft er encapsulation. For these reasons, sVEGFR1 ARPE-19 cells were selected for further 
experiments and an optimized protocol for APA microcapsule preparation for this cell line was 
determined.
8.2 Encapsulation of chondrocytes in different materials: 
selection of the most suitable material
To fi nd the most suitable material for chondrocyte encapsulation, diff erent hydrogel materials 
were tested. In addition, the most promising materials were tested with a non-woven poly-L/D-
lactide (PLDLA) scaff old by impregnating the cell-hydrogel suspension into this scaff old (the 
PLDLA scaff olds were obtained from Minna Kellomäki’s research group, Tampere University 
of Technology, Department of electronics and communications engineering, Laboratory 
for biomaterials and tissue engineering). Th e function of the PLDLA scaff old was to increase 
mechanical strength of the construct. Th e suitability of the materials were evaluated based on 
cell viability (alamarBlue and LIVE/DEAD staining with confocal imaging), cell morphology, 
mechanical stability during cultures (visual observation) and the ability to be used as an 
injectable vehicle. Cell morphology can be used to evaluate the phenotypic stability of 
chondrocytes: spherical cell shape is typical for chondrocytic phenotype, while spindle shape 
indicates dediff erentiation towards a fi broblast-like phenotype.
Th e investigated encapsulation matrixes included alginate, fi brin and type I collagen, alone or 
in combination with HA, nanocellulose (UPM-Kymmene Corporation, Finland), Extracel 
(commercial cross-linkable HA/gelatin hydrogel, Glycosan BioSystems), Puramatrix (commercial 
self-assembling peptide hydrogel, BD Biosciences) and photocross-linkable HA (methacrylated 
HA + photoinitiator Irgacure 2959). As collagen/HA/4SPEG and Extracel appeared to be the 
most promising materials for chondrocyte encapsulation, these hydrogels were tested also in 
combination with PLDLA scaff olds. Results are presented in Table 6.
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Table 6. Results from the experiments of chondrocyte encapsulation in diff erent materials. Positive/
negative properties of the materials, results of the viability experiments and morphology of the 
encapsulated cells are described.
Material Positive properties/results Negative properties/results Cell morphology2
Alginate (+HA)1 Good cell viability and mechanical 
properties
Degradation products foreign 
to the body, non-injectable
Spherical
Fibrin (+HA)1 Good cell viability Shrinkage during culture, non-
injectable
Some spherical, 
many spindle-
shaped
Type I collagen 
(+HA)1
Good cell viability, injectable Very poor mechanical 
properties.
Some spherical, 
many spindle-
shaped
Nanocellulose3 Good cell viability, injectable Very poor mechanical 
properties, degradation 
products foreign to the body.
Spherical, some 
spindle-shaped
Extracel4 Good cell viability, injectable Relatively poor mechanical 
properties
Mostly spherical, 
some spindle-shaped
Puramatrix5 Good cell viability, injectable Poor mechanical properties Some spherical, 
many spindle-
shaped
Photocross-
linkable HA6
Injectable Very poor cell viability -7
Type II collagen/
HA/4SPEG
Good cell viability and mechanical 
properties, injectable 
- Spherical
Type II collagen/
HA/4SPEG + 
PLDLA scaff old
Homogeneous distribution of the 
cell-hydrogel suspension inside 
the scaff old, good cell viability and 
mechanical properties
Th e composite scaff old is non-
injectable
Spherical, some 
spindle-shaped
Extracel + 
PLDLA scaff old
Relatively homogeneous 
distribution of the cell-hydrogel 
suspension inside the scaff old, 
good cell viability
Relatively poor mechanical 
properties of the hydrogel 
component: over time, the gel 
degraded/leaked out from the 
scaff old, the composite scaff old 
is non-injectable
Some spherical, 
many spindle-
shaped
HA = hyaluronic acid, PLDLA = poly-L/D-lactide, 4SPEG = polyethylene glycol ether 
tetrasuccinimidyl glutarate
1Addition of HA to the hydrogels did not have any eff ect on cell viability, but the composite hydrogels 
were slightly less stable.
2Round cell shape is typical for chondrocytic phenotype, spindle shape indicates dediff erentiation.
3Commercial cross-linkable HA/gelatin hydrogel, Glycosan BioSystems
4Commercial self-assembling peptide hydrogel, BD Biosciences
5Nanocellulose, UPM-Kymmene Corporation, Finland 
6Methacrylated HA + photoinitiator Irgacure 2959
7Practically all cells were dead immediately aft er encapsulation.
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Conclusions
Type II collagen/HA/4SPEG was selected to be used in further studies because of the many 
favourable properties of this hydrogel. Due to the advantages associated to injectability of 
a chondrocyte delivery vehicle and possible phenotypic instability of chondrocytes in the 
combined hydrogel-PLDLA scaff old (indicated as spindle-shaped cells), a plain collagen/
HA/4SPEG hydrogel was chosen for further studies.
8.3 Encapsulation of sVEGFR1 ARPE-19 cells in polyvinylidene 
fluoride hollow fibers with type I collagen/HA/4SPEG as 
an internal matrix
Proof-of-principle experiments on the usability of collagen/HA/4SPEG hydrogel as an internal 
matrix inside a semipermeable membrane were carried out using polyvinylidene fl uoride 
(PVDF) hollow fi bers (MWCO 500 kDa, fi ber diameter 1 mm, CellMax, Spectrum Laboratories, 
California, USA) as an outer membrane. sVEGFR1 ARPE-19 cells suspended in the hydrogel 
were injected inside the hollow fi bers, and individual macrocapsules were formed by heat sealing 
the ends of the fi bers. Th e cell capsules were grown in similar conditions as the plain hydrogel 
encapsulated cells (manuscript 3, Materials and methods, sections “Cell culture” and “Cell 
encapsulation in hydrogels”) and tested for cell viability (alamarBlue) and sVEGFR1 secretion 
(ELISA). 
According to the results, the cells remained viable inside the macrocapsules and were able to 
secrete sVEGFR1 out from the capsules at least for 1 month.
Additional unpublished experiments
79
9. SUMMARY OF THE MAIN EXPERIMENTAL 
RESULTS
In the fi rst study, a custom-made laboratory scale device for the production of cell microcapsules 
was designed, built and optimized, and the device was tested for reproducible capsule production 
and cell microencapsulation. Th e parameters aff ecting the size and quality of the produced 
microcapsules were (1) rate of gas fl ow, (2) rate of alginate fl ow, (3) distance between the needle 
tip and the cross-linking solution, (4) size of the nozzle opening and (5) size of the needle. By 
adjusting these parameters, capsules of diff erent sizes with good quality (narrow size distribution 
and symmetrical, spherical shape) could be produced. Importantly, the device allows production 
of also very small microcapsules, even below 200 μm in diameter. Experiments with ARPE-19 
cells genetically engineered to secrete a therapeutic protein showed that the device is usable for 
actual cell encapsulation; the microencapsulated cells remained viable and were able to secrete 
the therapeutic protein for several months aft er the encapsulation procedure.
In the second study, an injectable type II collagen/HA composite hydrogel cross-linked with 
4SPEG was shown to be suitable for the encapsulation of chondrocytes. Th e encapsulated cells 
were able to maintain viability and chondrocytic characteristics in the hydrogel for the 7-days 
culture period. Th e chondrocytic properties of the cells were indicated as spherical morphology 
(typical for the chondrocytic phenotype), cartilage-like ECM production and gene expression 
profi le (increase in the expression levels of type II collagen and aggrecan, genes specifi c for the 
chondrocytic phenotype). In addition, the system allowed incorporation of TGFβ1 into the 
hydrogel and this growth factor was shown to remain in the hydrogel for a relevant time-scale. 
In the third study, ARPE-19 cells genetically engineered to secrete an anti-angiogenic protein 
were successfully encapsulated in a type I collagen/HA hydrogel cross-linked with 4SPEG. An 
optimal hydrogel composition and cell density for a long-term protein delivery system was 
determined to be 5 mg/ml collagen cross-linked with 1 mM 4SPEG without supplemented HA 
and 20 million cells/ml hydrogel. ARPE-19 cells encapsulated in this optimized gel composition 
were able to maintain stable viability and secretion of the anti-angiogenic protein for a 50 days 
culture period. Th e developed PK/PD simulation model could be used to investigate intravitreal 
drug delivery of anti-angiogenic systems and predict the following responses. According to the 
simulations, the studied cell encapsulation system is not suffi  ciently eff ective as it is expected 
to lead to only modest anti-angiogenic action. However, modifi cations of the protein structure 
and/or secretion rate can be used to improve the effi  cacy of the system, and the eff ects of these 
modifi cations can be studied using the developed model. 
As overall results it can be concluded that (1) ARPE-19 is a suitable cell line for cell encapsulation 
(studies 1 and 3) and (2) the hydrogel system of collagen cross-linked with 4SPEG, possibly 
supplemented with HA, is a practical and fl exible material for cell encapsulation (studies 2 and 3). 
(1) ARPE-19 cells were shown to survive diff erent encapsulation processes and to remain viable 
in various hydrogel conditions. Th e cells could be genetically modifi ed to produce a therapeutic 
protein constantly at a stable level. Moreover, the encapsulated cells could be maintained in 
non-dividing state over long periods enabling long-term, stable protein secretion. (2) Th e cross-
linked collagen/HA hydrogel was shown to be suitable in cell encapsulation for both long-term 
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protein delivery and tissue engineering applications. Th e gel formation by cross-linking with 
4SPEG did not limit cell viability of either a cell line (ARPE-19) or primary cells (chondrocytes). 
Th e hydrogel was simple to use in the cell encapsulation process, and the composition could be 
varied within a large scale without compromising cell viability. 
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10. GENERAL DISCUSSION 
10.1  A custom-made microencapsulation device
Microencapsulation is a widely used approach in cell encapsulation. Capturing cells inside 
small, spherical capsules off ers certain advantages compared to larger encapsulation devices, 
including better mass-transfer, mechanical stability, non-invasive delivery and more favorable 
immunological properties (Hernandez et al. 2010, Acarregui 2012). However, the production 
of microcapsules with adequate quality is not straightforward. Cell microencapsulation is most 
oft en performed using extrusion based methods that require specifi c instrumentation. Because 
building such cell microencapsulation devices is diffi  cult without previous knowledge or precise 
instructions, cell microencapsulation is most oft en performed with commercially available 
devices. Nevertheless, there is also a need for custom-made, laboratory-scale devices, due to 
both research and cost related issues; commercial devices are not so simple to modify for specifi c 
research objectives, and these devices are expensive. Th us, to allow more laboratories to carry out 
research on cell microencapsulation with varying perspectives, using e.g. diff erent biomaterials 
and encapsulation strategies, the possibility for building in-house devices is important. 
Our aim was to provide such a precise and unambiguous description of the developed device 
that it can be built and assembled also in other laboratories without diffi  culties. Th us, detailed 
technical drawings and schematic fi gures of the settings were provided. We considered this 
important, because previous reports on custom-built devices have not enabled straightforward 
construction of the devices: the descriptions of the device structures have oft en been inadequate 
(Hardikar et al. 1999, Fiszman et al. 2002, Bressel et al. 2008) or, in some cases, building has 
required special skills or equipment (Ceausoglu & Hunkeler 2002, Sugiura et al. 2007). In 
addition, we concentrated on the fl exibility of the device use; we wanted to design an apparatus 
enabling modifi cations making it capable for diff erent encapsulation purposes and research 
approaches. Th e device settings that can be modifi ed include the rate of gas and polymer fl ows, 
distance between the needle tip and the cross-linking solution, and the size of the nozzle opening 
and the needle. By varying these parameters, the device can be adjusted to meet the needs of 
diff erent applications of cell microencapsulation.
Th e quality of the produced cell microcapsules is important considering both in vitro and in vivo 
experiments (van Schilfgaarde & de Vos 1999, Zimmermann et al. 2005, Rabanel et al. 2009). 
Th e size and shape of the microcapsules have eff ects on molecular permeability and mechanical 
stability of the capsules and consequently, on cell viability and functionality. Th us, reproducible 
and reliable results can only be achieved with uniform, homogeneous microcapsules with 
narrow size distribution and without deformities. Moreover, the quality of microcapsules has 
been associated with outcomes of in vivo experiments as spherical microcapsules with a smooth 
surface induce less immunological reactions (de Vos et al. 2002, Bünger et al. 2003, de Vos 
et al. 2003, Orive et al. 2006). However, using simple, laboratory-scale devices, the quality of 
the microcapsules has not always been especially good, but the capsules have been variable in 
size, asymmetrical or deformed (e.g. drop-shaped) (Hardikar et al. 1999, Fiszman et al. 2002, 
Sugiura et al. 2007, Bressel et al. 2008). Th erefore, we took specifi c attention on the quality of the 
microcapsules produced with the developed device; the simplicity of the encapsulation system 
must not limit the quality of capsules and reproducibility of the process. Indeed, it was shown 
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that symmetrical, smooth-surfaced microcapsules without deformities could be produced with 
the device. 
Another important aspect is the size-scale of the microcapsules. Commonly, cell microcapsules 
of 400–1000 ?m in diameter have been used in cell microencapsulation studies, because 
capsules within this size range are convenient to produce by traditional microencapsulation 
methods. Yet, also smaller sized capsules, below 400 ?m in diameter, have recently been studied 
for cell encapsulation, and the reduction of capsule size has been shown to off er advantages 
compared to traditional microcapsules (more eff ective diff usion, higher mechanical stability and 
biocompatibility, non-invasive delivery via injection) (Chicheportiche & Reach 1988, Robitaille 
et al. 1999, Canaple et al. 2002, Ross & Chang 2002, Sakai et al. 2006, Sakai & Kawakami 2010). 
Th us, the interest in the production of very small cell microcapsules has increased. Th e use of 
new technologies, such as microfl uidics, microlithography and micromolding, has enabled the 
reduction of capsule size to 100 ?m or even less in diameter (Selimović et al. 2012, Velasco et al. 
2012). However, with more simple, traditional methods, the production of small capsules, under 
300–400 ?m in diameter, of uniform shape and narrow size distribution has not been reported 
previously. In this study, we described an encapsulation device capable of producing high quality 
microcapsules under 200 μm in diameter with high reproducibility. Due to the improvements 
achieved with small sized capsules, the possibility to this size-scale of the microcapsules can be 
considered as a notable benefi t of the device.
An obvious requirement for a cell encapsulation technology is the survival of the cells from 
the encapsulation process; the procedure must be gentle enough not to limit cell viability. Th e 
principle of function of the developed device is co-axial gas fl ow extrusion where the beads 
are produced by dispersing the polymer solution with a laminar co-axial gas fl ow. Unlike 
some other extrusion methods, this procedure does not contain e.g. electrostatic potential or 
strong vibrations, and thus, it is a fairly gentle procedure for the cells. Experiments with ARPE-
19 cells showed that encapsulation with this device is possible without limiting cell viability 
or functionality; the microencapsulated cells maintained viability and protein secretion for 
prolonged periods aft er the encapsulation. In addition to ARPE-19 cells, microencapsulation of 
HEK293 cells was performed using the device, and also this cell type was able to remain viable in 
the process (unpublished data).
10.2  An injectable delivery vehicle for chondrocytes
Cell-based repair methods are potential treatment options for cartilage injuries or degeneration. 
As a tissue without blood or lymphatic vessels or nerves and with low cell density, cartilage 
lacks regenerative capabilities. Consequently, cartilage injuries are diffi  cult to treat with 
traditional surgical methods. (Poole et al. 2001, Chung & Burdick 2008, Mollenhauer 2008) 
Main limitation associated to cell therapy of cartilage is the availability of cells with adequate 
chondrocytic properties: due to the low cell density of cartilage, isolated primary chondrocytes 
must be expanded on a large-scale to get a suffi  cient amount of cells for implantation (Melero-
Martin & Al-Rubeai 2007). However, the expansion process in a monolayer culture may lead to 
dediff erentiated chondrocytes as the isolated primary cells will lose their chondrocytic properties 
in a 2D culture. Such dediff erentiated chondrocytes are typically not able to regenerate proper 
cartilage tissue. Means to improve the phenotypic stability of the cells include the use of diff erent 
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biomaterial scaff olds and addition of specifi c growth factors (Frenkel & Cesari 2004, Vinatier et 
al. 2009 b). Research on biomaterials and growth factors allowing stable chondrocytic phenotype 
and appropriate functionality of the encapsulated cells is thus one of the key issues in cell based 
cartilage tissue engineering.
Several diff erent materials and material forms have been used for cartilage tissue engineering 
including both natural and synthetic polymers in the forms of either injectable or implantable 
hydrogels, porous sponges and fi brous meshes (Lu et al. 2000, Chung & Burdick 2008). 
Considering the material types, hydrogels provide certain advantages compared to the other 
forms (Nicodemus & Bryant 2008, Hunt & Grover 2010, Th anos & Emerich 2008): As hydrogels 
possess structural similarity with tissues, they can exhibit the appropriate mechanical, swelling 
and lubricating properties. In hydrogels, the cells are encapsulated in a 3D environment similar 
to that in vivo as opposed to the 2D attachment in sponges and meshes. Moreover, hydrogels 
can oft en be processed under relatively mild conditions that do not limit cell viability. Th erefore, 
we preferred a hydrogel scaff old over other material forms. Type I collagen has been the 
predominant collagen used as a cell encapsulation material for cartilage engineering: this most 
abundant collagen type of the body is easily available and possesses good gel forming properties 
(Frenkel & Cesari 2004, Chang et al. 2005, Spiller et al. 2011). Yet, the specifi c collagen type of 
cartilage is type II collagen, and thus, the use of type II collagen for chondrocyte encapsulation 
is more reasonable; a common approach in biomaterial design for cell therapies is to mimic the 
native in vivo tissue environment. Based on this approach, we selected type II collagen as the 
scaff old material. Indeed, type II collagen has been shown to be superior compared to type I in 
supporting the chondrocytic phenotype of the seeded cells (Nehrer et al. 1997a, 1997b, 1998, 
Veilleux et al. 2004, Bosnakovski et al. 2006, Lu et al. 2010). Th e other component of the hydrogel 
system, HA, was chosen applying this same principle: HA is a GAG found in native cartilage 
tissue with both structural and regulatory roles (Akmal et al. 2005, Kim et al. 2011).
A crucial aspect considering biomaterial design in tissue engineering is the actual usability of the 
scaff olds. To enable the shift  from experimental studies to clinical trials and possible patient use, 
the material has to be practical and suffi  ciently simple to use. With these considerations in mind, 
we decided to use an injectable vehicle for chondrocytes, as injectability off ers many advantages, 
especially from the practical point of view (Lum & Elisseeff  2003, Amini & Nair 2012): Th e 
cells can be suspended into the precursors prior to the gel forming reaction easily enabling 
homogeneous distribution inside the stabilized hydrogel structure. Similarly, growth factors 
can be suspended into the precursor solutions allowing simple incorporation of these bioactive 
molecules. Th e cell-matrix suspension can be delivered non-invasively, possibly without open-
surgery. Aft er delivery to the body, the materials can eff ectively fi ll up the defect space promoting 
integration of the regenerating tissue with the surrounding environment. Th e studied collagen/
HA/4SPEG hydrogel system meets the requirements of simple encapsulation and injection 
process: prior to cross-linking, the collagen and HA solutions have low viscosity, enabling easy 
handling. Th e gel formation takes place in a suitable time-scale of a few minutes. Finally, the 
gel components are available commercially eliminating the need for specifi c synthesis. Overall, 
the studied injectable hydrogel is practical, and thus, usability of the system should not be a 
limitation for possible translation from the experimental phase to preclinical and clinical phases. 
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In addition to the above discussed benefi ts of an injectable hydrogel consisting of type II 
collagen and HA, the selection of the studied type II collagen/HA/4SPEG hydrogel was based 
on comparisons between several diff erent materials. Th e investigated encapsulation matrixes 
included alginate, fi brin and type I collagen, alone or in combination with HA, nanocellulose, 
Extracel (commercial cross-linkable HA/gelatin hydrogel, Glycosan BioSystems), Puramatrix 
(commercial self-assembling peptide hydrogel, BD Biosciences) and photocrosslinkable HA 
(unpublished data). Out of these materials, collagen/HA/4SPEG proved to be the most suitable 
vehicle for chondrocyte delivery; the desired properties of mechanical strength and stability, 
practical usability and maintenance of chondrocyte viability and phenotype were combined in 
this material. Although some other materials, such as alginate, Extracel and nanocellulose, were 
potential and provided certain benefi ts, these hydrogels were not as suitable considering all the 
properties: for instance, although alginate formed a mechanically strong and stable gel and cell 
viability was good, this material is not so convenient practically (due to gelling kinetics) and the 
degradation products are foreign to the body. Similarly, although cells encapsulated in Extracel 
and nanocellulose maintained their viability and phenotype, these materials were mechanically 
not suffi  cienly strong and stable. In addition to the plain hydrogels, the most promising materials 
were tested in combination with a mesh-type, non-woven PLDLA scaff old by impregnating the 
cell-hydrogel suspension into this scaff old. Th e purpose of the PLDLA scaff old was to improve 
mechanical properties of the construct. Using a hydrogel with suffi  ciently non-viscous precursors, 
the cell-matrix suspension could be loaded evenly inside the mesh, and cell distribution was 
homogeneous. However, the encapsulated cells tended to grow along the PLDLA fi bers leading 
to dediff erentiated phenotype. In addition, such a preformed scaff old supposedly limits the 
integration of the cells with the surrounding tissues in vivo due to non-optimal fi tting, and also 
requires more invasive surgery for delivery. Th us, we selected to investigate the plain type II 
collagen/HA/4SPEG as a delivery vehicle for chondrocytes, as it seemed to be the most suitable 
option for this purpose. 
Compared to other commonly used hydrogel scaff olds in cartilage tissue engineering, the type 
II collagen/HA/4SPEG hydrogel possesses certain advantages. As already mentioned, the gelling 
kinetics enables this hydrogel to be used as an convenient injectable delivery system in clinical 
applications. In addition, the composition of the gel can be varied without considerably aff ecting 
the gelation rate and thus not aff ecting injectability. Th is is not the case with e.g. the widely used 
alginate and fi brin hydrogels; in general, the formation of these gels takes place very fast and the 
gelation mechanisms are diffi  cult to control (Skjåk-Bræk et al. 1989, Dornish et al. 2006, Li et. 
al 2012). Moreover, the gel compositions cannot be modifi ed without compromised injectability 
(Kuo et al. 2001, Zhao et al. 2008). Alternatively, the gelation time of some other hydrogels 
may be too long for practical use: for instance, the gelling of Extracel may take over 2 hours 
(Serban et al. 2008), which probably will limit the clinical utility of this material for cartilage 
tissue engineering. A common problem with the materials used in cartilage regeneration is 
shrinkage of the cell seeded scaff olds over time, a characteristic reported especially for fi brin 
(Meinhart et al. 1999, Fussenegger et al. 2003), but also for other materials (Lee et al. 2000, 
2001). On the contrary, the studied collagen/HA hydrogel did not show any shrinkage during 3D 
cell cultures (Collin et al. 2011, Kontturi et al. 2014). Moreover, the hydrogel is biodegradable, 
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and the degradation products are mainly natural components of the body (collagen and HA), 
which is not the case with synthetic hydrogels (such as PEG, PLGA and PVA) or some naturally 
derived hydrogels (such alginate, agarose and chitosan). Insuffi  cient mechanical properties 
are also a typical disadvantage of hydrogel scaff olds, especially in the case of cartilage tissue 
engineering; as cartilage is exposed to considerable mechanical load in the body, the mechanical 
characteristics of the used materials are of particular importance. Th e mechanical properties of 
the collagen/HA hydrogel seem to be suitable for cartilage regeneration: the gel formed a fairly 
strong scaff old structure, and no degradation was observed during a 30 days culture.  Typically, 
plain gels without cross-linking do not form suffi  ciently strong or stable scaff olds (Orban et al. 
2004, O’Halloran et al. 2006, Ibusuki et al. 2007). In addition, according to our experiments, 
some cross-linked (Extracel) or self-assembling (Puramatrix) structures were weaker and less 
stable compared to the collagen/HA/4SPEG hydrogel (unpublished data). However, the actual 
suitability of the mechanical properties of the material for cartilage tissue engineering has to be 
confi rmed with in vivo experiments using appropriate test animals. 
In addition to injectable systems, preformed scaff olds have been widely used in cartilage 
engineering (Lu et al. 2000, Chung & Burdick 2008). Such scaff olds can be cultured in vitro 
in defi ned conditions prior to implantation into the body and thus generate mechanically 
stable structures with appropriate ECM forming chondrocytes already before transplantation. 
However, compared to in situ forming hydrogel systems, prefabricated forms require complex 
manufacturing and purifi cation processes and specifi c cell seeding techniques with the 
possibility of inhomogeneous cell distribution and leakage of cells. In addition, growth factor 
supplementation is more diffi  cult compared to injectable systems: as molecules cannot be 
directly mixed with the hydrogel precursors, growth factors have to be incorporated by specifi c 
means, e.g. by covalent cross-linking. Obviously, the implantation of preformed scaff olds is 
more invasive compared to delivery via injection. Finally, incomplete contact of the implanted, 
prefabricated cell/biomaterial graft  with the surrounding host tissues may prevent integration of 
the implanted chondrocytes, an issue signifi cant for successful cartilage repair (Khan et al. 2008). 
On the contrary, an injectable vehicle can fi ll up the possibly irregular-shaped defect site more 
eff ectively, making the integration more potential. (Lum & Elisseeff  2003, Amini & Nair 2012)
Experiments with chondrocytes encapsulated in the type II collagen/HA/4SPEG supported 
the suitability of this hydrogel for chondrocyte delivery; the encapsulated cells maintained 
viability and chondrocytic properties, and the hydrogel formed a stable and suffi  ciently strong 
scaff old. In addition, the material is biodegradable, and the degradation products are non-toxic. 
However, the results are preliminary. Firstly, the study period of 7 days is relatively short. Yet, 
this duration was justifi ed considering the intended application of the system: the vehicle is 
designed to be used particularly for cell delivery, not for in vitro culture prior to implantation. 
As the conditions in vitro diff er signifi cantly from those in vivo, the functionality of the vehicle 
cannot be demonstrated in long-term in vitro experiments. Instead, preclinical in vivo studies are 
required to prove the potential of the cell-material construct for cartilage regeneration. Secondly, 
the possibility for incorporation of growth factors should be investigated more deeply. In the 
study, TGFβ1 was used to demonstrate the possibility of growth factor incorporation into the 
hydrogel, and to investigate the release rate of these macromolecules from the gel. Indeed, the 
addition of a growth factor was shown to be possible, and this molecule remained in the hydrogel 
for a relatively long period. Th is is desired, because the encapsulated cells should be exposed to 
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the growth factor’s eff ects for a suffi  cient time to enable the tissue regeneration process (Silva 
et al. 2009). However, we did not study how the incorporated growth factor actually aff ects the 
encapsulated cells. Although not the scope of this study, this would be important to characterize 
before moving to more extensive studies. Th irdly, the rate of biodegradation of the scaff old in 
vivo is a critical factor for successful tissue regeneration, the optimal degradation rate depending 
on the rate of tissue formation of the delivered cells (O’Dea et al. 2013). Naturally, this aspect 
could not be investigated in this short-term in vitro study, but should be a subject of further 
experiments. Moreover, a general question considering clinical applicability of the hydrogel 
system is the possible immunogenic reactions of human tissues to collagen of bovine origin.
In general, cell based strategies for cartilage repair have been demonstrated to be feasible, and 
also some moderately promising clinical results have been achieved (Filardo et al. 2013, Kon 
et al. 2013). However, the regeneration of a tissue structure equal to the quality and stability of 
native cartilage has not been achieved so far; the formed neotissue is typically composed of a 
mixture of fi brous and cartilaginous tissues that does not adequately replace the functions of 
cartilage in the body (Vinatier et al. 2009 a, 200 b, Sharma et al. 2011, Portocarrero et al. 2013). 
Th e main reasons for this unsuccessful tissue regeneration include limited viability and non-
desired phenotypical characteristics (incomplete diff erentiation or instability of the chondrocytic 
phenotype) of the cells aft er transplantation and insuffi  cient integration of the cells with the host 
tissue. To overcome these problems, more sophisticated protocols for the combined use of cells, 
biomaterials and bioactive factors must be developed. Basically, the design of successful protocols 
relies on understanding the factors aff ecting chondrocyte diff erentiation and maintenance of 
the phenotype at the molecular level. Once the factors critical for each phase of development 
have been identifi ed, constructs of cells, biomaterials and growth factors capable of regenerating 
native-like tissue can in principle be developed. Naturally, also material science related challenges 
of engineering appropriate scaff olds with the correct spatial organization of growth factors in a 
bioactive form also exist.
10.3  Cell encapsulation for drug delivery to the posterior eye
As topical and systemic administration of drugs targeted to the posterior eye is very ineff ective, 
intravitreal delivery is the prevalent administration route for such therapeutics (Urtti 2006, 
Gaudana et al. 2010). Most commonly, drugs are administered to the retina via IVT injections 
allowing effi  cient drug delivery directly to the target site. Despite the effi  ciency, IVT injections 
are not the optimal choice in general, because repeated IVT injections are inconvenient for the 
patient, expensive and might result in complications. Since many of the diseases aff ecting the 
back of the eye are chronic in nature (e.g. AMD, DR and ROP) (Neely et al. 1998, Campochiaro 
2013), systems enabling long-term intravitreal drug delivery are needed. An alternative for the 
more traditional sustained delivery systems is drug delivery using polymer encapsulated cells. In 
principle, implantation of cells secreting a therapeutic factor can provide long-lasting, eff ective 
and safe intravitreal drug delivery without repeated, invasive dosing.
A cell encapsulation device designed for drug delivery consists of an outer semipermeable 
membrane isolating the encapsulated cells from the host’s immune system and an internal 
matrix providing a growth environment for the cells inside the membrane. Considerable eff orts 
have been taken on the research and design of the semipermeable membrane critical for the 
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immunoisolative capability of the device (Granicka et al. 2008, Uludag et al. 2000, Rihova 
2000, Nafea et al. 2011). However, the main component aff ecting viability and functionality of 
the encapsulated cells is the internal matrix. Th e matrix should provide the cells an artifi cial 
ECM that off ers appropriate structural and possible biochemical support. Although studies 
on the eff ects of the internal matrix on cell viability and device function have been performed 
(e.g. Zielinski & Aebischer 1994, Lahooti & Seft on 2000, Li et al. 2000), this aspect is still not 
fully utilized in the fi eld of cell immunoisolation; possibilities of diff erent materials, material 
composites and material forms as internal matrixes, as well as bioactive modifi cations of these 
materials can provide signifi cant advances for cell encapsulation applications.
An important consideration on the internal matrix is the process of loading the material inside 
the semipermeable membrane device. In some cases, a preformed matrix (in the form of e.g. 
foam or yarn) has been created inside the device, and the cells are transferred inside this matrix 
aft erwards (Li et al. 1998, Tao et al. 2002, Fjord-Larsen et al 2010). Another approach is to capture 
the cells inside the internal matrix at the same time the matrix is formed. Th is approach is used 
in cell microencapsulation where cells are encapsulated inside microbeads at the same time these 
hydrogel beads are generated (Lim & Sun 1980, Chia et al. 2002, Baruch & Machluf 2006, Sakai 
et al. 2007). Th e semipermeable membrane can be subsequently generated around the beads by 
e.g. polyelectrolyte complexation. Alternatively, the cells can be suspended into the precursors 
of an injectable hydrogel that is injected inside the membrane device (Winn et al. 1994, Zurn 
et al. 2000, Bloch et al. 2004). Aft er the cell-precursor suspension has been injected, it forms a 
hydrogel matrix with the dispersed cells inside the device. Th is approach is attractive for diverse 
macroencapsulation applications; when a suitable internal matrix material for a certain cell type 
is found, it can be used with several diff erent outer membranes depending on the requirements 
of the application.
We studied an injectable collagen/HA/4SPEG hydrogel intended to be used as an internal matrix 
inside a semipermeable cell macroencapsulation device for intravitreal protein delivery. Th is 
hydrogel appeared to be suitable for the encapsulation of ARPE-19 cells: as the cells inside the 
hydrogel were viable and functional, the permeability characteristics of the material seem to 
be adequate. However, as the supplementation of HA did not provide any benefi t for ARPE-19 
cells, a plain collagen/4SPEG hydrogel was chosen for long-term experiments. Th e mechanical 
properties of the hydrogel were suitable for this encapsulation application; aft er the cross-
linking reaction, the gel formed a mechanically stable structure allowing structural support 
for the cells and maintaining them dispersed in 3D without aggregation. Moreover, as the 
hydrogel is injectable, the loading of the cell-matrix suspension inside a membrane device is 
simple. Th is was shown in proof-of-principle experiments using PVDF hollow fi bers as outer 
membrane (unpublished data). Th e injection of cell-precursor solution into the hollow fi bers 
was convenient, and the cells remained viable within the cross-linked matrix inside the hollow 
fi ber devices for several weeks. However, an aspect to be considered is the biodegradation of the 
hydrogel. As collagen is a natural component of the body, it is degraded by endogenous enzymes 
(collagenases). Th e degradation kinetics of the gel in vivo has not been investigated yet, and 
it cannot be reliably predicted using results from in vitro experiments (Collin et al. 2011). It 
is likely that the degradation rate is slower in the vitreous compared to body sites with higher 
metabolic activity. Th erefore, degradation of the hydrogel matrix might not be a problem in a 
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device designed for long-term intravitreal protein delivery. Th is is, however, an issue that has to 
be taken into account and studied in vivo before more extensive experiments. 
Due to the inconvenience and risks associated to intravitreal administration, alternative methods 
for drug delivery to the posterior segment are of specifi c interest (Th rimawithana et al. 2011). 
Potential options are topical and periocular (subconjunctival, sub-Tenon and suprachoroidal) 
routes (Raghava  et al. 2004, Loft sson et al. 2008). As administration via these sites is less invasive 
and simple compared to intravitreal delivery, the disadvantages and possible complications 
of IVT injections can be avoided. However, drug delivery via topical and diff erent periocular 
routes of administration involve physical and blood fl ow barriers that limit the bioavailability 
to the retina and/or choroid (Urtti 2006, Gaudana et al. 2010). For topical administration, 
rapid drainage through the nasolacrimal ducts, low permeability of the corneal epithelium, 
systemic absorption and drug elimination from the anterior chamber limit drug penetration 
into the retina. For periocular administration, the factors restricting drug penetration include 
conjunctival blood fl ow and lymphatic circulations, high blood fl ow of the choroid, and 
the blood-retinal barrier. Th e involved barriers depend on the exact site of periocular drug 
administration; yet, retinal bioavailability is less than aft er intravitreal administration, but more 
than aft er topical ocular instillation. Due to these factors limiting drug penetration, a system 
designed for topical or periocular delivery routes must secrete the drug product at high quantities 
to enable therapeutic concentration at the target site. Encapsulated cells could possibly provide 
such a system. Sustained release systems using both periocular and topical administration have 
been investigated to some extent (e.g. Gilbert et al. 2003, Ayalasomayajula & Kompella 2005, 
Gomes dos Santos et al. 2006, Schultz et al. 2011, Davis et al. 2014). However, according to our 
knowledge, no cell encapsulation system for topical or periocular delivery has been presented.
A more novel approach for drug delivery via encapsulated cells is the use of a plain cell-
hydrogel matrix as an injectable device, without a surrounding membrane. Th is would enable 
the transplantation of the encapsulated cells via injection as opposed to implantation required 
for a traditional membrane-surrounded cell capsule. Th e main obstacle for this approach is the 
possible insuffi  cient immunoisolative capacity of the plain hydrogel matrix. Th is is, however, an 
issue that cannot be reliably studied in vitro, but requires in vivo studies; as the immunological 
response is a highly complex process involving several diff erent factors, components and 
signaling chains interacting with each other, these conditions are not possible to model in vitro. 
Interestingly, the eye might be a potential target for the approach of an injectable cell delivery 
device due to the partial immune privileged nature of the eye environment and thus, decreased 
possibility for immune rejection compared to some other parts of the body (Streilein 2003 a, 
2003 b, Taylor 2009). However, immunosuppressive medication might be needed, especially in 
a diseased eye, where barrier functions have weakened. An interesting possibility is also to use 
an injectable system via topical or periocular administration, enabling even more non-invasive 
and simple delivery. Considering the immunological aspects, topical administration might be 
especially preferable; in this approach the cells reside outside the body, hence probably not 
provoking an immunological response. However, systemic immune reactions might take place, 
as a considerable proportion of the topically delivered substances is absorbed systemically. 
Instead, periocular spaces are not immune privileged sites and thus, specifi c attention should 
be taken for immunological issues when using this administration route. Yet, as for intravitreal 
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administration, reliable information on the suffi  ciency of immune isolation requires in vivo 
experiments.
In addition to the alternative administration routes, the problems of IVT injections have been 
attempted to solve by the development of sustained release delivery systems. Th e most studied 
extended release systems include intravitreal implants, liposomes and micro- and nanoparticles 
(Hsu 2007, Del Amo & Urtti 2008, Th rimawithana et al. 2011). Naturally, each delivery method 
has its advantages and disadvantages. Intraocular implants, nanoparticles and microscale carriers 
provide controlled drug release for extended periods at the site of action, thus prolonging the 
duration of drug action and dosing interval. Th ese delivery systems may also be administered 
via periocular or topical routes enabling less invasive administration, but higher doses are 
needed in these cases. In principle, protein delivery by encapsulated cells would solve many of 
the problems associated with the above mentioned delivery methods as this technology enables 
continuous delivery of freshly produced proteins for extended periods, possibly even for many 
years, without repeated dosing. Especially, considering the stability of the proteins for long-term 
delivery systems, the encapsulated cells posses an advantage over other sustained release systems. 
Although diff erent means to stabilize the drug can be used, the stabilization of proteins in the 
formulations is a challenge. In encapsulated cells, this problem does not exist as the cells produce 
the protein constantly de novo and thus, this approach has the potential to provide considerably 
longer treatments without repeated dosing. Yet, as discussed earlier, delivery by encapsulated 
cells has its own challenges that have to be carefully considered before clinical applications, such 
as production, storage and immune reactions. 
10.4  PK/PD modeling of intraocular anti-angiogenic drug 
delivery
PK/PD modeling is a convenient tool for the investigation of drug effi  cacy and safety before in 
vivo experiments (Lavé et al. 2007, Rajman 2008). Simulations obtained with the models can be 
used to explore eff ects of diff erent delivery methods and systems simply, quickly and at a low 
cost. Accordingly, the methods and systems can be compared and optimized to a certain level 
already in the phase of in vitro experiments, reducing the amount of laborious and expensive 
in vivo experiments. We developed a PK/PD model to study the intravitreal delivery of anti-
angiogenic, VEGF inhibiting factors and the following ocular response. Th e rationale behind 
this kind of model was evident: Currently, there are several potent VEGF inhibitors on the 
market (e.g. bevacizumab, ranibizumab and VEGF Trap) that are delivered via repeated IVT 
injections (Andreoli & Miller 2007, Emerson & Lauer 2007, Ciulla & Rosenfeld 2009). Due to 
the disadvantages associated with this invasive administration, there is a need for new delivery 
methods, and the development of these methods can be assisted using a suitable simulation 
model.
In the model, we linked the concentration of the VEGF inhibiting factor to the concentration 
of its substrate, VEGF, using the association and dissociation reactions and related binding 
constants of (1) the inhibitor to VEGF and (2) VEGF to its receptor VEGFR. Consequently, 
the simulated intravitreal levels of free (non-bound) inhibitor and free VEGF were obtained. 
As VEGF is the main stimulator of retinal neovascularization (Penn et al. 2008), decrease in 
intravitreal VEGF concentration can be associated to the therapeutic response or reduction in 
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neovascularization. According to our knowledge, no in silico models linking the concentrations 
of VEGF inhibitors to intravitreal VEGF levels have been published previously. Th us, the model 
can be used to evaluate the therapeutic potencies of diff erent therapeutic factors and their 
intravitreal delivery more accurately. Th e model was applied to the intravitreal delivery of VEGF 
inhibitors both via IVT injections and sustained release.  
Simulations with commercial VEGF inhibitors administered by IVT injections supported the 
clinically used dosing intervals: for bevacizumab and ranibizumab, intravitreal VEGF levels 
remained low for approximately 1 month, while VEGF Trap, a molecule with considerably higher 
affi  nity to VEGF, was able to reduce VEGF levels for two months. Accordingly, bevacizumab 
and ranibizumab are commonly administered monthly and VEGF Trap bi-monthly (Rosenfeld 
et al. 2006, Lynch & Cheng 2007, CATT Research Group et al. 2011). Th e model can be used 
to investigate diff erent doses and dosing regimens (injection intervals) of these inhibitors. As 
an example, we studied the eff ects of both increased and decreased doses (compared to the 
clinically used dose) on the inhibitory eff ect of bevacizumab. Firstly, we investigated if the dosing 
interval of bevacizumab could be prolonged to two months by doubling the administered dose. 
According to the simulations, this is not possible: the increased dose was not able to maintain the 
inhibitory eff ect for the two-month period, but the VEGF concentration started to increase soon 
aft er 1 month following the injection. Actually, the diff erence in the duration of the inhibitory 
eff ect between the original and the doubled dose was only small. In addition, as the larger dose 
results in an increased peak concentration, the approach of increasing the dose to prolong the 
injection interval cannot be considered feasible. Secondly, we simulated the eff ect of smaller 
doses with the same (clinically used) dosing interval to the intravitreal drug concentration and 
response. Surprisingly, decreasing the dose to one half of the original amount did not have a 
signifi cant eff ect on the response: the VEGF concentration increased only slightly at the end 
of the dosing period, to 14% of the initial concentration. Th us, according to the simulations, 
the dose of bevacizumab could be reduced without losing the inhibitory eff ect. Th e explanation 
for this might be that although the drug concentration decreases considerably during the 1 
month period, the level still remains suffi  ciently high to produce the inhibitory eff ect. As in 
pharmacokinetic experiments the primary parameter measured is the drug concentration, not 
VEGF, the adequate dose might have been overestimated. Moreover, lowering the doses even 
more did not totally lose the response during the one month period: for a 1/4 dose, the VEGF 
concentration at the end of the dosing interval was 25%, and for a 1/8 dose, 45% of the initial 
VEGF concentration. Naturally, as in silico simulations, the reliability of the results and their 
applicability in vivo must be considered carefully. However, the results encourage to investigate 
the dosing of VEGF inhibiting factors more deeply. 
Th e model was used to investigate the effi  ciency of the sustained release system with encapsulated 
sVEGFR1 ARPE-19 cells using the sVEGFR1 secretion rate data obtained from in vitro studies. 
According to the simulations, the system seems to be inadequate for therapeutic effi  ciency: the 
decrease in intravitreal VEGF concentration was only 10%, which is probably not suffi  cient 
to signifi cantly reduce retinal neovascularization. Th erefore, we investigated how diff erent 
modifi cations aff ect the effi  ciency of this cell encapsulation system. Possible modifi cations 
to improve the potency of the system include increasing the affi  nity of the VEGF inhibitor 
(sVEGFR1) to VEGF and increasing the secretion rate of this protein from the cells. Simulations 
using systems with one or both of these modifi cations showed that the effi  ciency can be improved 
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considerably; with suitable adjustments, a prolonged and strong VEGF inhibiting eff ect can be 
achieved. 
Importantly, the model can be used to evaluate the extent of needed modifi cations by simulating 
intravitreal drug and VEGF concentrations for systems with diff erent modifi cations and 
combinations of these. By tuning and optimizing the properties of delivery systems already in 
the in vitro phase, only the most potent alternatives can be selected for in vivo experiments. 
According to our simulations using diff erent modifi ed systems, the secretion rate of the VEGF 
inhibitor seems to be a more powerful parameter in maintaining the therapeutic effi  cacy of 
the delivery system compared to the affi  nity of the inhibitor to VEGF: an increase in the initial 
VEGF concentration before treatment has a considerable eff ect on the inhibition potency of a 
system with very high inhibitor affi  nity combined to a low secretion rate, while with an opposite 
system (a system with a low inhibitor affi  nity combined to a high secretion rate), the inhibitory 
eff ect is not so sensitive and is maintained with diff erent initial VEGF concentrations. Th is is 
important, since VEGF concentrations in retinal neovascular diseases may vary considerably 
between patients. Th us, to achieve a therapeutic response in a large patient group, a delivery 
system with suitable combination of affi  nity and secretion rate must be used. 
Simulations indicated considerable advantages of the VEGF inhibitor delivery by a sustained 
release system (such as encapsulated cells) compared to delivery via IVT injections. Th e most 
evident fact was naturally the avoidance of very high peak concentrations of the drug with 
sustained release delivery. Using IVT injections, the local peak concentrations can be many 
times higher than the levels needed for therapeutic effi  cacy; in principle, the intravitreal Cmax 
of bevacizumab in the human eye is, directly aft er the injection, 310 ?g/ml, a concentration 
approximately 14 000 times higher than the reported median inhibition concentration of 
bevacizumab (22 ng/ml) (Wang et al 2004). However, such high concentrations must be 
administered to maintain the therapeutic drug levels between the injections to avoid very 
short dosing intervals. Using delivery with sustained release, the amount of the used drug can 
be reduced signifi cantly by adjusting the release rate to a suitable, constant level. Importantly, 
as VEGF is a physiological regulator of angiogenesis, the complete blockage of its action is not 
desirable (Campbell et al. 2013) – yet, such total inhibition of VEGF takes place aft er every IVT 
injection due to the high amount of VEGF inhibitor required. On the contrary, with a sustained 
release system, the delivery rate and resulting inhibitor concentration can be controlled more 
accurately. Th us, the levels can be set to enable eff ective inhibition of neovascularization, but 
allowing the normal angiogenic function of VEGF.
Naturally, as all in silico models, also the model developed in this study possesses some 
limitations. Firstly, the model was constructed using in vivo data from experiments with 
rabbits, which might bring some uncertainty to the model as there are certain diff erences 
between the human and the rabbit eye (e.g. diff erences in the vitreous volume and possibly in 
intravitreal clearance mechanisms of proteins) (Chastain 2003, Nomoto et al. 2009). Secondly, 
as the in vivo data is obtained from healthy rabbits, the parameters in a diseased eye with retinal 
neovascularization might be diff erent: e.g. elimination rates of proteins might be diff erent and 
they may vary along diff erent diseases states (Shen et al. 2014). Th irdly, the PD response to the 
administered VEGF inhibitors is simulated as the intravitreal VEGF concentration. Th e fi nal 
therapeutic response is, however, a decrease in retinal neovascularization as a result of anti-
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angiogenesis by VEGF inhibition. Since VEGF is considered to be the most important stimulator 
of retinal neovascularization, the relationship between VEGF concentration and angiogenesis is 
assumed to be relatively linear. However, as biological phenomena are generally very complex 
including several interacting factors and possible compensatory mechanisms, the magnitude of 
the therapeutic response cannot be fully predicted with the simulated VEGF level. Yet, validation 
of the model with data of clinically used VEGF inhibitors indicated that the simulated VEGF 
levels describe the therapeutic effi  ciency reasonably well: the simulated VEGF inhibiting eff ects 
of bevacizumab, ranibizumab and VEGF Trap were approximately the same length as the dosing 
intervals used for these drugs.
An additional consideration on the reliability of the model should be made for sVEGFR1. Th e 
mechanism of action for this factor has been simplifi ed in the model structure as the precise 
molecular mechanisms of sVEGFR1’s inhibitory eff ect are still unclear. Two possible mechanisms 
have been postulated (Kendall et al. 1996, Wu et al. 2010): Firstly, similar to bevacizumab, 
ranibizumab and VEGF Trap, sVEGFR1 binds to and sequesters VEGF and consequently, 
lowers the free VEGF concentration available for receptor activation. Secondly, sVEGFR1 
binds to surface VEGFRs, and the formed dominant-negative heterodimer complexes are not 
available for VEGF activation. Th e relative roles or signifi cances of these mechanisms for the 
total inhibitory eff ect are not known. In addition, no binding affi  nities of sVEGFR1 to VEGFRs 
have been presented in the literature. Th us, taking both of these mechanisms into account in the 
model structure would be diffi  cult and the results uncertain. Th erefore, we decided to restrict 
the inhibition mechanism to only VEGF trapping, and the eff ects occurring through VEGFR 
binding have not been considered. As a consequence, the model might slightly underestimate the 
actual inhibitory eff ect of sVEGFR1.
10.5  ARPE-19 cells for encapsulation 
Th e most important properties of the encapsulated cells for the application of long-term protein 
delivery are the abilities (1) to maintain stable viability during and aft er the encapsulation process 
and (2) to secrete the therapeutic product or products at the appropriate rate and for the desired 
duration. Considering both of these requirements, the cell type used in our studies, ARPE-19, 
seems to be a very suitable cell line for encapsulation purposes. 
ARPE-19 is a spontaneously arising RPE cell line derived from human eye (Dunn et al. 1996). 
Th ese cells are hardy and tolerant and thus, they can survive viable in harsh conditions and 
during diff erent encapsulation processes. Consequently, the materials and methods that can 
be used for encapsulation are not very limited, but various material types and encapsulation 
protocols can be applied. Moreover, the encapsulated cells can be implanted into diff erent sites 
in the body, including also sites of stringent environment such as the central nervous system 
and the eye. Another important property concerning the viability of ARPE-19 cells is their long 
life-span and ability to remain in a non-dividing state for prolonged periods. Th is is critical for 
stability and safety of the cell encapsulation system; cell proliferation inside the device might lead 
to cell escape and even rupture of the device, as well as changes in the levels of the therapeutic 
product secreted by the cells. Naturally, for a long-term delivery system, a long life-span of the 
encapsulated cells is necessary. ARPE-19 cells can be genetically engineered by stable transfection 
to produce therapeutic products at a constant level for long periods and with suffi  cient quantities 
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(Tao et al. 2002, Wikström et al. 2008, Fjord-Larsen et al. 2010, Kontturi et al. 2011). Additional 
advantages of the cells include human origin and non-tumorigenicity. ARPE-19 cells have been 
shown to provoke no or a very limited immune response aft er transplantation (Kauper et al. 
2012, Wahlberg et al. 2012).
Suitability of ARPE-19 cells for encapsulation was seen also when comparing the encapsulation 
results with another cell line used in our studies, HEK293 (unpublished data). Although HEK 
cells could be encapsulated in certain types of APA microcapsules, variability in the capsule type 
was considerably more limited than for ARPE-19 cells; HEK cells were able to remain viable only 
in a few microcapsule compositions. Moreover, the fast proliferation rate of HEK cells makes 
them unsuitable for long-term encapsulation: as HEK cells cannot remain in a non-dividing state 
such as ARPE-19 cells, continuous cell escape and capsule disintegration was seen. Although the 
proliferation of encapsulated ARPE-19 cells was not studied on the molecular level, the reduced 
or ceased proliferation was evident from stable cell viability and protein secretion profi le, stability 
of the capsules and absence of cell escape during long-term culture of ARPE-19 capsules.
In studies I and III of this thesis, we encapsulated ARPE-19 cells modifi ed to secrete sVEGFR1 
protein into APA microcapsules and into a cross-linked collagen-HA matrix. Th e encapsulated 
cells remained viable and were able to secrete the therapeutic protein for long periods in both 
of these capsule types. Th ese results indicate that ARPE-19 cells can be encapsulated into cross-
linkable hydrogels applying both ionic (alginate and divalent cations) and covalent (collagen 
and 4SPEG) interactions. Th e composition of the encapsulation materials could be modifi ed 
without aff ecting cell viability notably: APA microcapsules could be modifi ed using diff erent 
concentrations of alginate, PLL and the cross-linking ions, as well as varying the processing 
methods and conditions (unpublished data). Similarly, the cross-linked collagen-HA matrix 
could be modifi ed with diff erent concentrations of collagen, HA and the cross-linker without 
compromising cell viability. Genetically engineered ARPE-19 cells have been encapsulated also 
in hollow fi ber membranes of polyethersulfone (1) for implantation into the central nervous 
system to treat Alzheimer’s disease (NGF producing ARPE-19 cells) (Fjord-Larsen et al. 2010, 
2012) and (2) for intravitreal implantation for the treatment of retinal degenerative diseases 
(CNTF producing ARPE-19 cells) (Tao et al. 2002, Th anos et al. 2005). In clinical trials, these 
cell capsules have shown positive safety profi les and stable production of the therapeutic proteins 
for prolonged periods, for the CNTF secreting capsule even over 2 years (Sieving et al. 2006, 
Zhang et al. 2011, Kauper et al. 2012, Wahlberg et al. 2012). As a conclusion, ARPE-19 cells 
can be considered to be a potential cell line for varying encapsulation purposes with diff erent 
encapsulation methods and materials, as well as diff erent implantation sites in the body. Further 
studies will demonstrate the actual clinical applicability and functionality of this cell line in cell 
therapy.
10.6  Collagen/HA/4SPEG as a material for encapsulation
Th e collagen hydrogel cross-linked with 4SPEG and possibly supplemented with HA was shown 
to be suitable in cell encapsulation for both long-term protein delivery and tissue engineering 
applications. As a hydrogel, it provides a tissue-like environment for the encapsulated cells, 
and the gel formation by cross-linking with 4SPEG did not limit cell viability of either a cell 
line (ARPE-19) or primary cells (chondrocytes). Injectability of the system enables non-
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invasive and simple delivery of the cell-matrix suspension either to the defect site in vivo (tissue 
engineering) or inside a semipermeable cell immunoisolation device (protein delivery). Th e 
hydrogel was practical to use in cell encapsulation: cells could be suspended easily into the low-
viscosity solutions prior to the cross-linking reaction allowing homogeneous distribution of the 
encapsulated cells, and the hydrogel formed a mechanically stable and strong structure aft er the 
cross-linking in a suitable time scale. Moreover, the hydrogel system seemed to be robust; the 
composition could be varied within a large scale without limiting cell viability. Consequently, the 
properties of the hydrogel may be tuned for many applications according to specifi c demands. 
Th e degradation products of the hydrogel are non-toxic, and mainly natural components of the 
body (collagen and HA). 
However, further characterization of the material is still required. Th e degaradation kinetics of 
the hydrogel must be studied in vivo in diff erent environments (implantation sites) to obtain 
information on suitability for diff erent applications. In addition, the possibility to modify the 
properties of the hydrogel by adjusting its composition must be studies in more detail; despite 
some studies on the subject (Collin et al. 2011), the eff ects of composition on degradation rate, 
mechanical properties and gelation time should be studied more accurately and extensively using 
e.g. rheological measurements. Finally, the long-term stability of the HA network inside the 
hydrogel should be characterized. As this component is not part of the cross-linked structure, 
HA might diff use out of the system over time.
Collagen/HA/4SPEG has been studied previously for tissue engineering applications. Th e 
hydrogel has been shown to be potential for the encapsulation of nucleus pulposus cells for the 
tissue engineering of intervertebral discs (Collin et al. 2011). In addition, chondrocytes have 
been encapsulated in type I collagen cross-linked with 4SPEG (Taguchi et al. 2005). According 
to the knowledge of the authors, no studies on the use of this hydrogel for immunoisolative cell 
encapsulation devices have been published previously. However, considering the properties of 
the material and the results of our studies, the hydrogel is potential as an internal matrix in a cell 
encapsulation device, or even as a plain cell encapsulation matrix. To conclude, as an adjustable 
system, collagen/4SPEG with the possible supplementation of HA, appears to be a promising 
material for various cell encapsulation approaches. 
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11. CONCLUSIONS
In this study, cell encapsulation in hydrogel materials for cell therapy applications was 
investigated. Th e specifi c conclusions are the following:  
1. Th e production of cell microcapsules of good quality (symmetrical shape, narrow size 
distribution) is possible using a simple device with carefully designed structure and settings. 
Such a simple devices allows fl exibility; by adjusting the settings, diff erent sized capsules can 
be produced and diff erent encapsulation protocols and materials can be used. ARPE-19 cells 
encapsulated with the device remain viable and are able to secrete a therapeutic protein for 
prolonged periods.
2. A type II collagen hydrogel cross-linked with 4SPEG and supplemented with HA and TGFβ1 
seems to be a suitable delivery vehicle of chondrocytes for cartilage tissue engineering. Th e 
hydrogel supports viability and phenotype of the encapsulated chondrocytes, and it can be 
delivered non-invasively via injection. In addition, it forms a mechanically appropriately 
strong and stable, biodegradable scaff old. Further studies are needed to prove the suitability 
of the vehicle for cell delivery and tissue formation in vivo.
3. A type I collagen cross-linked with 4SPEG and supplemented with HA is a suitable 
encapsulation matrix for ARPE-19 cells. Th e hydrogel composition can be modifi ed to 
adjust the properties to be suitable for diff erent requirements. Th e encapsulated, genetically 
engineered cells maintain viability and are able to secrete the anti-angiogenic sVEGFR1 
protein at a constant rate for at least 50 days. Th e system might be potential for the 
intraocular treatment of retinal neovascularization. 
4. Th e developed PK/PD simulation model can be used to predict drug levels and therapeutic 
responses aft er intravitreal anti-angiogenic drug delivery. Using the simulations, design and 
optimization of intravitreal delivery systems can be done more accurately in the in vitro 
phase, reducing the need for in vivo experiments. Th us, the model can notably assist the 
development of delivery systems for the treatment of neovascular diseases of the retina.
In summary, the studies show that hydrogels are suitable for diverse applications in cell 
therapy. Th is material type can be used for cell encapsulation of very diff erent purposes from 
stable encapsulation systems for long-term protein delivery to temporary scaff olds in tissue 
regeneration. However, more deep and accurate understanding on the interactions of cells and 
biomaterials must be achieved. Th is will enable the design of functional and bioactive materials 
for advanced applications in the future.
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